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ABSTRACT 
 
Background: Although immune thrombocytopenia (ITP) is a common cause of 
thrombocytopenia among both children and adults, information regarding 
prognostic determinants of outcome of splenectomy and the management of 
patients who fail to respond to splenectomy is limited. 
Aims and Objectives of the study: To analyze the response to splenectomy and to 
assess the response to treatment of refractory ITP post splenectomy, in children 
and adults with persistent and chronic ITP in our institution. 
Methodology: All patients with persistent and chronic ITP seen in the Department 
of Haematology between 1995 and 2009 who underwent splenectomy and whose 
data could be retrieved were analyzed.  
Results: Of the 167 adults and 87 children, 82.6% of adults and 88.5% of children 
were in response at 2 months post splenectomy. After a median follow up of 18.6 
months (range:1-170) in adults and 12 months (range: 1-173) in children post 
splenectomy, 115 (68.9%) adults and 63 (72.4%) children showed a response, 
while 48 (28.7%) adults & 23 (26.4%) children were refractory to splenectomy. 
The overall mortality was 6 (3.6%) in adults and 1 (1.2%) in children. Among 
those who were refractory to splenectomy, subsequent drug treatment resulted in 
response in additional 25 (15%) of adults and 16 (17.2%) of children. The 5 & 10 
year event free survival of total cases were 75.2 ± 3.7% & 71.5 ± 4.5% in adults 
and 79.1 ± 4.6% & 70 ± 7.5% in children respectively. Among adults, females and 
those who had higher platelet count at splenectomy had a higher chance of 
response to splenectomy. While in children, persistent phase of the disease was 
associated with response. The median time to post splenectomy response was 
shorter and the median peak platelet count was higher among those who showed 
sustained response in both groups. 
Conclusion: In this first large series form India, comprehensively analyzing 
outcome of patients with ITP undergoing splenectomy, the response to treatment is 
similar to those reported in the literature in both adults and children from other 
population. Further analysis needs to be done to ascertain the predictive value of 
the variables associated with response.  
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INTRODUCTION 
 
Immune thrombocytopenia (ITP),12 an autoimmune disorder is a common cause of 
thrombocytopenia,1 among both children and adults, characterized by the 
development of auto-antibodies against platelets, a spectrum of clinical severity, 
and a minor to severe reduction in platelet count (<100 x109/L). 1,12,40,54   
 
 ITP has a combined prevalence of 1–13 per 100,000 persons1,15, with an 
overall female to male ratio of 2:136.  Despite similar pathogenetic mechanisms, 
the natural history of ITP differs between children and adults. In children, the 
disorder is often self-limited with short course, whereas in adults it is associated 
with a persistent and chronic course,12,20,34,39,48,54,55 a higher rate of complications, 
and an inadequate response to drug therapy3.  
 
Most ITP patients are treated initially with corticosteroids and, if no lasting 
response occurs, undergo splenectomy. 1,2,15 This initial approach results in a stable 
response in 60-70% of ITP patients.  Even in the present era, the response rates of 
splenectomy are 50-85% compared to the response rates of 15-30% when steroids 
are administered. Since sustained responses after discontinuation of the drug occur 
in only 25% or less, surgical therapy is preferred as it usually gives complete 
response.7  
 
 For patients who fail to respond to splenectomy and for those who 
experience a loss of response after splenectomy, treatment remains difficult and 
undefined. However there are not many Indian data addressing these issues.2,7  The 
present study is the retrospective and prospective review of the experience at our 
institution with splenectomy for persistent and chronic ITP in children and adults.  
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REVIEW OF LITERATURE: 
 
DEFINITIONS: 
Until recently, ITP was defined as isolated thrombocytopenic purpura  (platelet 
count < 150 x109/L)  in a patient who has no clinically apparent associated 
conditions or factors that can cause thrombocytopenia, including human 
immunodeficiency virus (HIV) infection, systemic lupus erythematosus, 
lymphoproliferative disorders, myelodysplasia, agammaglobulinemia, therapy with 
certain drugs, alloimmune thrombocytopenia, and congenital or hereditary 
thrombocytopenia.1,2,30,40,65 Thrombocytopenia lasting less than 6 months was 
termed as acute, and greater than 6 months as chronic.20, 30,34, 39,48,54,55 
 
However, an International Working Group (IWG; decided during the 5th 
official meeting of the European Hematology Association (EHA) Scientific 
Working Group on Thrombocytopenias) held on June 7, 2007, during the 12th 
EHA Congress in Vienna)12  addressed the pitfalls in the definitions and 
terminologies used in ITP and has put forth the below mentioned recommendations 
(Table:1).12  
 
The term “purpura” was felt inappropriate, because bleeding symptoms are 
absent or minimal in a large proportion of cases. The acronym ITP (now proposed 
to stand for immune thrombocytopenia) was preserved because of its widespread 
and time honored use and taking into account its utility for literature searches.12 
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Table:1 
Proposed definitions of disease12 
Primary ITP Primary ITP is an autoimmune disorder characterized by isolated 
thrombocytopenia (peripheral blood platelet count <100 x109/L) in the 
absence of other causes or disorders that may be associated with 
thrombocytopenia. The diagnosis of primary ITP remains one of 
exclusion; no robust clinical or laboratory parameters are currently 
available to establish its 
diagnosis with accuracy. The main clinical problem of primary ITP is an 
increased risk of bleeding, although bleeding symptoms may not always 
be present. 
Secondary ITP All forms of immune-mediated thrombocytopenia 
except primary ITP*  
 
Phases of the disease Newly diagnosed ITP: within 3 months from diagnosis 
Persistent ITP: between 3 to 12 months from diagnosis. Includes 
patients not reaching spontaneous remission or not maintaining 
complete response off therapy.  
Chronic ITP: lasting for more than 12 months Severe ITP: Presence of 
bleeding symptoms at presentation sufficient to mandate treatment, or 
occurrence of new bleeding symptoms requiring 
additional therapeutic intervention with a different platelet-enhancing 
agent or an increased dose 
*The acronym ITP should be followed by the name of the associated disease (for thrombocytopenia after exposure to drugs, 
the terms “drug-induced” should be used) in parentheses: for example, “secondary ITP (lupus-associated),” “secondary ITP 
(HIV-associated),” and “secondary ITP (drug-induced).” For manuscript titles, abstracts, and so on, definitions such as 
lupus-associated ITP or HIV-associated ITP can also be used. 
 
 
HISTORY: 
 
Idiopathic thrombocytopenic purpura (ITP), also known as immune 
thrombocytopenic purpura and autoimmune thrombocytopenic purpura, and most 
recently as immune thrombocytopenia12 has a long history. Purpura [the Latin 
derivative of the Greek word porphyra (Porfura), so-called for the purple-fish,  was 
recognized by the ancients, including Hippocrates and Galen, who described 
purpura associated with pestilential fevers.  Down the lane, Avicenna (10th century 
Arab physician), Amatus Lusitanus (1580) and Lazarus de la Rivie`re ([Riverius], 
France,1658) described purpura in association with fever and without fever.  
Idiopathic thrombocytopenic purpura (ITP) was first described by P.G. Werlhof in 
1735 as ‘Morbus Maculosus Hemorrhagicus.73,74   In 1951, works by Harrington, 
and Evans et al contributed to the understanding of the ‘immune component’ of  
ITP.     In the same year, Hirsch and Damashek described the important clinical 
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age when a female preponderance is observed in contrast to the equal sex 
distribution amongst cases of childhood ITP (prevalence rate ratio of 1.9 for 
female to male) and in the elderly. 29,36,40 A population based estimate of the 
incidence and survival of ITP in the UK reported that overall average incidence 
was statistically significantly higher in women (4.4, 95% CI: 4.1–4.7) compared to 
men (3.4; 95% CI: 3.1–3.7). 40 Among men, incidence was bimodal with peaks 
among ages under 18 and between 75–84 years. 40 A Danish group reported an 
annual incidence of adult ITP as 3.2 cases per 100,000 per year, with a median age 
of  56.4 years. In 2003, Neylon et al reported a median age at diagnosis of 56 years 
and noted an increased incidence in the > 60 year age group.21 
ETIOLOGY AND PATHOGENESIS:  
The precise mechanism underlying ITP remains largely unknown. Immune 
dysregulation and the development of auto-antibodies appear to play a major role. 
Auto-antibodies have been shown to cause accelerated platelet clearance.22 
In vivo plasma infusion studies by Harrington et al & Shulman et al first 
demonstrated that a plasma factor found in most patients who had ITP resulted in 
thrombocytopenia in normal individuals. 29 Subsequent plasma infusion studies by 
Shulman et al showed that the plasma factor destroyed both autologous and 
homologous platelets and that the thrombocytopenia effect was dose dependent 
and less pronounced in splenectomised recipients, those pretreated with 
corticosteroids, or after reticulo-endothelial blockade induced red cell membrane.49 
These auto-antibodies are mainly IgG, and occasionally IgM and IgA. They 
are present in about 50–70% of ITP patients and they recognize one or more 
platelet surface glycoproteins (GP) including GPIIb- IIIa, GPIb-IX and GPIa-IIa. 
Antibody-coated platelets are cleared via Fcγ receptors of macrophages in the 
reticuloendothelial system, particularly in the spleen. The auto antibodies are light-
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chain restricted with an over-representation of VH3-30 heavy chains. They are 
generated through the expansion of B cell clones under the control of T helper cells 
and the cytokines they produce. Th1 cytokines, IL-2 and IFN-γ are increased with 
reduced Th2 cytokines, IL-4 and IL-5, suggesting a type-1 cytokine polarization. 
The antigens that initiate the autoimmune response are altered platelet proteins or 
even viral or bacterial products that mimic these platelet peptides; 22   as suggested 
by  in vitro studies  that the CD4+HLA-DR restricted T cells of ITP proliferate 
when stimulated by GPIIb-IIIa tryptic peptides or recombinant fragments but not 
by intact GPIIb-IIIa polypeptide. 22 ,49   Mc Millan et al showed suppression of 
megakaryocyte production in vitro by ITP plasma containing anti- GPIb-IX  or 
anti-GPIIb- IIIa antibodies.79  
Besides antibody-mediated platelet destruction, cytotoxic Tcell-mediated 
lysis of autologous platelets has recently been demonstrated in vitro using 
CD3+/CD8+ lymphocytes of patients with active ITP. T cells interact intricately 
with B cells to cause antibody- and/or cell-mediated platelet destruction.22 
 Studies by several groups of investigators using indium-111 (111In)-labeled 
autologous platelets showed considerable heterogeneity in platelet turnover in 
chronic ITP. Although the platelet life span is often markedly decreased, in some 
patients the lifespan is only mildly reduced. Overall, approximately 40% of 
patients with ITP had a reduced platelet turnover.39 Increased  apoptosis and para-
apoptosis in ITP patients’ bone marrow megakaryocytes were demonstrated by 
ultrastructural studies done by Houwerzijl E et al, and  these changes were 
presumed to be caused by platelet autoantibodies in vivo (inhibiting 
megakaryopoiesis and pro-platelet formation). 22 
So far all the studies on ITP suggest immune system dysregulation as the 
primary abnormality. The exact mechanism of the immune dysfunction, however, 
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is generally not known. It is likely that genetic and environmental factors also have 
a role. 
Genetic factors:  There is a weak association with HLAB8DR3 in patients with 
ITP (Stanworth et al, 2002); linked to the development or clinical course of ITP in 
genetically homogeneous populations, such as the Japanese (Nomura et al, 1998). 
Nonetheless, immune recognition as a result of HLA may be critical in 
development of autoimmunity in heterogeneous populations as well. 24 
Environmental factors: 
Virus-associated ITP: Childhood ITP often occurs following a viral illness; 
probably initiates ITP either via molecular mimicry or B-cell stimulation. ITP is 
often associated with HIV (Bettaieb et al, 1992), Hepatitis C virus (HCV) infection 
(Pockros et al, 2002; Zhang et al, 2003) and EBV infection. 24 
MMR vaccine: Severe thrombocytopenia has been observed in children, in their 
second year of life following MMR vaccination. The exact pathogenesis is 
unclear.24 
Bacteria-associated ITP: H. pylori: There is strong evidence for an association 
between infection with H. pylori and ITP; related to molecular mimicry. H. Pylori 
strains shows geographic variations in the cytotoxin-associated gene A (CagA), 
which seems to correlate with the geographic variations in the incidence of H. 
Pylori associated ITP. 24 
CLINICAL FEATURES: 
The signs and symptoms of ITP may be generalized into two categories: dry and 
wet purpura. Dry purpura (cutaneous haemorrhage) appears as bruising or 
petechiae. In contrast, wet purpura is associated with bleeding of the mucous 
membranes including those of the gastrointestinal tract, mouth, nose and eyes. ITP 
in children is usually an acute self-limiting disease, characterized by the sudden 
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onset of petechiae or purpura approximately 2–3 weeks after viral infection or 
immunization. Boys and girls are affected equally and the peak of onset is 
normally around 5 yrs of age. In over 70% of cases, it resolves within 6 months.  
On the other hand, ITP in adults is usually persistent and chronic12 and has 
a subtle onset, with no prodromal illness. Some patients with ITP are 
asymptomatic or have only mild bruising while others with platelet counts below 
30 x109 ⁄L are thought to be at a high risk of serious bleeding events. Indeed, the 
most frequent cause of death in association with ITP is intracranial bleeding, with 
an estimated 5% rate of fatal haemorrhage in adults.22,26  
Physical examination usually reveals no abnormal signs, and specifically 
no splenomegaly. A study from the All India Institute of Medical Sciences, New 
Delhi, reported the incidence of presenting features as follows: skin bleed – 91.1%; 
mucosal bleed – 57.5%; hematuria – 7.2%; gastrointestinal bleed – 12.5% , 
intracraniall bleed – 2.8% and  per-vaginal bleeding – 31.2 % of females. History 
of preceding viral fever was seen in 13.1% and palpable spleen in 2.5%.84 
Table: 2 Diagnostic criteria for ITP27    
History 
Bleeding symptoms (type, severity, and duration of bleeding)
Systemic symptoms (weight loss, fever, headache, and symptoms of autoimmune disorders) 
Risk factors for HIV infection
Pregnancy status 
Medication (heparin, alcohol, quinine, sulphonamides, aspirin) 
Family history 
Physical examination 
Bleeding signs 
Liver, spleen, lymph nodes, and jaundice
Evidence of infection, autoimmune disease, and thrombosis 
 
Isolated thrombocytopenia (low platelet count with an otherwise normal complete blood 
count and blood smear) 
 
Exclusion of pseudothrombocytopenia (EDTA artefact) 
Absence of 
Other autoimmune diseases 
Disseminated intravascular coagulation 
Drug-induced thrombocytopenia 
HIV infection 
Lymphoproliferative disorders 
Myelodysplasia 
Agammaglobulinaemia 
Allo immune, congenital or hereditary thrombocytopenia 
10 
 
Clinical history and physical examination (Table:2) should be directed 
specifically to exclude thrombocytopenia secondary to diseases such as systemic 
lupus erythematosus, antiphospholipid syndrome, immunodeficiency states, 
lymphoproliferative disorders, infection with human immunodeficiency virus, 
hepatitis C and H. pylori, as well as acquired thrombocytopenic disorders (e.g., 
bone marrow disorders and liver disease).  
 
DIAGNOSIS: 
ITP remains a diagnosis made after exclusion of other causes of thrombocytopenia. 
Laboratory studies (Table 3, & 4) and history are the mainstay of diagnosis.20 It is 
usually not necessary to perform a bone marrow aspirate with isolated 
thrombocytopenia if a thorough physical examination and review of the blood 
smear is performed. However, bone marrow examination is recommended in the 
following situations; more than one cell lineage is decreased and the patient has 
splenomegaly or adenopathy, patients scheduled for splenectomy, adults with 
atypical features at diagnosis or in those >60 years, and  prior to administration of 
medications such as steroids, which might confound the diagnosis of leukemia, 
delay therapy, or trigger an unrecognized tumor lysis syndrome. 20,21,22,27,70 
 Antiplatelet autoantibody testing has flourished over the past 20 years, but 
it is rarely used to make the diagnosis of acute ITP in children as the other forms of 
thrombocytopenia, can generally be readily distinguished without this assay. 
Assays used to identify target antigens on the platelet surface have been used to in 
clinical research along with measurement of platelet bound autoantibody isotype 
using flow cytometry to determine whether certain antibodies are more likely to 
predict a more severe or chronic form of ITP. 20 Although there are techniques 
available to measure antibodies with glycoprotein IIb/IIIa and Ib/IX, IV and V 
11 
 
specificity, both platelet-associated and free in the plasma, the lack of sufficient 
sensitivity makes them of little diagnostic value. 20,22   
Table:3 Common laboratory tests in thrombocytopenic patient at presentation.20 
Complete blood count and 
differential review smear  
 
Rule out: Multilineage involvement leukemia or 
aplastic/myelodysplasia 
Evaluate platelet size (giant or “dust-like”) 
Reticulocyte count  Hemolytic anemia or chronic blood loss
Blood type, Rh, antibody 
screen 
Possible anti-D antibody treatment 
 Autoimmune hemolytic disease 
Chemistry panel  
 
Eliminate systemic disease, i.e., hemolytic uremic syndrome, 
hepatitis, hemolysis, occult malignancy with elevated LDH or uric 
acid 
DIC screen  Sepsis, Kasabach-Merritt syndrome
Quantitative 
immunoglobulin levels  
Rule out: common variable immune deficiency,  
Wiscott-Aldrich syndrome 
Viral titers/PCR  
 
Cytomegalovirus, Epstein-Barr virus, 
Human immundeficiency virus 
Collagen vascular panel 
(ANA, anti-DNA)  
Older patients, especially those with more chronic onset 
 
 
Table:4 Specialized laboratory tests evaluated as ITP diagnostic tools26 
 
• The direct platelet immunofluorescence test (PIFT) may be used to detect the presence of 
platelet-associated utoantibodies, particularly in patients with bone marrow failure and 
immune-mediated thrombocytopenia, and drug-dependent immune thrombocytopenia.  
PIFT may also be used to monitor the effect of third-line treatment in ITP patients refractory 
to first- and second-line treatments 
• A thrombopoietin (TPO) assay may be useful in distinguishing between reduced platelet 
production (high TPO level) and increased platelet destruction (normal-to-low TPO level) as 
a cause of low platelet levels (33); however, this test is not readily available and its routine 
use is not justified in the diagnosis of adult patient 
• Measurement of platelet RNA by flow cytometry can be used to assess platelet maturity; 
reticulated platelets increase with platelet production (28, 34), but again this test is not 
considered to be of great benefit in ITP patients 
• Serological assays and breath tests can be used to detect for the Helicobacter pylori 
microorganism that has been reported in someITP patients (28). Eradication of H. pylori may 
result in an increased platelet number and it is worthwhile testing for it, especially in 
countries of high background incidence 
• Fluorescent antinuclear antibody testing can be used to indicate chronicity in adult and 
childhood ITP (35); however, its routine use in the diagnosis of ITP patients is not considered 
beneficial 
 
TREATMENT: 
Principles of management: 
Hemostatic platelet count: The primary aim of treatment of patients with ITP is 
to maintain a hemostatic but ‘not’ necessarily a normal platelet count. The risk of 
bleeding is minimal when the platelet count is above 30 x109/L; below that level 
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the bleeding risk increases progressively, and it is highest <10 x109/L. Major 
bleeding including intracranial hemorrhage usually occurs when the platelet count 
is <20 x109/L. However, the presence of other risk factors can increase the risk of 
bleeding such as (i) old age, (ii) platelet dysfunction, (iii) coagulation defects, (iv) 
anatomic defects (active peptic ulcer, recent surgery and multiple trauma), (v) 
uncontrolled hypertension, and (vi) infection. In the presence of these risk factors, 
the platelet count should be kept at a higher level, >50 x109/ L, or higher 
depending on the clinical situation.12,22 
Emergency treatment: ITP patients with severe thrombocytopenia will require 
their platelet count to be raised rapidly if they have a major bleed or if they need 
emergency surgery. Emergency treatment includes methylprednisolone (1.0 g/ day 
in adults & 30 mg ⁄ kg ⁄ day in children IV for 3 days) and/or high-dose IVIG (1.0 
g/kg/ day for 2 days) .  Anti-D immunoglobulin (75µg/kg IV) may also be used in 
Rh D-positive presplenectomy individuals. Supportive treatments include; 
fibrinolysis inhibitors ( tranexamic acid, [cyklokapron], ε-aminocaproic acid 
[Amicar]), direct pressure on accessible bleeding sites (e.g., nasal packing) and 
progestational agents (to control menorrhagia) and Recombinant factor VIIa  (in 
uncontrolled bleeding).22,42 
Pre-splenectomy therapy: 
Initial treatment: 
 In patients with platelet counts <30 x109/ L), the aim of treatment is to obtain a 
stable, safe count and minimal side effects. Treatment options include 
corticosteroids, IVIG and anti-D.22,42 
Corticosteroids:  Prednisone is started at a dose of 1 mg/kg, and after 2–4 weeks 
the dose is tapered slowly to maintain a safe count with minimal side effects.  A 
good initial response is seen in 85% and a sustained response in 50%. This 
13 
 
regimen has advantages in being inexpensive and avoiding side effects from 
prolonged steroid treatment such as osteoporosis, impaired glucose tolerance, 
opportunistic infections and emotional lability. 22A single randomized trial showed 
no difference in response to low dose 0.25 mg⁄ kg ⁄ d vs 1 mg⁄ kg ⁄ d in 160 children 
and 223 adults (Bellucci et al, 1988). Long-term remission is seen in only 10–20% 
of patients following cessation of prednisolone therapy.42 
Other steroid regimen: 
High dose methyl prednisolone: A small study (Ozer et al, 2000) on 22 
children given an oral 7 day course (30 mg ⁄ kg ⁄ d for 3 days followed by 20 mg ⁄ 
kg ⁄ day for 4 days) demonstrated that all patients achieved platelet counts > 50 x 
109 ⁄ L by day 7. Courses were repeated monthly if the count was less than 20 x109 
⁄ L on day  30, for up to six courses.42 
Pulsed high dose dexamethasone: Pulsed high dose dexamethasone. This 
treatment appears to be less effective in children than in adults in producing long-
term remission, but may be useful as a temporary measure. Three small studies of 
11 (Kuhne et al, 1997), 17 (Borgna-Pignatti et al, 1997) and 7 children (Chen et al, 
1997) demonstrated some benefit in some children – 78% children achieved a 
platelet count > 100 x 109 ⁄ L within 72 hours in 41 cycles of treatment given to 11 
children with chronic ITP. 42 
IVIG:  Appropriate dose of IVIG is 1 g/kg/ day for 1 day, and 2 days for severe 
ITP. Non-responders may benefit from another dose on day 3. IVIG only has a 
transient effect with median time to relapse of 11 days.22 IVIG is generally well 
tolerated, the adverse reactions include headaches, fever, nausea, and increased 
blood pressure. Caution must be applied to patients with IgA deficiency and in 
particular, those with diabetes mellitus, preexisting renal disease, and old age (>70 
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years) in view of the reports of renal impairment with sucrose-containing 
preparations. 22 
Anti-D immunoglobulin: This should be given only to Rh-positive patients pre-
splenectomy. IV intermittent infusions can be given at 50–75 µg/kg/day whenever 
the platelet count drops below 30 x109 /L.22 Anti-D immunoglobulin can rarely 
cause intravascular haemolysis and disseminated intravascular coagulation. Anti-D 
should not be used, or used with extreme care, in patients with a positive direct 
antiglobulin test and a haemoglobin level that is less than 10 g/dl, due to the risk of 
increasing the severity of the anemia.39 
 
Subsequent treatment: If the platelet count remains persistently below 30 x109 /L 
on low-dose steroid, danazol or azathioprine is usually added. Another alternative 
is to use rituximab (anti-CD20). Other options are also available; the choice of any 
particular treatment depends on the physician’s preference. 22   
The aim of treatment is to keep the platelet count at a safe level without 
significant toxicity for 3–6 months until a decision on splenectomy is made or until 
remission is achieved.22 According to the recent recommendation by the 
International Working Group,  chances of spontaneous remissions are still 
significant during the 3-12 months period from diagnosis, making deferral of more 
aggressive therapeutic approaches (such as splenectomy) worthy of 
consideration.12 
 
Splenectomy: Splenectomy removes not only the site of platelet destruction but 
also an organ containing autoantibody-producing B-cells. It is the single most 
effective therapy for chronic adult ITP with a complete durable response rate of 
15 
 
66% and an additional of 22% partial response.22 Splenectomy is recommended if 
(i) safe platelet counts 
cannot be maintained; (ii) remission is considered unlikely; (iii) drug toxicity is 
severe; or (iv) treatments become burdensome, e.g., frequent blood tests or loss of 
work time, etc. Splenectomy used to be usually recommended 3–6 months after 
initial diagnosis. The International Working Group (June,2007), recommends to 
defer splenectomy during the first 3-12 months from diagnosis as chances of 
spontaneous remissions are still significant during this period.12 
 
However, in practice splenectomy is often delayed due to various reasons. 
The procedure is generally safe (mortality rates of 0.2 and 1.0% with laparoscopy 
and open laparotomy, respectively).22 Laparoscopic surgery is associated with 
lower morbidity, speedier recovery, and shorter hospitalization. Patients with 
counts <50 x 109/L may require pre-splenectomy treatment such as IVIG, anti-D, 
or steroids to boost the platelet count. Intra-operative platelet support may be 
necessary in patients who still have severe thrombocytopenia but platelets should 
be given after the splenic artery has been clamped.22 
 
Long-term complications of splenectomy are overwhelming bacterial sepsis 
and thrombosis; both are rare. The incidence of fatal infection after splenectomy is 
approximately 0.73 per 1000 patient-years. The patient should be immunized using 
haemophilus influenzae type b, pneumococcal and meningococcal vaccination at 
least 2 weeks prior to surgery. The BCSHTF guidelines recommend life-long 
prophylactic phenoxy-methypenicillin or erythromycin to reduce the incidence of 
post-splenectomy pneumococcal infection. Revaccination with pneumococcal 
vaccine is required every 5 years. 22 
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Post-splenectomy treatment: 
(also applies to those unfit or unwilling to have splenectomy) 
There is little or no evidence-based data to guide management in post-splenectomy 
ITP patients. One major difference between the initial treatment and post 
splenectomy treatment is that the latter is likely to be prolonged, and may last for 
months and even years. 22A systemic review by Wesely et al showed that the post-
splenectomy patients may be quite refractory to treatment; about 46% failed to 
respond.3 The aim is again to attain safe platelet counts with minimal drug toxicity. 
Patients with platelet counts persistently below 30x109/L may be treated but those 
with counts<10x109/L has a greater need of treatment 
First-line therapy:  
Patients who relapse after splenectomy usually respond to drugs used in the 
initial treatment such as corticosteroids and IVIG if they had responded previously. 
The exception is anti-D which is not effective in post-splenectomy patients. As the 
patients are likely to require more prolonged treatment, it is important to minimize 
or prevent drug toxicity, e.g., monitoring bone density in those on long-term 
corticosteroid. Another strategy is to use drug combinations such as prednisone 
and danazol (400–800 mg daily), taking advantage of its effect in reducing steroid 
dose. Experts now advocate the use of Rituximab (Mabthera, anti-CD20 chimeric 
fab) as a first-line therapy. The treatment regimen is the same as for treatment of 
lymphoma (IV 375 mg/ m2 /week for 4 weeks). A response can occur as early as 4 
weeks but may be delayed up to 4 months. Durable complete response rates of 
about 24% and partial response in another 34–43% have been reported.22 
Dapsone: Dapsone at a dose of 75–100 mg daily orally may be given to older 
patients instead of long-term prednisone to avoid steroid side effects. Male patients 
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must be screened for G6PD deficiency. Response, if it occurs, is seen within 2 
months but often does not last after cessation of treatment.22 
Vinca alkaloid: Vincristine 1–2 mg/IV weekly for 4–6 weeks, usually results in a 
transient platelet increase in two-thirds of patients lasting between 1 and 3 weeks. 
It is often used only as an adjunctive therapy.22 
Second-line therapy:  
Azathioprime:   Azathioprine is given in a dose of 2 mg⁄kg, usually up to a 
maximum of 150 mg⁄day; dose is adjusted to obtain a maximum effect without 
causing significant neutropenia. With azathioprine, the complete response rate is 
estimated to be ~18% and partial response rate 47–66%.22Azathioprine is slow-
acting, and should be continued for up to 6 months before being deemed a failure. 
When a platelet response occurs the dose should be reduced, while maintaining a 
safe platelet count. 42 
Cyclophosphamide:  Cyclophosphamide is an alkylating agent given at a dose of 
1-2mg/kg/day. Complete response is seen in 27–39% and partial response 29–35%. 
Side effects include myelosuppression, hemorrhagic cystitis and in the long-term 
second malignancy and MDS. It should be avoided as much as possible in young 
patients, particularly females in the reproductive age group.22 
Cyclosporine A:  Cyclosporine A is given at 1.25–2.5 mg /kg/day in two divided 
doses. The dose is adjusted according to the recommended plasma drug levels. The 
potential serious adverse effects are renal impairment, hepatotoxicity, 
hypertension, and secondary malignancies. 22 
Third-line therapies: 
 
For those who fail first- and second-line therapies, there are very few therapeutic 
options. Management of these patients is a dilemma. In old patients (>60 years) the 
morbidity and mortality are high, and in the young, their prognosis is unclear and 
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unpredictable. Many young healthy patients can tolerate persistently low platelet 
counts for several years without significant bleeding and yet they may suddenly 
suffer a fatal bleed during an infection or after incidental trauma. There is no 
evidence-based recommendation to treat or not to treat these patients. In some 
patients no treatment is an option. If a decision is made to treat, the options 
include: 
1.  High-dose cyclophosphamide: 1g/m2 once every 4 weeks alone or in 
combination with other cytotoxic agents as used in the treatment of 
lymphoma. 
2.  Mycophenolate mofetil:  0.5–1.0 g twice daily orally may result in partial 
response (57–71%) within 3–4 weeks. Association with secondary 
lymphoproliferative disorders and acute leukemia has been reported. 
3. Combination immunosuppressive therapy with azathioprine (100–200 
mg /day), cyclosporine (100–200 mg/day), and mycophenolate (1–2 
gm/day). It is well tolerated and a 46% response within 4–6 weeks has been 
reeported.22  
4.  Monoclonal antibody Campath-IH (anti-CD52) has been used in only a 
few patients with partial successes but is associated with significant side 
effects. 22 
5. Staphylococcal-Protein A (Staph-A) immunoadsorption column: This 
has less favorable results and significant toxicity (fever, chills, rash, 
respiratory distress, diarrhea, vasculitis, etc.). Although six treatments are 
recommended, most experts suggest a trial of three and then cessation of 
therapy if no response.22 
6. Campath-1H: Lim et al (1993) treated six patients with refractory ITP 
(three patients had underlying CLL ⁄ non-Hodgkin’s lymphoma and one 
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had Hodgkin’s disease). A response was seen in four of five evaluable 
patients, and in three of these the response lasted more than 4–9 months. In 
most cases it took between 4 and 6 weeks for a response to occur. Side 
effects were significant and included rigors and fever during the infusion, 
and marked lymphopenia (< 0.1x109⁄L) in all patients treated. Worsening of 
thrombocytopenia was noted in two patients during therapy. A more recent 
study of the use of Campath-1H in patients with a variety of cytopenias has 
shown that it was well tolerated with encouraging responses.42 
 
Experimental therapy: Stem cell transplantation has been tried in a limited 
number of patients with refractory ITP with reasonable success. In a recent study 
reported by Huhn et al, 14 refractory ITP patients underwent G-CSF-mobilized 
hematopoietic stem cell transplant using high-dose cyclophosphamide (50 mg/kg/ 
day) for conditioning. Six patients had good durable responses (platelets >100x109 
/L) with no ongoing treatment, and two partial responses over a maximum follow-
up of 42 months. The procedure was fairly well tolerated with a few bleeding 
events, febrile episodes in all patients but no death. 22 
Thrombopoietic agents: Thrombopoietin (TPO) is a potent endogenous cytokine 
and the principal regulator of platelet production. The first generation of 
thrombopoietic growth factors are recombinant human thrombopoietin (rhTPO) 
and pegylated human recombinant megakaryocyte growth and development factor 
(PEG-rHuMGDF). Although clinical results showed that these agents were 
effective in promoting increases in platelet counts, clinical development was halted 
when studies demonstrated risk for autoantibody formation with cross-reactivity to 
endogenous TPO. A second generation of thrombopoietic growth factors, 
including TPO peptide and nonpeptide mimetics and TPO agonist antibodies, 
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utilizing different mechanisms to promote platelet production, are currently in 
development. The TPO peptide mimetic AMG531 and the nonpeptide mimetic 
eltrombopag are in advanced clinical trials and have both resulted in dose-
dependent increases in platelets in healthy subjects and in significant increases in 
platelets in patients with chronic immune thrombocytopenic purpura (ITP). 
Currently available data on second-generation thrombopoietic growth factors 
(AMG 531,eltrombopag, AKR-501) suggest no evidence of the same risk for 
creating autoantibodies that will neutralize endogenous 
TPO. Long-term treatment with thrombopoietic growth factors may lead to 
increased bone marrow reticulin or deposition of collagen.62 
 
Other experimental therapies: In a recent report, three consecutive patients with 
chronic refractory ITP responded completely to treatment with etanercept, an 
inhibitor of tumor necrosis factor- α. These patients had failed 6–11 previous 
treatments.22 
Others include a monoclonal antibody against Fcγ RI (MDX-33), CTLA-4 
immunoglobulin or anti-CD40 ligand. The latter trial was stopped early because of 
thrombosis. 22 
 
RESPONSE TO TREATMENT: 
Definition of response: The definition of a treatment response according to the 
current recommendation by IWG is that; it should ideally reflect clinically 
important endpoints including bleeding and quality of life, rather than rely 
exclusively on surrogate end points (platelet count) with arbitrary thresholds. 
Nevertheless, the platelet count is a useful measure of response that is objective, 
clinically relevant, and easily compared (Table:5 & 6)  
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Table :5 Proposed criteria for assessing response to ITP treatments: 12 
Quality of response*† 
● Complete response (CR): platelet count ≥ 100 x109/L and absence of bleeding 
● Response (R): platelet count ≥ 30 x109/L and at least 2-fold increase the baseline count 
and absence of bleeding 
● Time to response: time from starting treatment to time of achievement of CR/R‡ 
● No response (NR): platelet count < 30 x109/L or less than 2-fold increase of baseline 
platelet count or bleeding 
● Loss of CR or R: platelet count below 100 x109/L or bleeding (from CR) or 
below 30 x109/L or less than 2-fold increase of baseline platelet count or 
bleeding (from R) 
Timing of assessment of response to ITP treatments
● Variable, depends on the type of treatment 
Duration of response§ 
● Measured from the achievement of CR or R to loss of CR or R 
● Measured as the proportion of the cumulative time spent in CR or R during the 
period under examination as well as the total time observed from which the 
proportion is derived 
Corticosteroid-dependence 
● The need for ongoing or repeated doses administration of corticosteroids for at 
least 2 months to maintain a platelet count at or above 30x109/L and/or to 
avoid bleeding (patients with corticosteroid dependence are considered 
nonresponders) 
Supplemental outcomes (whenever possible) 
 
● Bleeding symptoms measured by a validated scale (requires additional 
studies) 
● Health-related quality of life assessment measured by a validated instrument 
(requires additional studies) 
*Platelet counts should be confirmed on at least 2 separate occasions (at least 7 days apart when used to define CR, R) or 1 day apart when 
used to define NR or loss of response. 
†Baseline platelet count refers to platelet count at the time of starting of the investigated treatment; for post-splenectomy response evaluation, 
basal platelet count refers to the platelet count before patient was first treated (initial treatment). ‡Late responses not attributable to the 
investigated treatment should not be defined as CR or R (see Table 3). §The 2 definitions are not mutually exclusive: the first definition, 
collectively represented using Kaplan-Meyer analysis, is more suitable for short-course treatments aimed at inducing prolonged remission of 
the disease, whereas the second one is more suitable to evaluate the overall benefit of continuous or intermittent repeated administration of 
agents requiring dose adjustments with anticipated temporary losses of CR or R. 
 
Table.6: Individual agents for treatment of ITP and the time to the first and peak 
responses if using the reported dose range.12 
Agent/treatment  
 
Reported dose range  Time to initial 
response*  
Time to peak 
response* 
Prednisone 1-4 mg/kg po daily x 1-4 wk 4-14 d 7-28d 
Dexamethasone  40 mg po or iv daily x4 d for 4-
6 courses every 14-28 d 
2-14 d 4-28d 
IVIg 0.4g-1 g/kg per dose iv (1-5 
doses) 
1-3 d 2-7d 
Anti D 75μg/kg per dose iv  1-3 d  3-7 d 
Rituximab  375 mg/m2 per dose iv (4 
weekly doses)  
7-56 d  14-180 d 
SPLENECTOMY LAPAROSCOPIC 1-56 Days 7-56 Days 
Vincristine   up to 2 mg/dose iv (46 weekly 
doses)  
7-14 d  7-42 d 
Vinblastine 0.1 mg/kg per dose iv (6 
weekly doses)  
7-14 d  7-42 d 
Danazol  400800 mg po daily 14-90 d 28-180 d 
Azathioprine 2 mg/kg po daily 30-90 d 30-180 d 
AMG531 3-10μg/kg weekly sc  5-14 d  14-60 d 
Eltrombopag 50-75 mg po daily  7-28 d  14-90 d 
 
22 
 
After splenectomy, the timing to assess the response in terms of platelet 
count should be within 1 to 2 months after surgery and removed from any 
treatment. Late responses not attributable to the investigated treatment 
(“spontaneous remission”), are not be defined as CR or R.12 
REFRACTORY ITP: (Definition, therapeutic goals, and response 
assessment12 
Refractory ITP (Table:7) 
Definition (all should be met) 
● Failure to achieve at least R or loss of R after splenectomy 
● Need of treatment(s) (including, but not limited to, low dose of corticosteroids) to minimize 
the risk of clinically significant bleeding. Need of on-demand or adjunctive therapy alone does 
not qualify the patient as refractory. 
● Primary ITP confirmed by excluding other supervened causes of thrombocytopenia 
Definition of on-demand therapy 
● Any therapy used to temporarily increase the platelet count sufficiently to safely perform 
invasive procedures or in case of major bleeding or trauma 
Definition of adjunctive therapy 
● Any non-ITP specific therapy that may decrease bleeding (eg, antifibrinolytic agents, 
hormonal agents, DDAVP, recombinant factor VIIa, fibrin sealants).  
Platelet transfusion is also included. 
Definition of response to therapy in refractory ITP 
● Ability to maintain a platelet count sufficient to prevent clinically significant bleeding 
● Ability to decrease toxic therapy (eg, corticosteroids) does not qualify for response but 
should be reported 
Definition of response to on-demand therapy 
● Control of bleeding in the specific situation 
● Achievement of a platelet count sufficient to perform procedure or minimize bleeding from 
trauma 
 
The main goal of therapy in refractory ITP is generally the achievement of 
a platelet count sufficient to prevent clinically significant bleeding with the least 
toxicity. So, in this population, treatments should be evaluated for the potential to 
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induce an acute response and also a long-lasting response with minimum side 
effects/toxicity. As for any other phase of the disease, adjunctive or combination 
therapy or even platelet transfusion may be required for severe mucosal/organ or 
life-threatening bleeding.12 
 
CONCLUDING REMARKS: 
ITP is an autoimmune disorder in which platelets are destroyed by an antibody 
mediated and cytotoxic T cell-mediated process. Diagnosis is made clinically by 
exclusion of other causes of thrombocytopenia. Only patients with a persistently 
low platelet count of <30 · 109 L)1 require treatment. The initial treatment is 
corticosteroid, high-dose IVIG or anti-D. After 3–12 months, if it is not possible to 
maintain a safe platelet count with minimal drug side effects, splenectomy is 
recommended. This has a complete response rate of about 66%.22 A patient who 
fails 
splenectomy, first- and second-line therapies, is a management dilemma. The 
therapeutic option is no treatment, third-line treatment, or experimental therapy. 
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AIMS AND OBJECTIVES 
 
1. To analyze the response to splenectomy in children and adults with persistent 
 and chronic immune thrombocytopenia.  
2. To assess response to treatment of refractory immune thrombocytopenia in  
children and adults.  
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PATIENTS AND METHODS 
This study protocol was approved by our Institutional Review Board (IRB). 
Duration of the Scheme: January 1995 to July 2009.  
Settings of the study: Department of Clinical Hematology,  
Diagnostic criteria: Immune thrombocytopenia (ITP) was diagnosed, according to 
the guidelines of the American Society of Hematology, as isolated 
thrombocytopenia (peripheral blood platelet count <100 x109/L)12 in a patient who 
has no clinically apparent associated conditions or factors that can cause 
thrombocytopenia, including human immunodeficiency virus (HIV) infection, 
systemic lupus erythematosus, lymphoproliferative disorders, myelodysplasia, 
agammaglobulinemia, therapy with certain drugs, alloimmune thrombocytopenia, 
and congenital or hereditary thrombocytopenia12 .  
Splenectomy was generally performed when patients did not respond to medical 
therapy. 
PATIENTS   
Inclusion criteria: 
All patients seen in the Department of Clinical Haematology between 
January 1995 to July 2009 with persistent or chronic immune thrombocytopenia12, 
and had undergone therapeutic splenectomy were included in this study if they had 
a minimum follow up of 3 months.  
Exclusion criteria: 
• Patients with insufficient data to assess response (a minimum of 2 post 
splenectomy platelet counts at least one week apart). 
• Patients who underwent splenectomy within 3 months from the date of 
diagnosis (newly diagnosed immune thrombocytopenia).  
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METHODS 
Data collection:  
After approval by the IRB, the patient data base at our institution were reviewed to 
identify all adults (age > 14 years) and children (age ≤ 14 years) with ITP who 
underwent splenectomy at our institute from January 1995 to July 2009. 
Prospective cases were enrolled as and when splenectomy was performed. Medical 
information (regarding the clinical details at diagnosis, pre-splenectomy treatment, 
splenectomy, post splenectomy status and follow up and other co-morbidities) and 
blood counts were obtained from the patients themselves or parents in case of 
children, or review of their hospital records (laboratory reports/ physician 
documentation in hospital charts/hospital discharge summaries). Repeated attempts 
were made to contact all patients via mail (postal/electronic) for further follow up 
information, including details of any subsequent treatment. Patients who did not 
get reviewed in the last one year, and/or who failed to respond to repeated attempts 
of communication through mail (postal/electronic) were categorised as ‘lost to 
follow up’.  
Response criteria: 
The definition of response criteria12 was as follows: 
• Complete response (CR): Platelet count ≥ 100 x109/L and absence of 
bleeding. 
• Response (R): Platelet count ≥ 30 x109/L and at least 2-fold increase the 
baseline count and absence of bleeding.  
• Time to response: Time from starting treatment (splenectomy) to time of 
achievement of CR or R.  
• No-Response (NR): Platelet count < 30 x109/L or less than 2-fold increase 
of baseline platelet count or bleeding. (Late responses not attributable to the 
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investigated treatment (splenectomyare defined as “spontaneous 
remission”). 
• Loss of CR or R: platelet count below 100 x109/L or bleeding (from CR) 
or below 30 x109/L or less than 2-fold increase of baseline platelet count or 
bleeding (from R). 
• Time to loss of Response: Time from attaining R or CR post splenectomy 
to loss of R (platelet count below 30 x109/L or less than 2-fold increase of 
baseline platelet count or bleeding [from R]). 
• Duration of response: Measured from the achievement of CR or R to loss 
of CR or R; measured as the proportion of the cumulative time spent in CR 
or R during the period under examination as well as the total time observed 
from which the proportion is derived.  
• Corticosteroid-dependence: The need for ongoing or repeated doses 
administration of corticosteroids for at least 2 months to maintain a platelet 
count at or above 30x109/L and/or to avoid bleeding (patients with 
corticosteroid dependence are considered non-responders. 
• Refractory ITP: Definition (all should be met) 
o Failure to achieve at least R or loss of R after splenectomy. 
o Need of treatment(s) (including, but not limited to, low dose of 
corticosteroids) to minimize the risk of clinically significant bleeding.† 
Need of on-demand or adjunctive therapy alone does not qualify the 
patient as refractory. 
o Primary ITP confirmed by excluding other supervened causes of 
thrombocytopenia. 
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Data analysis:  
 
Statistical analyses were performed with SPSS (windows 11.01 version, SPSS inc, 
Chicago), for all variables. Descriptive statistics was calculated for all variables. 
The χ2 test/ Fishers exact test or t-test / Mann Whitney U test was used as 
appropriate to compare the differences between groups for response to therapy. 
Overall survival (OS) was defined as the time from initiation of treatment to death 
or lost follow up. Event free survival (EFS) was defined as the time from initiation 
of treatment till first event or lost follow up. The event can be loss of response or 
death. The probability of OS and EFS was estimated using Kaplan-Meier method. 
For all tests, a two-sided p-value of 0.05 or less was considered statistically 
significant.  
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RESULTS: 
 
Patients with ITP were categorized as adult and children ie; patients aged >14 
years were considered as adults and those with age ≤ 14 years as children (age 
corrected to the nearest whole number). After applying afore mentioned inclusion 
and exclusion criteria, a total of 271 patients (173 adults and 98 children) were 
included in the study. This comprises 21.4% of the total splenectomies (n=1263)  
and 84% of the splenectomies done for ITP (n=322; including 271 cases of 
persistent and chronic ITP, 5 cases of newly diagnosed ITP,  6 cases of SLE, 12 
cases of Evan’s syndrome and 28 cases of ITP splenectomy with no details 
available) during the study period in this institution.   
 
Of the 271 cases, for 11 children (4 male: 7 female) and 6 adults (3 male:3 
female), two post splenectomy platelet values at 1 week apart couldn’t be obtained 
from the retrievable data. These are excluded from the subsequent analysis as they 
do not satisfy the criteria for response/no response. 
 
The results of the remaining 254 patients (167 adults and 87 children) are 
analysed below. Certain data are available on all patients while other data are 
available only on a portion of the patients. For each result category, the numbers of 
patients involved are mentioned. Adults and children are analyzed separately 
beneath each heading. 
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A. ANNUAL DISTRIBUTION OF CASES: (Fig:1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Among the analyzed cases (n=254), the average number of splenectomy per year was 17 (11 adults and 6 children).  
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B. DEMOGRAPHICS OF ITP PATIENTS: 
Table.1:  Age and sex distribution: 
       
 
 
 
 
 
 
 
 
Patient variables 
 
ADULTS (n=167)  CHILDREN (n=87) 
n (%)/ 
Median (Range) 
n (%)/ 
Median (Range) 
Total cases 
 Age at diagnosis (years) 
 
24 (5-64) 
 
8 (2-14) 
 Age at splenectomy (years) 27 (16-65) 10 (4-14) 
 Male :Female  44:123 49:38 
Persistent ITP    
Number of cases 74 (44.3) 29 (33.3) 
Age at diagnosis (years) 28 (9-64) 9 (5-14) 
Age at splenectomy (years) 28 (15-65) 10 (6-14) 
Male :Female 16:58 17:12 
Chronic ITP   
Number of cases 93 (55.7) 58 (66.7) 
Age at diagnosis (years) 23 (5-60) 7 (2-13) 
Age at splenectomy (years) 27 (15-61) 10 (4-14) 
Male : Female 28:65 32:26 
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C. PRE-SPLENECTOMY VARIABLES: 
Table.2: Clinical features at diagnosis: 
 
Patient Variables  
 
ADULTS 
(n=167) 
CHILDREN 
(n=87) 
n (%) n (%) 
Symptoms at diagnosis 
           Asymptomatic  
 
2 (1.2) 
 
1 (1.2) 
          Skin bleed only 29 (17.4) 37 (42.5) 
          Oro-nasal bleed only* 5 (3) 3 (3.4) 
          Skin+/oro-nasal ± other bleed# 54 (32.3) 40 (45.9) 
          Menorrhagia ± any other bleed 69 (41.3) 4 (4.6) 
          IC bleed$ ± any other bleed 6 (3.6) 1 (1.2) 
          Data not available 2 (1.2) 1 (1.2) 
Platelet count at diagnosis ** 
Median platelet count  (1x109/L)          
 
10 (1-65) 
 
10 (1-41) 
Patients with platelet count  ≤ 10 x 109/L 76 (56.3) 32 (55.2) 
Patients with platelet count 11-30 x 109/L 49 (36.3) 22 (37.9) 
Patients with Platelet count 31-100x109/L 10 (7.4) 4 (6.9) 
* Gum bleeds and epistaxis   
#Gastrointstinal bleed (hematemesis, malena, hematochezia), Hematuria, subconjuctival bleed, post 
surgical bleed (dental extraction, TURP), $ In adults, 3 patients had intra-cerebral bleed and  other 3 
had subdural hematoma. In children the 1 case was with subarachnoid + vitreous bleed.  
**Data for the platelet count at diagnosis was available only for 135 adults and 58 children. 
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Table.3:  Co-morbidities at diagnosis: 
Patient Variables 
 
ADULTS  
(n=167) 
CHILDREN 
(n=87) 
n (%) n (%) 
Co-morbidities   
    Hypothryoidism on treatment* 11 (6.6) -- 
    Hypertension/IHD/RHD^                        9 (5.4) 1 (1.2) 
    Diabetes mellitus  10 (6) 1 (1.2) 
    H/o Tuberculosis/Hansen’s disease# 5 (3) 1 (1.2) 
    Others$ 19 (11.4) 6 (6.8) 
    Nil  111 (66.4) 76 (87.3) 
    Data not available 2 (1.2) 2 (2.3) 
* One female patient was diagnosed to have Hashimoto’s thyroiditis and another one had associated weak ANA positivity.  
^ 2 adults had IHD.  1 child had history of Rheumatic heart disease (RHD)  
# One adult had history of treatment for Hansen’s disease and all others had history treatment for pulmonary tuberculosis..  
 $ Osteoarthritis, peripheral neuropathy, benign serous cystadenoma ovary, iron deficiency anemia, fistula in ano,  
   thalassemia  minor, choledochal cyst.  
 
Table.4:  Other laboratory parameters at diagnosis 
 
Laboratory Variables 
 
ADULTS  
(n=167) 
CHILDREN 
(n=87) 
n (%) n (%) 
Auto-immune markers * 
      Antinuclear antibody:         Positive        
 
24 (14.4) 
 
7 (8) 
      Direct coombs test:             Positive        20 (12) 9 (10.3) 
Viral markers (n=162/83) 
      Hepatitis C antibody:           Positive       
 
-- 
 
1 (1.2) 
      Hepatitis B antigen :            Positive 2 (1.2) -- 
 
Data for auto-immune markers was available in 109 adults and 46 children; while for viral markers data was 
available in 162 adults and 83 children. 
 * 9 adults and 2 children were tested positive for both markers (ANA & DCT). 
 - 3 adults and 1 child with ANA positivity were refractory to splenectomy.  
- Among those positive for DCT, 5 adults and 5 children were refractory to splenectomy.  
- 2 adult females with ANA positivity (1 patient positive for both ANA & DCT), developed mixed connective 
tissue disorder 1 year after splenectomy. The patient positive for both markers turned out to be refractory ITP 
but attained response to azathioprine and is in response on drug at last follow up; while the other patient, an 
initial responder, continues to be in response.  
- One child who on follow up developed autoimmune myocarditis with left hemiparesis and transient ischemic 
attack (after10 years post splenectomy), was DCT positive and ANA negative at diagnosis. 
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Table.5: Treatment and response at diagnosis:  
 
Patient Variables  
ADULTS  
(n=167) 
CHILDREN 
(n=87) 
n (%) n (%) 
Initial treatment   
         Steroids*  
 
157 (94) 
 
78 (89.7) 
         IVIG (± Pred/M.pred) 7 (4.2) 9 (10.3) 
         Anti-D + Pred 1 (0.6) -- 
         Pred+Vincristine 1 (0.6) -- 
         Data not available  1 (0.6) -- 
Response to initial treatment    
   Patients who responded (R+CR) 97 (58.1) 47 (54) 
          Patients in ‘Response’ (R) 57 (34.1) 24 (27.6) 
          Patients in ‘Complete Response’ (CR) 40 (24) 23 (26.4) 
   Patients in  ‘No Response’ (NR)               68 (40.7)         40 (46) 
   Data not available 2 (1.2)            -- 
Pre-splenectomy Loss of R$   
          Patients with 1 Loss of R 46 (66.7) 22 (73.3) 
          Patients with  ≥ 2 Loss of R 23 (33.3) 8 (26.7) 
          Median number of Loss of R 1 (1-4) 1 (1-3) 
Subsequent treatment    
      Steroids  36 (21.6) 23 (26.4) 
      Dapsone ± steroid 32 (19.2) 14 (16.1) 
      Azathioprine ± steroid 18 (10.8) 5 (5.7) 
      Dapsone + Azoran ± steroid 42 (25.1) 25 (28.7) 
      Danazol ±steroid 4 (2.4) -- 
      Dapsone±Azoran + Danazol ± Steroid 8 (4.8) 5 (5.7) 
      Combination treatment#  17(10.2) 9 (10.3) 
      No treatment 8 (4.8) 2 (2.3) 
      Data not available 2 (1.2) 4 (4.6) 
 
*Prednisolone/Methyl Prednisolone/ Dexamethasone/ Hydrocortisone. 
$Proper documentation of loss of Response was available only in 69 adults and 30 children. 
#Combination of above drugs with either cyclosporine, mycophenolate, cyclophosphamide,  
vincristine, Anti-D or IVIG. 
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Table.6:  Pre-splenectomy treatment response and complications: 
 
 $Dapsone, Danazol, Azathioprine, Cyclophosphamide, Mycophenolate, Cyclosporine. 
#Hypertension. Diabetes mellitus, cushingoid features, acne vulgaris. proximal myopathy.  
*Dapsone induced hemolysis, meth-hemoglobinemia, peripheral   neuropathy, hepatitis.  
^Eczema, Bell’s palsy, post-infectious glomerulonephritis, epilepsy. 
 
 
 
 
 
 
 
 
 
 
 
Patient Variables  
 
ADULTS  
(n=167) 
CHILDREN 
(n=87) 
n (%) n (%) 
Overall presplenectomy response status 
      Steroid dependent (SD) 
 
60 (36) 
 
26 (30) 
      Not responding to steroids 27 (16.1) 17 (19.5) 
      Not responding to multiple drugs$ 78 (46.7) 44 (50.5) 
      Data not available 2 (1.2) -- 
Health problems during presplenectomy 
treatment period 
  
   Steroid related problems# 39 (23.3) 8 (9.1) 
   Tuberculosis 4 (2.4) -- 
   Dapsone related problems * 4 (2.4) -- 
   Other problems^ 5 (3) 1 (1.2) 
   No documented complications 115 (68.9) 78 (89.7) 
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D. PERI-SPLENECTOMY VARIABLES^:  
Table.7: Pre-splenectomy clinical status:  
 
Patient variables 
ADULTS  
(n=167) 
CHILDREN 
(n=87) 
n (%) n (%) 
Clinical symptoms    
      Asymptomatic  58 (34.7) 28 (32.2) 
      Skin bleed only 14 (8.3) 20 (23) 
      Oro-nasal bleed only* 12 (7.2) 11 (12.6) 
      Skin+/oro-nasal ± others # 15 (9) 18 (20.7) 
      Menorrhagia ± any other bleeds 55 (33) 5 (5.7) 
      IC bleed ±  any other bleeds 10 (6) 3 (3.4) 
      Data not available 3 (1.8) 2 (2.4) 
^The period from when the decision for splenectomy is made to immediate post splenectomy period 
(during hospital stay or upto 30 days, whichever is longer) * Gum bleeds and epistaxis,  
#Gastrointestinal bleed (hematemesis, malena, hematochezia), Hematuria, subconjuctival bleed. 
 
Table.8: Immediate Pre-splenectomy treatment:  
          
Treatment 
 
ADULTS  
(n=167) 
CHILDREN 
(n=87) 
n (%) n (%) 
    High dose dexamethasone (HDD^) 95 (56.9) 41 (47.1) 
    Prednisolone 18 (10.8) 10 (11.5) 
    Hydrocortisone (HC^) -- 1 (1.2) 
    IVIG±HDD$ 3 (1.8) -- 
    No treatment  35 (20.9) 20 (23) 
    Data not available 16 (9.6) 15 (17.2) 
Platelet transfusion:       Yes 80 (48) 49 (56) 
                                          No 72 (43) 31 (36) 
                                          Data not available 15 (9) 7 (8) 
^HDD=high dose dexamethasone, HC= hydrocortisone.  $ 2 cases received IVIG + HDD and 1 case 
IVIG alone.  
All emergency splenectomies except 3 adults (1 with platelet count 175x 109/L, 1 with 80 x109/L, 
and one with 11 x109/L) and 1 child (with platelet count 9x 109/L) received PRC transfusions.  
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Table.9: Immediate Pre-splenectomy platelet count: 
 
Platelet count** 
 
ADULT  
(n=167) 
CHILDREN 
(n=87) 
n (%) 
Median (Range) 
n (%) 
Median (Range) 
Median platelet count (1x109/L)  20 (1-369) 13 (1-182) 
    Platelet count   ≤ 10 x 109/L 58 (34.7%) 32 (36.8%) 
    Platelet count  11-30 x109/L 37 (22.2%) 25 (28.7%) 
    Platelet count   31-100 x 109/L 44 (26.3%) 16 (18.4%) 
    Platelet count   > 100 x109/L 24 (14.4%) 11 (12.6%) 
Data not available 4 (2.4%) 3 (3.5%) 
Median platelet count in those who 
received HDD±IVIG$ (1x109/L) 
33 (2-369) 12 (1-182) 
Median platelet count in those who 
received prednisolone/HC  (1x109/L) 
34 (1-219) 20 (6-180) 
 
Median platelet count in those who 
received no treatment pre-splenectomy 
(1x109/L) 
11 (2-199) 10 (3-146) 
 
$ 3 adults received IVIG along with HDD. Among those who received HDD, 53 adults (54.6% ) 
and 13 (31.7%) children  had a pre-splenectomy platelet count of >30 x109/L.  
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Table.10: Vaccination and surgery:  
 
 
 
Patient variables 
 
ADULTS  
(n=167) 
CHILDREN 
(n=87) 
n (%)/ 
Median (Range) 
n (%) 
Median 
(Range) 
Peri-splenectomy vaccination: 
                                     Patients vaccinated 
 
132 (79) 
 
64 (73.6) 
Time to splenectomy from vaccination 
(days) $ 
35 (0-1555) 28 (1-1011) 
                          Vaccination in ≤ 10 days  27 (20.5) 12 (18.8) 
                          Vaccination in  ≥ 11 days 105 (79.5) 52 (81.3) 
Time to splenectomy from diagnosis 
(months) 
14.3 (3-290) 18.1 (4-117) 
Nature of surgery:    
Elective:                                                        
                                                Laparotomy 136 (90.1) 79 (94) 
                                                Laparoscopy 15 (9.9) 5 (6) 
                                                   Total  151 (90.4) 84 (96.6) 
Emergency *: 15 (93.8) 3 (100) 
              Laparotomy    
                                                Laparoscopy  1 (6.2) -- 
                                                   Total 16 (9.6) 3 (3.4) 
 
$ There was no statistically significant difference in the incidence of post splenectomy sepsis among 
those who got vaccinated in less than or more than 10 days pre-splenectomy. 
*In children, the indications were intracranial bleed in all 3 cases (1-Sub-dural hemorrhage, 1-Sub-
arachnoid hemorrhage, 1-Intracerebral hemorrhage). In adults 8 were for intracranial bleed (2-
SDH,1-SAH,5-Intracerebral bleed), 3 for  uncontrolled gastrointestinal bleed, 1 for hemorrhage into 
cystadenoma ovary, and the remaining 4 were done as part of emergency surgery for other causes 
ie; pregnancy with fetal distess, acute calculous cholecystitis, carcinoma rectum and non-healing 
fistula in ano with abscess. Indication for the 1 laparoscopic emergency splenectomy was IC bleed. 
 
 
39 
 
Table.11: Splenectomy and immediate post splenectomy details:  
 
Patient variables 
ADULTS  
(n=167) 
CHILDREN 
(n=87) 
n (%) n (%) 
Presence of splenunculi 17 (10.2) 16 (18.4) 
Spleen HPR$     
         Congestion  119 (71.3) 49 (56.3) 
         Follicular hyperplasia 12 (7.2) 15 (17.2) 
         Tuberculosis  4 (2.4) -- 
         Hyaline arteriolar sclerosis --  1 (1.2) 
Peri-splenectomy complications*    
         Hemorrhage@ 9 (5.4) 1 (1.2) 
         Infection# 32 (19.2) 4 (4.6) 
         DVT+PE 1 (0.6) -- 
         Nil documented 126 (75.4) 82 (94) 
         Death 4 (2.4) 1 (1.2) 
Median duration of hospital stay (days) 9 (2-39) 6 (3-22) 
Antibiotic requirement  78 (46.7) 43 (49.4) 
 
*Those occurring during hospital stay or within thirty days of surgery.  
$ Data could not be retrieved in 32 adults and 22 children.  One case with splenic tuberculosis was 
refractory to splenectomy and  the child with hyaline arteriolar sclerosis  of spleen was a responder.  
@In adults the haemorrhages were; 3 - per-operative bleed, 2 -post operative  retroperitoneal bleed,  
1-hematoma perineum, 1- bleed from suture site, and 1- hematuria + IC bleed.(expired), and 1- IC 
bleed (expired). In children, 1 case had IC bleed (expired.). 
# the infections were; in adults, 13-had short febrile illness, 8- pneumonia, 2 - intra-abdominal 
collection with infection, 3 –URTI, 1-UTI , 3 -wound site infection and  2- septicemia (expired).  In 
children, 3-had short febrile illness and 1-wound site infection. 2 adults had associated pancreatitis. 
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E.  POST SPLENECTOMY VARIABLES:  
Table.12:  Initial Post splenectomy Response:  
 
Response variables 
ADULTS  
(n=167) 
CHILDREN 
(n=87) 
n (%)/ 
Median (Range) 
n (%) 
Median (Range)
Initial Response  
  Responders (R+CR) 
 
148 (88.6) 
 
       81 (93.1) 
              Response (R) 21 (12.6) 19 (21.8) 
             Complete Response (CR) 127 (76) 62 (71.3) 
  No Response (NR)                                   15 (9) 5 (5.7) 
  Expired 4 (2.4) 1 (1.2) 
Time to initial response [days]* 1 (1-54) 1 (1-28) 
Peak post splenectomy platelet:  
       Median count [1x109/L]  
 
306 (1-1831) 
 
292 (5-2161) 
       Time to peak platelet count (days) 7 (1-56) 7 (1-50) 
Initial Response with/without drug    
   No drug 140 (94.6) 80 (98.8) 
   While on drug@  8 (5.4) 1 (1.2) 
                    Steroid only 3 (2) -- 
                    Danazol + steroid 1 (0.7) -- 
                    Azathioprine ± steroid 3 (2) 1 (1.2) 
                    Cyclosporine + steroid 1 (0.7) -- 
   Total  148 (88.6) 81 (93) 
Post splenectomy Loss of Response    
         Patients with 1 Loss of R 27 (82) 15 (83.3) 
         Patients with  ≥ 2 Loss of R 6 (18) 3 (16.7) 
         Total  33 (22.2) 18 (22.2) 
Time to post splenectomy loss of 
R(months) ^ 
8.8 (1-108) 5.9 (1-116) 
*The mean time to initial response in days were 5.4 for adults and 3.6 for children. 
@ The 8 adults and 1 child who responded while on treatment subsequently lost response and were 
eventually categorised as refractory ITP.  
^In adults, 21 out of 33 (63.6%) and in children 7 out of 18 (39%) cases lost their response in the 
first year post splenectomy. 
 
41 
 
F. LAPAROSCOPY VERSUS LAPAROTOMY SPLENECTOMY: 
Table.13: Laparoscopy versus Laparotomy* 
 
Patient variables 
 
 
Laparoscopic  
n (%);  
median (range) 
 
Laparotomy  
n (%);  
median (range) 
 
p  
ADULTS:                            Total cases 16 (9.6) 151 (90.4)  
   Duration of  hospital stay (days) 7.5 (3-20) 9 (2-39) 0.126
   Number of initial responders (R+CR) 16 (100) 132 (87.4) 0.221
   Time to Initial response (days) 3 (1-30) 1 (1-60) 0.378
   Post splenectomy loss of Response 5 (31) 28 (21.2) 0.317
   Peri splenectomy complications  4 (25) 37 (24.5) 1.000
   Late post splenectomy 
infection/sepsis 
4 (25) 30 (9.8) 0.744
CHILDREN:                         Total 
cases 
5 (5.7) 82 (94.3)  
   Duration of  hospital stay (days) 6 (4-7) 6 (3-22) 0.540
   Number of initial responders (R+CR) 5 (100) 76 (92.7) 1.000
   Time to Initial response (days) 7 (1-28) 1 (1-61) 0.172
   Post splenectomy loss of Response 1 (0.2) 17 (22.4) 1.000
   Peri splenectomy complications  -- 5 (6) 1.000
   Late post splenectomy 
infection/sepsis 
-- 7 (8.5) 1.000
 
*There was no statistically significant difference in any of the variables correlated  
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G. REFRACTORY ITP: 
Refractory ITP included those cases; (1) who failed to achieve at least 
‘Response’ (R; platelet count >30 x 109/L) or, after an initial response have lost 
Response, and (2) have severe ITP or have a risk of bleeding requiring additional 
treatment.  
In this study all adults and children with the above characteristics are 
analysed as refractory cases even though the above definition is not strictly 
applicable to children.12.  
The refractory cases were categorised into 5 treatment groups (detailed 
below; detailed description in Appendix I & II) for the purpose of analysis, 
depending upon the drugs they received throughout the post splenectomy treatment 
period. 
 
Refractory ITP treatment groups: 
Group  0 Nil (No Treatment)                                        
Group  1 Steroid Alone                                                 
      Prednisolone  
      Dexamethasone  
Group  2 Dapsone/Azathioprine/Danazol ±Steroid:      
Group  3 Combination Treatment:                            
Cyclophosphamide/Cyclosporine/Mycophenolate/Vincristine  
with/without Group 1& 2 Drugs 
Group  4 Alternative Treatment:                               
(Homeopathic, Siddha, Ayurvedic medicines) 
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Table.14: Treatment and Response of total refractory cases: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment Groups* : see Appendix 1 & II 
Treatment 
Groups*  
For those who responded at any time, the duration in response (months) Response status to treatment at last follow up 
On drug  
Median(Range) 
Off drug  
Median(Range) 
 
Cumulative  
Median(Range) 
 
In Response 
n (%) 
Not  in response 
n (%) 
Total 
n (%) 
 ADULTS: (n=38) ADULTS: (n=48) 
Group 0 0.5 (0-1) 43.5 (29-58) 44 (29-59) -- 4 (17.4) 4(8.3) 
Group 1 1 (0-6) 17 (1-116) 18 (1-118) 4 (16) 2 (8.7) 6(12.5) 
Group 2 9 (0-74) 13 (0-133) 20 (1-145) 16 (64) 11 (47.8) 27(56.3) 
Group 3 9.5 (2-37) 36 (7-105) 45 (9-142) 5 (20) 4 (17.4) 9(18.8) 
Group 4 -- -- -- -- 2 (8.7) 2 (4.2) 
Total 3.5 (0-74) 18 (0-133) 22.5 (1-145) 25 (52.1) 23 (47.9) 48(100) 
 CHILDREN: (n=21) CHILDREN: (n=23) 
Group 0 -- 118 118 1 (6.3) 1 (14.3) 2 (8.7) 
Group 1 1 (1-2) 18 (14-78) 20 (15-79) 3 (18.8) -- 3 (13) 
Group 2 4 (0-20) 7 (0-92) 21 (2-101) 10 (62.5) 3 (42.9) 13 (56.5) 
Group 3 1 (0-18) 1 (0-1) 1 (1-18) 1 (6.3) 3 (42.9) 4 (17.4) 
Group 4 55 -- 55 1 (6.3) -- 1 (4.3) 
Total 3 (0-55) 7 (0-118) 20 (1-118) 16 (69.6) 7(30.4) 23 (100) 
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Table.15: Details of Refractory cases who showed response at last follow up:   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Treatment Groups* : see Appendix 1 & II      $ Time  from the date of splenectomy to the date of last response 
 
 
 
 
Treatment 
Groups* 
Patients in R/CR at last follow up Time to R/CR$ 
(months) 
For patients who showed response at last follow up, the duration in 
response (months) 
On drug Off drug Total On drug Off drug Cumulative 
n (%) n (%) n (%) Median(Range) Median(Range) Median(Range) Median(Range) 
ADULTS (n=25) 
Group 0 -- -- -- -- -- -- -- 
Group 1 -- 4 (16) 4 (16) 10.1 (5-16) 3.5 (0-6) 25 (13-116) 25.5 (15-118) 
Group 2 9 (36) 7 (28) 16 (64) 11.2 (2-129) 10.5 (0-36) 19.5 (1-133) 27 (9-145) 
Group 3 2 (8) 3 (12) 5 (20) 19.4 (9-140) 15 (3-37) 50 (15-105) 53 (19-142) 
Group 4 -- -- -- -- -- -- -- 
Total  11 (44) 14 (56) 25 (100)  10 (0-37) 24 (1-133) 34 (9-145) 
CHILDREN (n=16) 
Group 0 -- 1 (6.3) 1 (6.3) 12 -- 118 118 
Group 1 1 (6.3) 2(12.5) 3 (18.8) 17.7 (8-29) 1 (1-2) 18 (14-78) 20 (15-79) 
Group 2 3(18.8) 7(43.8) 10 (62.5) 10.5 (3-116) 5 (0-20) 30.5 (0-92) 34.5 (2-101) 
Group 3 1 (6.3) -- 1 (6.3) 14.4 18  -- 18 
Group 4 1 (6.3) -- 1 (6.3) 78.6 55 -- 55 
Total  6 (37.5) 10 (62.5) 16 (100)  4 (0-55) 19 (0-118) 47 (2-118) 
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Table.16: Treatment details of individual refractory cases who responded to treatment-Adults 
 
 
Treatment 
Groups 
Post splenectomy response Number of  cases Follow up  Drugs to which response was noticed in 
the Pre-splenectomy period Drugs received throughout 
the treatment period 
Drug to which 
responded  
Total On drug 
 
Off drug On /Lost 
(n) 
1 Pred* Pred 2 - 2 2/- 1-Pred, Dap, Dexa (SD) 
1-Pred, M.Pred*, Dan, CSA* (SD) 
Pulse Dexa Pulse Dexa 2 - 2 1/1 2 - Pred 
2 Aza* Aza 3 1 2 2/1 1 –Dap, Pred 
2-Pred 
Pred, Aza 4-Pred, Aza 4 3 1 3/1 1-Dap 
2-Pred, Dap 
1-Pred 
Dap* Dapsone 5 3 2 4/1 1 -Aza 
1-Pred 
3-No response to any agent
Pred, Dap 2-Pred, Dap 
1-Pulse Dexa, Dap 
3 2 1 3/- 1-Pulse Dexa (SD) 
1-Pulse Dexa, Dap 
1-No response to any agent 
Pred, Dap,Aza Dap 1 - 1 -/1  Dap 
3 Pred,Cyclo* Pred,Cyclo 1 1 - -/1 Pred (SD) 
Pred, CSA Pred,CSA 1 - 1 1/- Pred, Dap, Aza 
Pred, Dap, Aza,Cyclo 1$-response to all drugs 
1- Pred 
2 - 2 2/- 1-Pred 
1- No response to any agent 
Pred,Dap,MMF*  MMF 1 1 - 1/- Pred, Aza,Dap (SD) 
Total  25 11 14 19/6  
*Pred=Prednisolone., MMF=Mycophenolate, CSA=Cyclosporine, M.Pred=Methyl prednisolone, Dexa=Dexamethasone, Aza=Azathioprine, Cyclo=Cyclophosphamide, Dap=Dapsone, Dan=Danazol.  $1 case had total of 4 loss 
of responses and showed response to different combinations given following each loss of response. 
 
60% (n=15) of adults responded to steroid based therapy. The refractory cases who responded to post splenectomy steroid treatment were found to be responsive to steroids in the 
pre-splenectomy period also. Those who showed response to other drugs did not show any correlation; however the numbers of cases are too small for a statistical correlation to be 
done. 
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Table.17: Treatment details of individual refractory cases who responded to treatment-Children 
 
 
Treatment 
Groups 
Post splenectomy response Number of cases Follow up  Drug to which response was noticed in 
the Pre-splenectomy period 
Drugs received throughout 
the treatment period 
Drug to which 
responded  
Total On drug Off drug  On/Lost 
(n) 
0 Nil  - 1 - 1 -/1 No response to any agents 
1 Pulse Dexa* Pulse Dexa 1 - 1 1/- Pred, Dap, Aza 
 Pred * Pred 2 1 1 1/1 1- No response to any agents  
1-Pred 
2 Aza* Aza  2 1 1 1/1 1- No response to any agents  
1-Pred 
 Dap* Dap 2 1 1 1/1 1- No response to any agents  
1-Pred 
 Pred, 
Dap 
2-Pred,Dap 2 - 2 2/- 1- No response to any agents  
1-M.Pred, IVIG 
 Pred,Aza 2-Pred,Aza 2 - 2 1/1 1-Pred,Dan,Dap(SD) 
1-Pred, Aza,Dap(SD) 
 Pred, Dap, Aza Pred, Dap, Aza 1 1 - -/1  No response to any agents  
 Pred, Dap, Dan* Pred, Dap, Dan 1 - 1 -/1 Pred,Dap 
3 Pred, Aza,MMF* Pred, Aza, MMF 1 1 - 1/- Pred,Dap, Aza (SD) 
4 Alternative medicine# Alternative medicine#  1 1 - 1/- Pred 
Total  16 6 10 9/7  
*Pred=Prednisolone., MMF=Mycophenolate, CSA=Cyclosporine, M.Pred=Methyl prednisolone, Dexa=Dexamethasone, Aza=Azathioprine, Cyclo=Cyclophosphamide, Dap=Dapsone, Dan=Danazol, 
IVIG=IV immunoglobulin G.  # Siddha  medicine 
 
68.7% (n=11) of children responded to steroid based therapy. The refractory cases who responded to post splenectomy steroid treatment were found to be responsive to steroids in 
the pre-splenectomy period also. One child who responded to Azathioprine and another who responded to Dapsone showed a similar response pattern in the pre-splenectomy period. 
The numbers of cases are too small for a statistical correlation to be done. 
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Table.18: Final response status of refractory cases versus phase of ITP  
 
Patients 
 
Phase of ITP  
at splenectomy 
 
 
n 
Final response to treatment 
Responded 
n (%) 
Not responded 
n(%) 
p 
Adults  
(n=48)  
Persistent  20 10 (20.8) 10 (20.8)  
0.961 Chronic  28 15 (31.3)  13 (27.1)  
Children 
(n=23) 
Persistent 3 1 (4.4) 2 (8.7)  
0.211 Chronic  20 15 (65.2)  5 (21.7) 
 
Although in children 65.2% of the refractory cases (who were in chronic phase of ITP at splenectomy) 
responded to treatment, the observation showed no statistical significance.  
 
Table.19: Clinical status of Refractory cases at last follow up  
 
Patient variables 
ADULTS 
(n=48) 
CHILDREN      
(n=23) 
n (%) n (%) 
NR + loss of R who responded to treatment         25 (52.1) 16 (69.6) 
NR who went into spontaneous remission -- 1 (6.2) 
Patients who continued in NR:                        10 (20.8) 2 (8.7) 
                Symptomatic 3 (30) 1 (50) 
                   Asymptomatic  7 (70) 1 (50) 
                                    Expired 1 (10) -- 
               On treatment  5 (50) 1 (50) 
Patients who continued in Loss of R          13 (27) 5 (21.7) 
                                    Symptomatic 6 (46) 4 (80) 
                                    Asymptomatic 7 (54) 1 (20) 
                                    Expired 1 (7.7) -- 
                On treatment 9 (69) 3 (60) 
Refractory cases alive at last follow up *  46 (95.8) 23 (100) 
Mortality   2 (4.2) -- 
 
* 2 cases out of total adult 48 refractory ITP, expired while on follow up.  
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H.  POST SPLENECTOMY MORBIDITIES AND MORTALITIES: 
Table.20: Post splenectomy health problems^ 
 
Health variables 
 
ADULTS  
(n=167) 
CHILDREN 
(n=87) 
n (%) n (%) 
               Thrombo-embolism (DVT/CAD) 3(1.8) -- 
               Intestinal obstruction 1(0.6) -- 
               Infection 34 (20.5) 7 (8) 
  Malignancy$  4 (2.4) -- 
               Collagen vascular disease* 2 (1.2) 1 (1.2) 
               ICH 3 (1.8) -- 
               Peritoneal/GI bleed 7 (4.2) 1 (1.2) 
               More than one complications  3 (1.8) -- 
               Residual  spleen  1(0.6) -- 
               Nil documented 110 (65.9) 78 (89.6) 
^ Health problems encountered anytime post splenectomy (upto the last follow –up) 
$ 1-Mantle cell lymphoma (diagnosed 2 years 8 months post splenectomy), 1-Follicular lymphoma (diagnosed 11 years 4 months 
post splenectomy), 1-carcinoma breast (diagnosed 10 years post splenectomy), 1-Adenocarcinoma of the stomach (diagnosed more 
than 1 year post splenectomy). *2 adults developed mixed connective tissue disorder (after 1 year of splenectomy) and one child 
developed autoimmune myocarditis with transient ischemic attack after 10 years of splenectomy.  
 
Table.21 Mortality Details:  
 
Patient variables 
ADULTS 
(n=167) 
CHILDREN 
(n=87) 
n (%)/ 
Median (Range) 
n  (%)/ 
Median (Range) 
Sex  (Male:Female) 2:4 1:0 
Phase of ITP:    Persistent 3 (50) -- 
                           Chronic  3 (50) 1 (100) 
Time to death from splenectomy (days)   12 (1-558) 1 
Age at diagnosis (years) 27.5 (16-57) 3 
Age at splenectomy (years) 30 (16-61) 5 
Cause of death*: 
                    Bacterial sepsis 
 
1 (16.7) 
 
-- 
                    Sepsis + massive GI  bleed  1 (16.7) -- 
                    Sepsis + IC Bleed 1 (16.7) -- 
                    Intracranial hemorrhage 3 (50) 1 (100) 
Total 6 (3.6) 1 (1.2) 
*5 expired (4 adults and 1 child)  in the early post splenectomy period. The remaining 2 adult cases expired at 16 and 19 months 
post splenectomy following severe gram negative sepsis + massive GI bleed, and  intracerebral hemorrhage respectively. The lady 
who expired at 16 months post splenectomy, was an initial responder who subsequently lost response 4 months later and remained 
refractory to treatment (Treatment Group 3; steroid, dapsone, danazol, cyclosporine, IVIG). The second case was in “No response” 
(NR) throughout and remained refractory to steroid, danazol and mycophenolate (Treatment Group 3). 
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I.  SURVIVAL CHARACTERISTICS: 
Table.22: Survival characteristics: 
 
Survival variables 
Data available (n=adult/children) 
ADULTS 
(n=167) 
CHILDREN 
(n=87) 
n (%) 
Mean; Median 
(Range) 
n (%) 
Mean; Median 
(Range) 
Alive as on last follow up 161 (96.4%) 86 (98.8%) 
Total death 06 (3.6%) 01 (1.2%) 
Total cases on follow up^  75 (46.6%) 37 (43%) 
Total cases lost to follow up*  86 (53.4%) 49 (57%) 
Follow up duration (in months)   
Total cases  
 
38.9; 18.6 (1-170) 
 
33.8; 12(1-173) 
Responders  (n=115/63) 33.5; 11.9 (1-164) 29.5; 4.5 (1-173) 
Refractory cases (n=48/23)  38.6; 38.7 (1-170) 48.3; 20.1 (7-154) 
Refractory in response (n=25/26) 56.5; 38.4 (4-148) 51; 20.5 (10-154) 
Refractory not in response (n=23/7) 53.8; 38.9 (1-170) 42; 12.6 (7-125) 
Overall survival#  of:   
              Total cases  93.4% ± 3% 
(4-290 months) 
98% ± 1.6% 
(4-214 months) 
              Responders  (n=115/63) 100% 100% 
              Refractory cases (n=48/23) 94.7% ± 3.7% 100% 
Event free survival@ of:   
             Total cases (n=167/87) 71.5% ± 4.5% 
(0-290 months) 
70% ± 7.5% 
(0-193 months) 
At 5 yrs:        Overall Survival 96.9% ± 1.6% 98% ± 1.6% 
                       Event Free Survival  75.2 % ± 3.7% 79.1% ± 4.6% 
At 10 yrs:      Overall Survival 93.4% ± 3% 98% ± 1.6% 
                       Event Free Survival 71.5 % ± 4.5% 70% ± 7.5% 
^57 adults and  21 children had more than 5 years of  follow up. 
*52 (31%) adults and 29 (33.3%) children were lost to follow up within one year, and 72 (43%) adults 
and 44 (50.5%) children were lost within 5 years post splenectomy.   
# Figure: 4   @ Figure:5,6 
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Fig:4 Overall Survival: Adult total cases (n=167) 
 
                   
Fig:5 Event Free Survival: Adult total cases (n=167) 
 
 
 
 
 
   Fig:6. Event Free Survival: Child total cases (n=87) 
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             J.  Table 23. PROGNOSTIC DETERMINANTS OF RESPONSE TO SPLENECTOMY:  
Variables (adult/child) Adults (n=163) @ Children  (n=86)@ 
Responders Refractory p value Responders Refractory p value 
Number of patients 115 (70.6%)@ 48 (29.4)  63 (73.3%)@ 23 (26.7)  
Presplenectomy variables: 
Male:Female 23:92 19:29 0.011 34:29 14:09 0.63 
Age at diagnosis (years) 24 (5-64) 28 (12-60) 0.061 08 (2-14) 07 (2-14) 0.462 
Persistent: chronic  52:63 20:28 0.731 26:37 03:20 0.019 
Platelet at diagnosis (1x109/L) $  10 (1-65) 10 (1-49) 0.882 9.5 (1-40) 10 (1-41) 0.371 
Age at splenectomy (years) $ 26 (15-65) 31 (15-61) 0.061 10 (4-14) 09 (4-14) 0.411 
Initial treatment (steroids:steroid+others) ** 108:06 46:02 0.821 58:05 20:03 0.433 
Response to initial treatment (R+CR:NR)** 66:47 28:20 0.723 35:28 12:11 0.921 
No. of Presplenectomy loss of R (1:2) 29:16 16:5 0.521 16:4 6:4 0.381 
Presplenectomy status(SD:SNR:MDNR) ** 46:20:47 12:6:30 0.071 18:13:32 8:4:11 0.842 
Time to splenectomy from diagnosis(mths) $ 13.9 (3-290) 15.5 (6-167) 0.757 15.2 (4-117) 27 (7-69) 0.087 
Platelet at splenectomy(1x109/L) $ 30 (2-369) 10 (2-258) 0.004 15.5 (1-179) 9.3 (2-182) 0.161 
Post splenectomy variables 
Laparotomy:Laparoscopy 104:11 43:5 1.000 59:4 22:1 1.000 
Splenunculi 10 07 0.211 14 02 0.323 
Time to initial response (R/CR) $ days 1 (1-55) 3 (1-60) 0.031 1 (1-28) 3 (1-61) 0.138 
Peak post splenectomy platelet (1x109/L) $ 400 (30-1831) 125 (1-1406) 0.000 335 (45-2161) 139 (5-1738) 0.001 
Time to peak platelet (days) $ 7 (1-56) 7 (1-54) 0.152 7 (1-50) 7 (1-50) 0.755 
                   @Patients who expired in the immediate post splenectomy period (4 adults & 1 child) are excluded. So,   n=163 in adults and n=86 in children .  #: n (%);    
                $: median (range)     **Data not available for all the 115 responders.  SD:steroid dependent, SNR:steroid  non- responsive, MDNR: multiple drug non responsive. 
 
             Analysis in adults showed that higher platelet count at splenectomy (p=0.004), female sex (p=0.011), shorter time to response to  splenectomy  
           (p=0.031)  and higher peak post splenectomy platelet count (p=0.000) as significant predictors of  response. Among responders in children, higher  
           peak post splenectomy platelet count (p=0.001) and persistent phase of the disease (p=0.019)showed a significant  p value . 
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           K. OVERALL OUTCOME:  The overall post splenectomy outcome of the total cases is summarised in the table below as, ‘initial response’  
           (ie;  response at any time within the first 2 months [56 days] post splenectomy), ‘response status at 2 months’ and ‘at last follow up’. 
Table.24:  Overall Post splenectomy outcome of total cases: 
                
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
               
#Time period for initial response is the first 2 months (day 1-day 56)  post splenectomy. A few of those who responded initially (within day 1 –day 56) had lost their  
               Response  by the end of  2  months post splenectomy. 
              * Among the148 adults and 81 children who responded initially, 8 adults and 1 child achieved response while on drug treatment.  
              $At 2 months, out of the 148 adults and 77 children in response, 7 adults and 1 child were on drug treatment. 
Response variables 
Data available (adult/children) 
Adults (n=167) Children (n=87) 
Initial 
response# 
Status at 2 
months# 
At Last follow 
up 
Initial 
response# 
Status at 2 
months# 
At Last 
follow up 
n (%) n (%) n (%) n (%) n (%) n (%) 
Initial Responders:  
(continued in R/CR ) 
 
148* (88.6) 
 
138$ (82.6) 
 
115 (68.9) 
 
81* (93.1) 
 
77$ (88.5) 
 
63 (72.4) 
             In Response (R) 21 (12.6) 21 (12.6) 14 (8.4) 19 (21.8) 21 (24) 17 (19.5) 
             In Complete Response (CR)     127 (76) 117 (70.1) 101 (60.5) 62 (71.3) 56 (64.4) 46 (52.9) 
Responders on follow up  -- 101 (73.2) 44 (38.2) -- 53 (68.8) 25 (39.7) 
Responders lost to follow up -- 37 (26.8) 71 (61.7) -- 24 (31.2) 38 (60.3) 
Refractory ITP: (NR+Loss of R) 15 (9.0) 25 (15) 48 (28.7) 5 (5.7) 9 (10.3) 23 (26.4) 
  Continued in NR 15 (9.0) 15 (9.0) 10 (6) 5 (5.7) 5 (5.7) 2 (2.3) 
  In loss of R -- 9 (5.4) 13 (7.8) -- 3 (3.4) 5 (5.7) 
 Refractory cases who responded to treatment -- 1 (0.6) 25 (15) -- 1 (1.2) 15 (17.2) 
NR who went into spontaneous remission -- -- -- -- -- 1 (4.3) 
Refractory cases  on follow up  -- 23 (92) 31 (64.6) -- 9 (100) 12 (52.2) 
Refractory cases  lost to follow up -- 2 (8.0) 15 (31.2) -- -- 11 (47.8) 
Death: Additional deaths -- -- 2(4.2) -- -- -- 
Total  death 4 (2.4) 4 (2.4) 6(3.6) 1 (1.2) 1(1.2) 1 (1.2) 
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DISCUSSION: 
 
    Of the total 254 patients analysed, 167 were adults (age: > 14 years) and 87 
were children (age: ≤ 14 years). Patients were followed up post splenectomy for a 
median of 18.6 months (range:1-170; mean-38.9) in adults and 12 months (range: 1-
173; mean-33.8) in children. 86 (53.4%) adults and 49 (57%) children were lost to 
follow up. As on last follow up 161 (96.4%) adults and 86 (98.8%) children were alive 
and 6 (3.6%) adults and 1 (1.2%) child respectively had expired.  
 
     Of the total cases of ITP, persistent and chronic cases comprised of 74 
(44.3%) and 93 (55.7%) in adults, and 29 (33.3%) and 58 (66.7%) in children. After a 
median follow up of  18.6 months (range:1-170) in adults and 12 months (range: 1-
173) in children from splenectomy, 115 (68.9%) adults and 63 (72.4%) children 
continued to be in response, while 48 (28.7%) adults & 23 (26.4%) children were 
refractory to splenectomy. Among those continuing in response, 44 (38.2%) adults and 
25 (39.7%) children respectively are on follow up; while in the refractory group, those 
who continue to be on follow up are 31 (64.6%) adults and 12 (52.2%) children 
respectively. 2 (1.2%) of the adult refractory patients expired while on follow up.  
 
        In those patients who continued in response, the median duration of follow 
up was  11.9 (range:1-164; mean-33.5) & 4.5 (range:1-173; mean-29.5) months in 
adults and children respectively; while in patients with refractory ITP, the median 
duration of follow up was 38.7 months (range: 1-170; mean-38.6) in adults, and 20.1 
months (range:7-154; mean-48.3) in children.  
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A. ANNUAL DISTRIBUTION OF CASES: (Fig:1) 
           Among the analyzed cases (n=254), the average number of splenectomy 
was 17 per year (11 adults and 6 children).  
 
B. DEMOGRAPHICS OF ITP PATIENTS: (Tables: 1, 23, 25, 26) 
 
Age:  The median age at diagnosis and splenectomy of total cases were 24 (5-64) & 27 
(16-65) years in adults and 8 (2-14) & 10 (4-14) years in children. Among the 
responders to splenectomy, the median age at diagnosis and splenectomy were 24 (5-
64) & 26 (15-65) years in adults and 8 (2-14) & 10 years (4-14) in children. In 
refractory cases the median age were 28 (12-60) & 31 (15-61) years in adults and 7 (2-
14) & 9 (4-14) years in children at diagnosis and splenectomy respectively. Younger 
age at diagnosis and splenectomy was found have a near statistically significant p value 
(0.061). In a study by Kumar S et al1, the younger age at splenectomy was found to be a 
significant predictor of response.  
 
Sex distribution: The male: female ratio was 44:123 in adults and 49:38 in children. 
The male: female ratio in responders and refractory were 23:92 and 19:29 in adults and 
34:29 and 14:9 in children. The female preponderance observed among adult 
responders was found to be statistically significant (p=0.01). The sex distribution of 
cases in adults was found to be similar to other published studies, ie; Kumar S et al1, 
Schwartz J et al15, Shojaiefard A et al76, Bourgeois E et al77. 
 
Phase of ITP:  The persistent to chronic ITP ratio at splenectomy was 74:93 in adults 
and 29:58 in children. The same ratio in responders and refractory cases were 52:63 
and 20:28 in adults and 26:37 and 3:20 in children. Among responders in children, 
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persistent phase of the disease showed a statistical significance (p=0.019). There is no 
available comparable literature for this observation.  
 
C. PRE-SPLENECTOMY VARIABLES: (Tables 2-6, 23,25,26) 
Clinical features at initial diagnosis:  In both adults and children 97.6% of cases were 
symptomatic at the initial diagnosis.  
 
Platelet count at diagnosis and splenectomy: The median platelet count of total cases 
at diagnosis was 10 x 109/L in both adults and children with a range of 1-65 x 109/L 
and 1-41 x 109/L in either group respectively. The platelet count at diagnosis was 
observed to be in the same range as reported in other studies.1 The median platelet 
count at diagnosis showed a similar pattern in responders (adult:children =10 x 109/L: 
9.5 x 109/L) and refractory (adult: children=10 x 109/L :10 x 109/L ) cases. Platelet at 
diagnosis was not found to have any statistical correlation with the response outcome.  
 
Auto-immune markers at diagnosis: Positive test for auto-immune markers, ie; 
antinuclear antibody (ANA) and direct coomb’s test (DCT) were noted in 24 (14.4%) 
and 20 (12%) cases of adults and 7 (8%) and 9 (10.3%) cases of children respectively.  
 
Treatments, response status, & complications at diagnosis & subsequently:  Nearly 
all patients were treated with corticosteroids (Prednisolone, Dexamethasone or Methyl 
Prednisolone) at the time of initial diagnosis, ie; 99.4% of adults and 100% of children. 
58.1% (n=97) of the adults and 54% (n=47) of children showed response (R/CR) to 
initial treatment. Comparable patterns of response to initial treatment were observed in 
responders (adults: children = 66:35; 57.4%:55.6%) & refractory (adults: children 
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=28:12; 58.3%:52.1%) cases. This is in contradiction to the observation by some 
workers (Kumar S et al1 and Fabris S et al87). 
 
       Prior to splenectomy, 60 (36%) adults and 26 (30%) children were found to 
be steroid dependent and the remaining showed neither response to steroids nor 
multiple other treatment regimens. Among adults and children, steroid dependency in 
the pre-splenectomy period was observed in 40% (n=46) and 28.6% (n=18) of 
responders and 25% (n=12) and 34.8% (n=8) of refractory cases respectively.  
 
         Steroid related toxicities were the most observed (39 [23.3%] adults and 8 
[9.1%] children) health problems during the pre-splenectomy drug treatment.  
 
D. PERI-SPLENECTOMY VARIABLES: (Tables 7-11, 23, 25, 26) 
 
                In the immediate pre-splenectomy period, 63.5% of adults and 65.4% of 
children were symptomatic. 56.9% (n=95) adults and 47.1% (n=41) children received 
high dose dexamethasone for four days prior to splenectomy.  
 
                 At splenectomy, the median platelet count of total cases was 20 x109/L 
(1-369 x 109/L) in adults and 13 x 109/L (1-182 x 109/L) in children. In majority of the 
cases (34.7% adults & 36.8% children) the platelet count was below 10 x109/L. Among 
those who received high dose dexamethasone therapy in the immediate pre-
splenectomy period, the median platelet count was 33 x109/L & 12 x109/L respectively 
in adults and children. In responders & refractory cases the median platelet count at 
diagnosis was 30 x 109/L and 10 x 109/L in adults and 15.5 x 109/L & 9.3 x 109/L in 
children. In adults, the higher platelet count at splenectomy noted in responders 
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compared to refractory cases (30 x 109/L vs 10 x 109/L) showed statistical significance 
(p=0.004) and this is in accordance with the observation by Kumar S et al.1 However in 
children, the same showed no statistical significance (15.3 x109/L versus 9.3 x 109/L; 
p=0.161).  
 
        Data on the vaccination status was available only for 132 adults and 64 
children and all of them were vaccinated. The median time to splenectomy from 
vaccination was 35 (0-1555) days in adults and 28 (1-1011) days in children. There was 
no significant difference in the incidence of post splenectomy infections in the patients 
who received vaccination at a shorter interval of less than 10 days pre-splenectomy 
from those who received at more than 10 days prior to splenectomy.  
 
            The median time to splenectomy from diagnosis was 14.3 (3-290) months 
and 18.1 (4-117) months in adults and children respectively. The adult:child ratio of the 
median time to splenectomy in responders and refractory cases were 13.9:15.2 months 
and 15.5:27 months respectively. This is longer than the median time to splenectomy 
reported by other workers (Kumar S et al1, Schwartz J et al15, Shojaiefard A et al76, 
Bourgeois E et al77). 
 
            Splenectomy in 90.4% (n=151) of adults & 96.6% (n=84) of children were 
done as elective procedure. Of these laparotomy & laparoscopy constituted 90.1% and 
9.9% in adults and 94% and 6% respectively in children. Emergency splenectomy was 
done in 16 adults and 3 children. All (except in 1 adult) were done by laparotomy 
procedure. Intracerebral bleed was the commonest indication for emergency 
splenectomy (8 adults and all 3 children). Other indications included uncontrolled 
gastrointestinal bleed and hemorrhage into cystadenoma ovary. 4 cases were done as 
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part of emergency surgery for other causes (ie; pregnancy with fetal distress, acute 
calculous cholecystitis, carcinoma rectum and non-healing fistula in ano with abscess). 
The one laparoscopic emergency splenectomy was done for IC bleed. Splenunculi were 
identified in 17 (10.2%) adults and 16 (18.4%) children. Among adults, splenunculi 
was observed in 10 responders and 7 refractory cases; while in children splenunculi 
was observed in 14 and 2 cases respectively. The presence of splenunculi showed no 
significant statistical correlation (p=0.211 in adults & 0.323 in children) with final 
outcome.  
 
             Infection (ranging from short febrile illness with no identifiable focus to 
frank sepsis) was the most frequent complication in the peri-operative period with an 
incidence of 19.2% (n=32) in adults and 4.6% (n=4) in children. 4 adults and 1 child 
expired in the immediate post operative period (2 adults expired due to septicaemia, 
and 2 adults and 1 child expired following intra-cerebral bleed). The median duration 
of hospital stay was 9 and 6 days in adults and children respectively. Around 50% of 
patients in each group received either therapeutic or prophylactic antibiotic 
administration during the hospital stay. There was no statistically significant difference 
in the duration of hospital stay among patients who underwent laparotomy or 
laparoscopy.   
 
E. POST SPLENECTOMY VARIABLES: (Tables 12,23,24,25,26) 
  
                    The initial response was assessed within first 56 days post splenectomy as 
this is the expected time of response to splenectomy, as per the current observation and 
recommendation.12 88.6% (n=148) of adults and 93.1% (n=81) of children showed 
initial response (R/CR) to splenectomy. The median time to response was 1 day in both 
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groups with a mean and range of 5.4 & 1-54 days in adults, and 3.6 & 1-28 days in 
children respectively. The median time to initial post splenectomy response in 
responders and refractory cases were 1 day (range:1-55) & 3 days (range:1-60) in 
adults, and 1day (range:1-28) & 3 days (range:1-61) days in children. The shorter time 
to response observed among responders compared to the refractory cases showed a 
statistical significance (p=0.031) in adults. Among the 148 (88.6%) adults and 81 
(93.1%) children who were initial responders, 10 adults and 4 children subsequently 
lost response during the first 2 months post splenectomy. It is possible that the initial 
response noted in these patients might have been the effect of the peri-splenectomy 
treatment received. At 2 months post splenectomy, 82.6% adults and 88.5% children 
were in response; and at last follow up 115 (68.9%) adults and 63 (72.4%) children 
showed a response, while 48 (28.7%) adults & 23 (26.4%) children were refractory to 
splenectomy. 
 
                   Most of the patients who were steroid dependent in the pre-splenectomy 
period, 76.7% [46 out of 60 cases] of adults and 69% [18 out of 26 cases] of children 
responded to splenectomy. This observation however was not statistically significant 
(p=0.071 in adults, p=0.842 in children).  
 
                   The median peak post splenectomy platelet count observed were 306 x 
109/L (1-1831 x 109/L) and 292 x 109/L (5-2161 x 109/L) for adults and children 
respectively. The median time to peak platelet count was 7 days in both groups with the 
range of 1-56 and 1-50 days respectively in adults and children. The median peak post 
splenectomy platelet count among responders and refractory cases were 400 x 109/L 
(30-1831 x 109/L) & 125 x 109/L (1-1406 x 109/L) in adults, and 335 x 109/L (45-2161 x 
109/L) & 139 x 109/L (5-1738 x 109/L) in children. The median time to peak platelet 
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count was 7 days each in responders and refractory cases in adult as well as in children. 
The median peak platelet count was similar to the observation by Shojaiefard et al 76. 
As observed by Kumar s et al1 and Shojaiefard et al,76  the higher peak platelet count 
was found to be a significant predictor of response both in adults (p=0.000) and 
children (p=0.001).  
 
                 Among the initial responders, 94.6% (n=140) of adults and 98.8% (n=80) of 
children achieved response without any additional drug treatment. 8 adults achieved 
response status while on treatment with additional drugs (steroid (n=3), danazol + 
steroid (n=1), azathioprine ± steroid (n=3) and cyclosporine + steroid (n=1)), which 
were continued for more than 2 months post splenectomy. One child achieved response 
status while on treatment with azathioprine. All these cases who responded while on 
additional drug treatment, subsequently lost their response (1 adult lost response within 
2 months and the rest after 2 months post-splenectomy), and were eventually grouped 
as refractory ITP. Among the initial responders, 33 (22.2%) adults and 18 (22.2%) 
children subsequently lost response, and the median time to loss of response was 8.8 
(1-108) months in adults and 5.9 (1 -116) months in children. In adults, majority 
(63.6%; n=21) of the ‘loss of response’ was observed in the first year post splenectomy; 
while in children, only 7 out of the 18 (39%) cases showed loss of response in the first 
year post splenectomy. The time to loss of response observed is in concordance with 
that reported by Kumar S et al1 and Shojaiefard et al.76 
  
F. LAPAROSCOPY VERSUS LAPAROTOMY SPLENECTOMY: (Table.13) 
          A comparison of the pre and post splenectomy variables showed no 
statistically significant difference in the mean duration of hospital stay, time to initial 
response to splenectomy, number of initial responders, number of post splenectomy 
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loss of response or early and late post splenectomy complications, among those who 
underwent laparotomy and laparoscopy.  
 
G. REFRACTORY ITP: (Tables 14-19) 
 
                    To evaluate the response to treatment, the patients were divided into 
arbitrarily defined response groups depending on the type of drugs they received 
throughout. 
 
Group 0: Not received any treatment; patients who attained response in this group 
were categorised as spontaneous remission or remission of uncertain origin12. 
Group 1: Patients who received treatment with steroids alone (Prednisolone, pulsed 
high dose dexamethasone). 
Group 2: Patients treated with Dapsone, danazol or azathioprine, either alone or in 
combination, with or without steroids. 
Group 3: Patients who received Cyclophosphamide, Cyclosporine, Mycophenolate or 
Vincristine, either alone or in combination, with or without Group 1& 2 Drugs 
Group 4:  Patients on alternative medicines (ie; Homeopathic, Siddha or Ayurvedic 
medicines). 
 
Treatment and Response of refractory cases: Of the 48 adults and 23 children with 
refractory ITP, 38 (79.2%) adults and 21 (91.3%) children attained response to drug 
treatment at some point of time, but only 25 (52.1%) adults and 16 (69.6%) children 
respectively were in response status at last follow up. Among the cases who were in 
response at last follow up, 64% of adults (n=16) and 62.5% of children (n=10) 
belonged to the treatment group 2. The median cumulative duration in response (total 
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time in response throughout the follow up period, ie; duration in response on drug + 
duration in response off drug) for those who were in response at last follow up was 34 
months (range:9-145) in adults and 47 months (range:2-118) in children. 
 Of those who responded to treatment, 14 (56%) adults and 10 (62.5%) 
children were off treatment as on last follow up, and 11 (44%) adults and 6 (37.5%) 
children continue to be on treatment.  One child who belonged to group 0 responded 
(spontaneous remission) 12 one year after splenectomy (platelet count at last follow up- 
50 x 109/L, ie at 1 year 10 months post splenectomy).  
 
 The drugs to which these patients responded post splenectomy were 
compared to the drugs they had shown response to at any point of time during the pre-
splenectomy period. Of the refractory cases who were in response, 60% (n=15) of 
adults and 68.7% (n=11) of children responded to steroid based therapy. It was 
observed that those patients who showed pre-splenectomy response to steroid 
continued to be responsive to steroid in the post splenectomy period also. All the 
steroid dependent adults continued to be steroid dependent, whereas only 1 out of 3 
continued to be steroid dependent among children. 
 
 Among the refractory cases in response, 24% (n=6) of adults and 
12.5% (n=2) of children showed response to Dapsone alone; while only 1 adult case 
among them had shown response to Dapsone in the presplenectomy period. 12% (n=3) 
of adults and 12.5% (n=2) of children showed response to azathioprine alone; none 
among them had shown response to azathioprine in the pre-splenectomy period. The 
number of cases however is insufficient for a statistical correlation to be done.  
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Final outcome of refractory cases versus phase of ITP:  Among the refractory cases 
who responded subsequently to drug treatment, 15 cases each of adults (31.3%) and 
children (65.2%) were in chronic phase of the disease at splenectomy, while only 10 
(20.8%) adults and 1 (4.4%) child were in the persistent phase. These observation 
showed no statistical significance (p=0.211). 
 
Clinical status of refractory cases at last follow up:   Among those who were with 
‘no-response’ at last follow up, 70% (n=7) adults and 50% (n=1) of children were 
asymptomatic at last follow up; while those who were in ‘loss of response’, 54% (n=7) 
adults and 20% (n=1) children respectively were asymptomatic.  
 
H. POST SPLENECTOMY MORBIDITY AND MORTALITY: (Tables 20,21) 
 
Post splenectomy health problems: Post splenectomy complications observed more 
frequently in adults than in children was possibly because the adults were more in 
number than children (167 adults vs 87 children). Infections (short febrile episodes or 
septicaemia) were reported in 34 (20.5%) adults and 7 (8%) children. Major post 
splenectomy sepsis was documented among 5 adults; 2 cases were in the early post 
splenectomy period (out of which 1 expired), and 3 cases (1 responder, 2 refractory 
cases) had late post splenectomy sepsis (out of which one refractory case expired 
following severe gram negative sepsis and gastrointestinal bleed at 16 months post 
splenectomy). Among the 2 children (refractory cases) who developed major post 
splenectomy sepsis, 1 was in the early post operative period and the other one child had 
2 episodes of late sepsis with hypotension.  
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                        Other health problems encountered were deep vein thrombosis (2 adults; 
one of them had pulmonary embolism), coronoary artery thrombosis (1 adult), and 
thrombocytosis (occlusive vasculitis of the left eye was seen in an adult with platelet 
count 645 x 109/L and one child had asymptomatic thrombocytosis of 541x 109/L).  A 
few of the patients presented with certain malignancies while on follow up, ie;  mantle 
cell lymphoma (1 adult responder at 2 years 8 months post splenectomy), follicular 
lymphoma (1 adult responder at 11 years 4 months post splenectomy), carcinoma of 
breast (1 adult refractory case at 10 years post splenectomy), and adenocarcinoma of 
stomach (1 adult responder at more than 1 year post splenectomy). 2 adults developed 
mixed connective tissue disorder (after 1 year of splenectomy) and one child developed 
autoimmune myocarditis with transient ischemic attack after 10 years of splenectomy. 
3 adults with refractory ITP developed intracranial bleed, and one of them expired due 
to the same at 19 months post splenectomy. Incidence of venous thrombosis is in 
concordance with that reported by Schwartz et al15.  
 
Mortality:  Total deaths were 6 (3.6%) in adults and 1 (1.2%) in children. The median 
time to death was 12 days (range:1-38) in adults and 1 day in children. 4 adults and the 
1 child expired in the early post splenectomy period. The cause of death was intra-
cerebral bleed in 2 adults and the 1 child. Death was due to sepsis in the third adult 
patient and sepsis with intra-cerebral bleed in the fourth. 2 cases of late mortality were 
in adult females in the refractory group. One lady expired at 16 months post 
splenectomy following severe gram negative sepsis with massive gastro-intestinal bleed 
& the second case expired at 19 months post splenectomy following intra-cerebral 
bleed. Similar mortality pattern has been reported by Swartz et al15 & Bourgeois et al77. 
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I.  SURVIVAL CHARACTERISTICS: (Table 22) 
          
                        As on last follow up, 161(96.4%) adult patients were alive and 75 
(46.6%) among them were on follow up. Among children, 86 (98.8%) were alive with 
37 (43%) being on follow up. In responders, the mean duration of follow up was 33.5 
months (median: 11.9, range: 1-164) in adults and 29.5 months (median: 4.5, range:1-
173) in children. For refractory cases it was 38.6 months (median: 38.7, range:1-170) 
in adults and 48.3 months (median:20.1, range:7-154) in children. 
 
                        The 5 year and 10 year overall survival was 96.9 ± 1.6%  & 93.4 ± 3% 
in adults and 98 ± 1.6% & 98 ±1.6% in children respectively. The 5 and 10 year event 
free survival was 75.2 ± 3.7% & 71.5 ± 4.5% in adults and 79.1 ± 4.6% and 70 ±7.5% 
in children respectively. These observations are similar to that reported by Kumar S et 
al1 and Schwartz et al15. 
 
J. PROGNOSTIC DETERMINANTS AND LITERATURE COMPARISON: 
  Analysis in adults showed that higher median platelet count at 
splenectomy (p=0.004), female sex (p=0.011), shorter median time to initial response 
to splenectomy (p=0.031) and higher median peak post splenectomy platelet count 
(p=0.000) observed in responders as compared to refractory cases are statistically 
significant. In adults, the younger age at diagnosis and splenectomy was observed to 
have near statistically significant p value (p=0.061). Comparison with published data 
showed a similar observation for platelet count at splenectomy, peak post splenectomy 
platelet count (Kumar S et al1, Bourgeois et al77, Shojaiefard et al76), younger age at 
splenectomy (Kumar S et al1) and female sex (Bourgeois et al77).   
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 Among responders in children, higher median peak post splenectomy 
platelet count (p=0.001) and persistent phase of the disease (p=0.019) were observed to 
be statistically significant. There is no available comparable literature for the 
observations in children.  
 
 The observations and the prognostic determinants analyzed in the 
present study are compared with the available literature in the tables that ensues (tables: 
25,26). 
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        Table. 25. Splenectomy for persistent and chronic ITP in adults and children: a comparison of present study and literature  
Variables (adult/child) Present study Schwartz et al15
Adults 
KumarS et al1 
Adults 
Bourgeois et al77 
Adults  Children  Adult+child Child 
Time period (duration in years) 1995-2009(15)  1988-1993(5) 1985-1998(14) 1985-1994(10)  
Number of patients 167 87 56 140 183(158+25) 25 
Male:Female 44:123 49:38 11:45 58:82 66:117 -- 
Persistent: chronic 74:93 29:58 -- -- -- -- 
Platelet at diagnosis (1x109/L) $ 10 (1-65) 10 (1-41) -- 15 (1-95) -- --
Age at splenectomy (years) $ 27 (16-65) 10(4-14) 37 (15-81) 56(18-90) -- -- 
Response to initial treatment# 148 (88.6%) 81 (93.1%) -- -- -- -- 
Platelet at splenectomy(1x109/L) $ 20(1-369) 13(1-182) 14.5(2-90) 46.5(1-266) -- -- 
Time to splenectomy (months) $ 14.3(3-290) 18.1(3.1-117) 12 (0.5-233) 7.5(0-26) -- -- 
Laparotomy:Laparoscopy 151:16 82:5 -- -- -- -- 
Splenunculi# 17(10.2) 16 (18.4) 6 (11%) -- -- -- 
Initial responders [CR/R] #   148(88.6%) 81(93.1%) 48 (86%) 123(88%) 159(87%) -- 
Time to initial response(R/CR)-days$ 1(1-54) 1(1-28) -- -- -- -- 
Peak post splenectomy platelet$ 306(1-1831) 292(5-2161) -- -- -- -- 
Time to peak platelet (days) $ 7(1-56) 7(1-50) -- -- -- -- 
Initial Non-responders# 15(9%) 5(5.7%) 8 (14%) 17(12.1%) 24(13%)* 2(8%) 
Post operative deaths# 4 (2.4%) 1(1.2%) -- 2(1.4%) 0 -- 
Subsequent loss of R# 33(22.2%) 18(22.2%) 11(19.6%) 22(15.7%) 29(16%) 5(20%) 
Time to loss of R (months) $ 8.8(0.4-108) 5.9(0.4-116) 4-8.5 yrs 3(1-38) -- -- 
Total  Refractory cases #  48(28.7%) 23(26.7%) 19 (34%) 39(27.9%) 53(29%) -- 
Total patients in response [R/CR] # 115(68.9%) 63(72.4%) 37 (63%) -- -- -- 
Refractory cases responded Rx# 25(52%) 16(69.6%) 5 8(20.5%) 42(79%) 6(24%) 
Refractory in spontaneous remission# 0 (0%) 1(1.2) -- -- 4(2.2%) -- 
Follow up of  total cases (months)$ 38.9 (mean) 33.8 (mean) -- 37.5(0-183) -- -- 
Follow up of  responders$ 11.9(0.2-164) 4.5(0.2-172.7) 7.5yrs (5-10.5) -- -- -- 
Follow up of refractory cases$ 38.7(0.2-169.3) 20.1(6.8-153.7) -- -- 7.5(5-15)yrs -- 
Post splenectomy thrombosis$ 3 (1.8) 0(0) -- 5.7% -- -- 
OS of responders$ 100% 100% --- -- -- -- 
OS  of refractory cases $ 94.7%±3.7% 100% -- -- -- -- 
5 year  EFS# of total cases 75.2 %± 3.7% 79.1 ± 4.6% -- 75% -- -- 
Total number of death# 6 (3.6%) 1(1.2%) 0 (0%) 25(17.9%) -- --
                   #: n (%);   $: median (range)  *14 (10%) had  transient response   
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         Table. 25. Splenectomy for persistent & chronic ITP in adults and children: a comparison of present study & literature contd.. 
Variables (adult/child) Present study Mc Millan R et al2 Shojaiefard et al76 
Adults  Children  Adult refractory cases Adults   
Time period (duration in years) 1995-2009(15)  1986-1998 (13) 2002-2004(2) 
Number of patients 167 87 114 31 
Male:Female 44:123 49:38 41:73 10:21 
Persistent: chronic 74:93 29:58 -- -- 
Platelet at diagnosis (1x109/L) $ 10 (1-65) 10 (1-41) -- --
Age at splenectomy (years) $ 27 (16-65) 10(4-14) 37 ±18.4 yrs 33 
Response to initial treatment# 148 (88.6%) 81 (93.1%) -- 22 
Platelet at splenectomy(1x109/L) $ 20(1-369) 13(1-182) -- 22 
Time to splenectomy (months) $ 14.3(3-290) 18.1(3.1-117) 3-120 5(1-120) 
Laparotomy:Laparoscopy 151:16 82:5 -- -- 
Splenunculi# 17(10.2) 16 (18.4) -- 3 
Initial responders [CR/R] #   148(88.6%) 81(93.1%) 75 (74.1%) 29(93%) 
Time to initial response(R/CR)-days$ 1(1-54) 1(1-28) -- -- 
Peak post splenectomy platelet$ 306(1-1831) 292(5-2161) -- 307(±199) 
Time to peak platelet (days) $ 7(1-56) 7(1-50) -- -- 
Initial Non-responders# 15(9%) 5(5.7%) 23 2(7%) 
Post operative deaths# 4 (2.4%) 1(1.2%) -- -- 
Subsequent loss of R# 33(22.2%) 18(22.2%) -- 5 
Time to loss of R (months) $ 8.8(0.4-108) 5.9(0.4-116) -- 6 
Total  Refractory cases #  48(28.7%) 23(26.7%) 98 5 
Total patients in response [R/CR] # 115(68.9%) 63(72.4%) 51 (48.6%) 26 
Refractory cases responded Rx# 25(52%) 16(69.6%) -- 1 
Refractory in spontaneous remission# 0 (0%) 1(1.2) -- -- 
Follow up of  total cases (months)$ 38.9 (mean) 33.8 (mean) -- -- 
Follow up of  responders$ 11.9(0.2-164) 4.5(0.2-172.7) -- -- 
Follow up of refractory cases$ 38.7(0.2-169.3) 20.1(6.8-153.7) -- -- 
Post splenectomy thrombosis$ 3 (1.8) 0(0) -- -- 
OS of responders$ 100% 100% -- --
OS  of refractory cases $ 94.7%±3.7% 100% -- -- 
5 year  EFS# of total cases 75.2 %± 3.7% 79.1 ± 4.6% -- -- 
Total number of death# 6 (3.6%) 1(1.2%) -- -- 
                            #: n (%);   $: median (range)  *14 (10%) had  transient response   
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        Table. 26. Prognostic determinants of splenectomy outcome- responders versus refractory cases (present study and literature) 
Variables (adult/child) 
 
Present study Schwartz et al15 Kumar S et al1 
Adults  p Children  p Adults p Adults p 
Univariate analysis 
Time period(duration in years) 1995-2009(15) --  -- 1988-1993(5) -- 1985-1998(14) -- 
Number of patients 167 -- 87 -- 56 -- 140 -- 
Male:Female 23:92 vs 19:29 0.011 34:29 vs 14:9 0.631 11:45 0.218 58:82 -- 
Persistent: chronic  52:63 vs 20:28 0.731 26:37 vs 3:20 0.019 -- -- -- -- 
Platelet at diagnosis (1x109/L) $ 10 vs 10 0.882 9.5 vs 10 0.371 -- -- 15 (1-95) -- 
Age at splenectomy (years) $ 26 vs 31 0.061 10 vs 9 0.411 37 (15-81) 0.074 51 vs 73 <0.001 
Response to initial treatment at diagnosis# 57.4% vs 58.3% 0.723 55.6& vs 52% 0.921 -- -- 91% vs 76% 0.03 
Platelet at splenectomy(1x109/L) $ 30 vs 10 0.004 15.5 vs 9.3 0.161 14.5(2-90) -- 59 vs 27 0.008 
Time to splenectomy (months) $ 13.9 vs 15.5 0.757 15.2 vs 27 0.871 12 (0.5-233) 0.397 7.5(0-26) -- 
Laparotomy:Laparoscopy 104:11 vs 43:5 1.000 59:4 vs 22:1 1.000 -- -- -- -- 
Splenunculi 10 vs 7 0.211 14 vs 2 0.323 6 (11%) -- -- -- 
Time to initial response(R/CR)-days$ 1 vs 3 0.013 1 vs 3 0.138 -- -- -- -- 
Peak post splenectomy platelet(1x109/L) $ 400 vs 125 0.000 335 vs 139 0.001 -- -- 385 vs  135 0.001 
Time to peak platelet (days) $ 7 vs 7 0.152 7 vs 7 0.755   -- -- 
Multivariate analysis: 
Higher peak platelet count -- -- -- -- -- -- -- 0.007 
Younger age -- -- -- -- --- -- -- 0.03 
                    #: n (%);   $: median (range)   
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         Table. 26. Prognostic determinants of splenectomy outcome (present study and literature) contd... 
Variables (adult/child) 
Univariate analysis 
Present study Bourgeois et al77    Shojaiefard et al76   Fabris et al87 
Adults  p Children  p Adult/child p  p Adult+child p 
Time period(duration in years) 1995-2009(15) -- -- -- 1985-1998(14 ) -- 2002-
2004(2) 
-- -- -- 
Number of patients 167 -- 87 -- 140 -- 31 -- 61 -- 
Male:Female 23:92 vs 19:29 0.011 34:29 vs 14:9 0.631 53%:69% vs 
47%:31% 
0.07 9:17 vs 1:4 NS 12:24 vs 
8:10 
0.60 
Persistent: chronic  52:63 vs 20:28 0.731 26:37 vs 3:20 0.019 -- -- -- -- -- -- 
Platelet at diagnosis (1x109/L) $ 10 vs 10 0.882 9.5 vs 10 0.371 -- -- 22 vs 19 NS -- -- 
Age at splenectomy (years) $ 26 vs 31 0.061 10 vs 9 0.411 35 vs 39 0.10 -- -- 31 vs 41 0.19 
Response to initial treatment at diagnosis# 58.4% vs 58.4% 0.723 55.6& vs 
52% 
0.921 -- -- -- -- 88% vs 12% -- 
Platelet at splenectomy(1x109/L) $ 30 vs 10 0.004 15.5 vs 9.3 0.161 33 vs 25 0.07 -- -- -- -- 
Time to splenectomy (months) $  13.9 vs 15.5 0.757 15.2 vs 27 0.871 -- -- -- -- -- -- 
Laparotomy:Laparoscopy 104:11 vs 43:5 1.000 59:4 vs 22:1 1.000 -- -- -- -- -- -- 
Splenunculi 10 vs 7 0.211 14 vs 2 0.323 -- -- -- -- -- -- 
Time to initial response(R/CR)-days$ 1 vs 3 0.013 1 vs 3 0.138 -- -- -- -- -- -- 
Peak post splenectomy platelet(1x109/L) $ 400 vs 125 0.000 335 vs 139 0.001 650 vs 346 <0.001 307 vs 309 NS -- -- 
Time to peak platelet (days) $ 7 vs 7 0.152 7 vs 7 0.755 -- -- -- -- -- -- 
Multivariate analysis: 
Higher peak platelet count$: -- -- -- -- -- -- -- -- -- --
Younger age -- -- -- -- -- -- -- -- -- --
Platelet at 1 month after splenectomy$: -- -- -- -- -- -- 328 vs 171 NS -- -- 
Platelet at 3 month after splenectomy$: -- -- -- -- -- -- 275 vs 159 NS -- -- 
Platelet at 6 month after splenectomy$: -- -- -- -- -- -- 262 vs 68 <0.05 -- -- 
Platelet at 12 month after splenectomy$: -- -- -- -- -- -- 262 vs 32 <0.01 -- --
Platelet at 24 months after splenectomy$: -- -- -- -- -- -- 261 vs 35 <0.01 -- -- 
                           #: n (%);   $: median     
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LIMITATIONS OF THE STUDY : 
 
1. Retrospective analysis: As majority are retrospective cases, the clinical, laboratory, 
and follow up parameters in the required detail could not be obtained for all cases due 
to incomplete documentation or missing documents. 
2. Follow up: One of the limitations to data interpretation is the fact that more than 50% 
cases (53.4% in adults and 57% in children) are lost to follow up, with 52 (31%) 
adults and 29 (33.3%) children lost to follow up within one year, and 72 (43%) adults 
and 44 (50.5%) children lost within 5 years post splenectomy.  
3. Change in the terminologies and definitions: The present study is analyzed 
according to the new recommendations and definitions put forth by the international 
working group (IWG),12  applied to a cohort diagnosed and treated as per the old 
definitions, terminologies and outcome criteria. 
4. Comparable clinical trials: Comparable studies analyzed according to the new 
recommendation are lacking.  
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 CONCLUSIONS: 
Splenectomy has the potential to provide long-term control of disease in adults and children with 
ITP who have failed to respond to steroid therapy or who are steroid dependant. The procedure is 
associated with low morbidity and minimal mortality; and nearly two-thirds of patients (adults 
and children) undergoing splenectomy for ITP can be expected to have long-term control of their 
disease. In patients who are in persistent phase of the disease and no life threatening bleeding, 
drug trial may be tried for a reasonable period (at least 12 months) before resorting to 
splenectomy. Most of the loss of responses occurs within first year after splenectomy. Although 
certain pre and post splenectomy variables (ie; females, higher platelet count at splenectomy and 
peak post splenectomy  platelet count),  shows significant correlation with response, this needs 
further analysis to ascertain the predictive value of the variables associated with the response. In 
patients who fail to respond or who have a loss of response after splenectomy, adequate control 
of the disease can often be achieved to some extent with various therapeutic maneuvers. 
Corticosteroids should be the first line of therapy for these patients because the rate of response 
is high, even among those who were refractory to corticosteroids before splenectomy. Other 
agents that can be of benefit include Dapsone, immunosuppressive agents mainly Azathioprine 
and Mycophenolate and Danazol. Life threatening post splenectomy sepsis is an infrequent long 
term complication of the procedure. 
********** 
i 
 
APPENDIX- I 
 
REFRACTORY ITP TREATMENT GROUPS (description) 
Groups Drugs Adults Children 
Group  0 Nil (No Treatment)                                        4 2 
                                                                        Total cases 4 2 
Group  1 Steroid Alone                                                   
      Prednisolone  4 2 
      Dexamethasone  2 1 
                                                                        Total cases 6 3 
Group  2 Dapsone/Azathioprine/Danazol ±Steroid:        
      Dapsone Alone  8 2 
      Dapsone+Steroid 4 5 
      Azathioprine  Alone 5 2 
      Azathioprine+Steroid 6 2 
      Dapsone+Azathioprine+Steroid 3 1 
      Prednisolone,Dapsone,Danazol 0 1 
      Prednisolone,Dapsone,Azathioprine,Danazol 1 1 
                                                                        Total cases 27 14 
Group  3 Combination Treatment:                           
Cyclophosphamide/CSA/MMF/VCR ± Group 1& 2 
Drugs 
  
     Prednisolone,Dapsone,MMF* 1 0 
     Prednisolone,Cyclophosphamide 1 0 
     Pulse Dexa,Dapsone,MMF,CSA* 1 0 
     Prednisolone,Azathioprine,MMF 0 1 
   Prednisolone,Dexamethasone,Dapsone,Azathioprine, 
MMF, CSA,Cylophosphamide,VCR* 
0 1 
     Prednisolone,Dapsone,Azathioprine, 
                 Cyclophosphamide 
3 0 
     Prednisolone,CSA 1 0 
     Prednisolone,Dexamethasone,Dapsone,Azathioprine, 
                 Danazol,CSA,IVIG,VCR 
1 0 
     Danazol,MMF 1 0 
     Prednisolone, Dapsone, Azathioprine,MMF, CSA  0 1 
                                                                        Total cases 9 3 
Group  4 Alternative Treatment:                               
(Homeopathic, Siddha, Ayurvedic medicines) 
2 1 
                                                                        Total cases 2 1 
             *MMF=Mycophenolate, CSA=Cyclosporine A, VCR=Vincristine 
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APPENDIX- II 
 
 
 
 
 
 
 
 
 
 
 
 
DOSAGE OF THE DRUGS USED 
Sl.No Drugs Dosage 
1 Prednisolone  1-2mg/Kg/day 
2 Dexamethasone  0.8/Kg/day 
3 Dapsone  100mgin adults; 1.5mg/Kg/day in children 
4 Azathioprine 1-2 mg/kg/day 
5 Danazol 200mg 3-4 times daily 
6 Cyclophosphamide 1g every 3-4 weeks x 4 doses 
7 Mycophenolate 500mg -1g twice daily  
8 Cyclosporine A 2.5mg/Kg twice daily 
9 Vincristine 1.4mg/m2 every week x 4 doses 
10 IVIG 1g/Kg  x 2 days 
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PROFORMA: 
 
Title:  Splenectomy for children and adults with persistent and chronic immune 
thrombocytopenia: long term results 
Sl.No: 
Name:         Hospital No:    Sex: 
Age at diagnosis:         Date of diagnosis:  
Age at splenectomy:         Date of splenectomy: 
A. Pre-splenectomy clinical and laboratory parameters: 
1. Phase of ITP :    2. Symptoms: 
3. Platelet count:    4. Auto-immune markers: 
5. Viral markers:    6. Bone marrow findings: 
7. Co-morbidities:    8. Initial treatment: 
9. Response to initial treatment:  10.Subsequent treatment: 
11. Response to subsequent treatment: 
12. Total number of presplenctomy loss of response: 
13. Health problems during pre-splenectomy treatment: 
B. Perisplenectomy variables: 
1. Pre-splenectomy status (Steroid dependent/not responsive to steroid or 
multiple agents): 
2. Peri-splenectomy symptoms: 
3. Date of vaccination: 
4. Peri-splenectomy treatment (including Platelet  transfusions): 
5. Pre-splenectomy platelet count: 
6. Date of splenectomy 
7. Nature of splenectomy: Emergency/Elective (if emergency, indication) 
8. Type of splenectomy: Laparotomy/Laparoscopy 
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9. Place of splenectomy: CMC/outside 
10. Splenunculi: Yes/No 
11. Spleen HPR: 
12. Immediate post splenectomy complications: 
13. Antibiotic requirement: 
14. Number of hospital stay: 
C. Post splenectomy variables: 
1. Post splenectomy platelet count at 24hrs, 72hrs, 7 days, 14 days, 1 
month, 2 months, 3 months, 6 months, 9months, 1 year, 2 years, 3 yrs, 
5yrs, 10yrs, 15yrs. 
2. Post splenectomy treatments: (drug/drugs, duration, response) 
3. Type of initial response (R/CR/NR) 
4. Date of initial response: 
5. Peak post splenectomy platelet count & the date of Peak platelet count: 
6. Response status at 2 months (56 days) post splenectomy;: 
7. Dates of subsequent loss of responses: 
8. Treatments at loss of responses (drug/drugs, duration, response) 
9. Total number of post splenectomy loss of responses: 
D. Follow up and final response status: 
 
1. Date of last follow up: 
2. Platelet count at last follow up: 
3. Response status at last follow up (responder/refractory; if refractory 
whether in response to treatment or not): 
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4. Treatment at last follow up (if on treatment, the type, time since when 
on treatment, steroid dependency?) 
5. If in response at last follow up, date since when in response 
6. If not in response, whether symptomatic or not, date of last loss of 
response 
7. If dead, date and cause of death 
8. Post splenectomy health problems (including post splenectomy 
sepsis): 
9. Follow up status (on/lost). 
Sample of follow up letter & form:  
Vellore  
Date: 
Dear Mr. / Ms. ______________________, 
 
Our records show that you / your child, ________________________, CMC No: 
________________,  underwent splenectomy (removal of the spleen) in this hospital 
in __________, _______. (month / year).  
We are analysing the response to treatment of all patients with Immune 
thrombocytopenia (ITP), who underwent splenectomy in this hospital. We therefore 
request you to provide your / your child's current status as per the form attached to 
this letter. Please send the information back to us at the earliest in the self addressed 
envelope provided or by email in the id; haemat@cmcvellore.ac.in 
Thanking you, 
Dr.Alok Srivastava, 
Professor& HOD, 
Department of Hematology, 
Christian Medical College, 
Vellore, Tamilnadu-632004. India. 
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FORM-1 (2009) 
 
Name: 
Hosp No:  
 
1. What are you doing at present?  Working         Studying         At home 
  
 
2. What are the medications you have taken after the last visit to CMCH & for  
 
how long? 
 
Medicine      
Duration  
(from …to …) 
    
 
 
4. Are you on any medications at present?  Yes     No   
   
 
If yes, kindly specify the medicine and for how long you have been taking it; 
   
Medicine: 
 
  Duration (from… to..): 
 
 
 
3. Details of blood tests done after the last visit to CMCH: 
     
Date       
Platelet count        
 
 
 
6. With regard to your current health status kindly tick the appropriate box: 
 
 
 Bleeding problems at present:  Yes  No 
 
  
Site of bleeding:   Gums Nose         Skin          Menstrual  
  
 
Alive:   Dead:      
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7. If not alive; 
 
When was the date of demise?    ………………….. 
 
What was the cause of death?     ……………..……. 
 
 
We request you to send us with your most up to date contact information. 
 
Kindly include: 
 
Postal address: 
Telephone number: 
Mobile number: 
E-mail address: 
 
 
We look forward to seeing you on your next visit and would request you to send us 
information on your current status every year for our records using this form. 
 
Warm regards, 
 
 
 
Dr.Alok Srivastava 
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MASTER CHART: 
CODES : 
 
Expansion of the abbreviations used in Column Headings (in the master chart): 
DOD Date of diagnosis  SHPR Spleen Histopathology 
DOS Date of splenectomy PerSCo Perisplenectomy complications 
Phase  Phase of ITP AB Antibiotics  
AOD Age at diagnosis HS Hospital stay 
AOS Age of splenectomy IPoSR Initial post splenectomy response 
SAD Symptom at diagnosis DOIPoSR Date of initial post splenectomy response 
PAD Platelet at diagnosis PePC Peak post splenectomy platelet count 
DCT Direct coomb’s test TtPePC Time to peak post splenectomy platelet count 
ANA Antinuclear antibody IPSoRDr Initial post splenectomy response with drug 
VM Viral markers PoSLOR Post splenectomy loss of response 
CM Co-morbidities DOPoSLOR Date of  post splenectomy loss of response 
IT Initial treatment PoSR-2mo Post splenectomy response at 2 months 
RTIT Response to initial treatment TPoSLOR Total post splenectomy loss of  response 
TPrSLOR Total presplenectomy loss of response OAT&R-Ref Overall treatment & response of REF cases 
SPrST Subsequent presplenectomy treatment DOLFU Date of  last follow up 
PrSR Presplenectomy response status PLFU Platelet count at last follow up 
PerSS Perisplenectomy symptoms TLFU Treatment at last follow up 
DOV Date of vaccination D/A Dead/Alive 
PrSPC Presplenectomy platelet count Res/Ref Type according to response to splenectomy-
Responder/refractory 
PerST Perisplenectomy treatment FR-LFU Final response outcome as on last follow up 
Ls/Lp Laparoscopic/laparotomy splenectomy OFUS Over all follow up status 
TOS Type of splenectomy Res-DOR For responders, date since when in response 
PRC PRC transfusion Ref-DOR For ref ITP in response, date since when in last 
response 
Spln Splenunculi DODe Date of death 
 
 
 
 
               
 
 
 
    
 PHASE OF ITP  
 
 
 
 
 
 
 
 
 
SYMPTOMS AT DIAGNOSIS; PERI SPLENECTOMY 
SYMPTOMS 
1 PERSISTENT 0 NA  
2 CHRONIC 1 Skin only 
VIRAL MARKERS 2 Mucosal only 
0 NA 3 Skin+ /Mucosal + Other 
1 Hepatitis C positive 4 Menorrhagia  ± Other Bleeds 
2 Hepatitis B positive 5 ICH+/Other Bleed 
3 Negative 6 Asymptomatic  
AUTO – IMMUNE MARKERS  
0 NA 
1 POSITIVE 
 
CO-MORBIDITIES 
 
 
 
 
 
RESPONSE TO INTIAL TREATMENT 
0 NA 0 NA 
1 Thyroid Disease-Hypothyroidism 1 R (Response) 
2 Hypertension/IHD 2 CR (Complete Response) 
3 Diabetes Mellitus 3 NR (No Response) 
4 H/O Tuberculosis/Hansen’s Disease  
5 Others 
6 Nil 
xx 
 
 
 
 
 
 
               
 
 
 
 
 
 
INITIAL POST SPLENECTOMY RESPONSE (CR/R/NR) 
 
- POST SPLENECTOMY RESPONSE AT 2 MONTHS 
 
 
 
 
 
-INITIAL POST SPLENECTOMY RESPONSE 
with/without DRUG 
-TREATMENT AT LAST FOLLOW UP  
0 Not applicable (NA) 0  not applicable (Cases with NR [No 
Response]) 
1 R (Response) 1 No Drug 
2 CR (Complete response) 2 On Steroid 
3 
3a 
LOCR (Loss of CR) 
LOCR and then responded 
3 On Dapsone± Steroid 
4 
4a 
LOR (Loss of Response) 
LOR and then responded 
4 On Danazol ± Steroid 
5 NR (No response) 5 On Azoran ± Steroid 
6 LFU (Lost for follow up) 6 On Combination Chemo 
7 EXPIRED 7 Others 
 
PLATELET COUNT AT DIAGNOSIS   
 PRE-SPLENECTOMY PLATELET COUNT 
 
 
 
 
INITIAL TREATMENT (DRUG) 
0 NA 0 NA 
1 Patients with platelet count   ≤ 10 x 109/L 1 STEROIDS (pred,dexa,M.pred) 
2 Patients with platelet count   11-30 x 109/L 2 IVIG +/pred 
3 Patients with Platelet count   31-100 x 109/L 3 ANTI-D/pred 
4 Patients with platelet count   > 100 x 109/L 4 Others (pred+vincristine) 
 
SUBSEQUENT PRESPLENECTOMY TREATMENT REGIMENS 
        
 TYPE OF SPLENECTOMY 
 
0 NA 1 Laparotomy  
1 Pred,M.pred, HC,Dexa 2 Laparoscopic  
2 Dapsone ± steroid   
3 Danazol ±steroid 1 Elective  
4 Azathioprine ± steroid 2 Emergency  
5 Cyclophosphamide /vincristine ± steroid    
6 Cyclosporine/MMF ± steroid PRE SPLENECTOMY RESPONSE 
STATUS
7 Dapsone + Azoran ± steroid 0 NA 
8 Dapsone±Azoran + Danazol ± Steroid 1 SD (Steroid dependent) 
9 Other combination chemotherapy ±  anti-D/IVIG 2 SR (Not Responding To 
Steroid) 
10 Others (Homeo/Siddha/Ayurveda) 3 Not Responding To Multiple 
Agents 
(Steroid/Dapsone/Azoran) 
11 No treatment   
PERI SPLENECTOMY TREATMENT  
 
 
PRC TRANSFUSION 
0 NA 0 NA 
1 HDD 1 yes 
2 PRED 2 no 
3 HC (Hydrocortisone)   
4 IVIG ± steroid  
5 No Treatment  
SPLENECULI  
 
PERI SPLENECTOMY COMPLICATIONS 
0 NA 0 NA 
1 YES 1 Hemorrhage  
2 NIL 2  Infection 
SPLEEN HPR  3 Death 
0 NA 4 DVT/PE 
1 Congestion 5 NIL 
2 Follicular Hyperplasia ANTIBIOTIC REQUIREMENT 
3 Tuberculosis 0 NA 
4 Hyaline Arteriolar Sclerosis 1 YES 
2 NO 
xxi 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
POST SPLENECTOMY LOSS OF R1 (YES/NO) 
 
 
 
 
 
POST SPLENECTOMY FOLLOW UP AT 2 MONTHS 
 
0 NA (No Response/Lost for follow up) 1 On follow up 
 
1 
 
yes 
2 Lost for follow up 
2 no 
 
 
 
 
 
 
Number of post splenectomy loss of R 
 
 
 
 
 
 
 
 
 
 
 
DEAD/ALIVE AS ON LAST Follow up 
 
0 
 
NA-NR/EXPIRED 
1 Alive 
1 one  2 Dead 
2 two TYPES OF ITP ACCORDING TO RESPONSE TO 
SPLENECTOMY 
3 Three 0 NA (Expired immediate post splenectomy) 
4 four 1 Responders (R/CR/LOCR) 
5 five 2 Refractory ITP (NR/LOR)Responders (R/CR/LOCR) 
6 nil   
7 lost for follow up   
FINAL OUTCOME AS ON LAST FOLLOW UP: 
1-5, 7,8,9: REFRACTORY CASES 
1-5: REFRACTORY CASES (NR/LOR) WHO RESPONDED TO Rx & are in response 
1 R1/CR1 
2 R2/CR2 
3 R3/CR3 
4 R4/CR4 
5 R5/CR5 
RESPONDERS: (Cases in R, CR and LOCR) 
6 RESPONDRES with no subsequent loss of R1 (continuing in initial R1/CR1/LOCR1) 
7: REF ITP- CONTINUED IN (NR) 
 
7 
7 SYMPTOMATIC 
7a ASYMPTOMATIC 
8: REF ITP IN LOSS OF R 
 
8 
8 SYMPTOMATIC 
8a ASYMPTOMATIC 
9 NR went into spontaneous remission 
10 EXPIRED 
OVERALL FOLLOW UP STATUS  OVERALL TREATMENT & RESPONSE OF 
REFRACTORY ITP
1 on follow up Code Treatment + response status 
2 lost to follow up 0 Group 0, responder 
  0a Group 0, non-responder 
3 EXPIRED 1 Group 1, responder 
TREATMENT STATUS AS ON LAST FOLLOW UP 1a Group 1, non-responder 
0 NA (EXPIRED) 2 Group 2, responder 
1 On treatment 2a Group 2, non-responder 
2 Steroid dependent 3 Group 3, responder 
3 Off treatment 3a Group 3, non-responder 
  4 Group 4, responder 
  4a Group 4, non-responder 
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MASTER CHART 
 
Sl No 
 
Sex 
 
DOD 
 
DOS 
 
PHASE 
 
AOD 
 
AOS 
 
SAD 
 
PAD 
 
DCT 
 
ANA 
 
VM 
 
CM 
 
IT 
 
RTIT 
 
TPrSLOR 
 
SPrST 
 
PrSR 
 
PerSS 
 
DOV 
 
PrSPC 
 
PerST 
 
Ls/Lp 
 
TOS 
 
PRC 
1 F 01.01.1985 03.14.1995 2 12 22 4 1 2 2 3 6 1 1 0 1 1 6 NA 1 5 1 1 1 
2 F 01.01.1991 05.23.1995 2 12 16 0 0 0 0 0 0 1 2 0 0 0 0 NA 4 5 1 1 2 
3 F 01.01.1993 06.20.1995 2 14 16 0 0 0 0 0 0 1 3 0 11 2 0 NA 2 5 1 1 0 
4 F 02.14.1995 11.08.1995 1 26 26 4 0 2 2 3 6 1 3 0 11 2 4 NA 2 5 1 1 0 
5 F 05.01.1995 11.13.1995 1 23 23 4 0 0 0 3 6 1 3 0 11 2 4 NA 3 5 1 1 1 
6 M 09.03.1995 03.07.1996 1 23 23 1 2 2 0 3 6 1 3 0 11 2 6 02.20.1996 2 5 1 1 0 
7 M 01.01.1989 03.26.1996 2 9 15 1 0 0 0 3 6 1 2 0 1 1 6 NA 3 5 1 1 2 
8 F 04.01.1994 07.16.1996 2 24 26 4 0 0 0 3 5 1 1 1 1 1 4 NA 3 5 1 1 2 
9 F 01.01.1996 12.01.1996 1 31 31 4 0 0 0 3 6 0 0 0 0 0 0 NA 0 0 1 1 0 
10 F 04.01.1996 11.01.1996 1 22 22 4 0 0 0 3 6 1 3 0 11 2 4 NA 2 5 1 1 1 
11 F 05.01.1996 12.03.1996 1 51 54 1 0 0 0 3 2 1 3 0 3 3 1 NA 2 5 1 1 1 
12 F 05.15.1996 12.02.1996 1 29 30 1 2 2 2 3 6 1 1 0 1 2 1 NA 1 5 1 1 1 
13 F 12.01.1995 03.12.1996 1 26 27 3 2 0 2 3 6 1 2 1 1 1 2 NA 2 0 1 1 1 
14 F 06.01.1996 02.14.1997 1 28 24 1 1 0 0 3 6 1 1 0 1 2 6 NA 3 1 1 1 2 
15 F 09.01.1996 05.26.1997 1 29 30 3 2 0 0 2 6 1 2 1 1 2 3 NA 2 2 1 1 1 
16 F 03.01.1997 09.11.1997 1 33 35 3 0 0 0 3 6 1 3 0 1 1 3 NA 3 2 1 1 2 
17 M 01.01.1996 01.28.1998 2 33 35 3 0 2 2 3 4 1 3 0 2 3 1 01.01.1998 1 5 1 1 1 
18 F 11.01.1996 03.04.1998 2 27 29 4 1 2 2 3 6 1 2 1 1 1 4 NA 3 1 1 1 2 
19 F 01.01.1997 03.31.1998 2 39 40 3 0 2 2 3 6 1 2 1 1 2 6 NA 3 1 1 1 1 
20 F 08.24.1996 04.21.1998 2 18 20 4 0 1 1 3 6 1 2 3 1 1 6 12.19.1997 2 2 2 1 2 
21 F 09.01.1997 05.05.1998 1 42 43 1 2 2 2 3 6 1 2 1 3 3 1 04.21.1998 1 0 1 1 1 
22 M 11.01.1996 04.28.1998 2 46 48 1 1 2 1 3 2 1 2 1 1 1 6 01.01.1997 3 1 1 1 2 
23 M 06.01.1997 04.22.1998 1 64 65 3 2 0 0 3 3 1 1 0 7 3 3 02.13.1998 2 5 1 1 2 
24 F 04.27.1993 06.19.1998 2 13 17 4 3 0 0 3 5 1 2 2 1 1 4 05.18.1998 2 2 1 1 2 
25 F 02.01.1998 12.22.1998 1 51 52 3 0 2 2 3 6 1 3 0 4 3 3 NA 3 2 1 1 2 
26 F 01.01.1987 02.09.1998 2 8 19 4 1 2 2 3 5 1 1 0 1 2 4 01.09.1998 2 1 2 1 1 
27 F 01.01.1998 01.08.1999 2 26 27 4 0 2 0 3 6 1 3 0 4 3 4 10.09.1998 2 0 1 1 1 
28 F 06.01.1998 01.05.1999 1 22 22 3 1 2 2 3 5 1 3 0 1 2 2 NA 1 0 1 1 1 
29 F 04.01.1998 02.10.1999 1 15 16 4 1 0 0 3 6 1 3 0 1 2 4 NA 1 0 1 1 1 
30 F 02.01.1998 02.24.1999 2 22 23 4 1 2 2 3 6 1 2 1 1 1 4 01.15.1999 4 1 1 1 2 
31 F 11.01.1998 06.09.1999 1 31 32 1 1 0 0 3 6 1 1 0 8 3 6 NA 1 0 1 1 0 
32 F 11.01.1998 11.22.1999 2 38 39 4 1 2 2 3 6 1 3 0 2 3 1 11.17.1999 3 0 1 1 2 
33 M 04.01.1999 11.17.1999 1 28 28 3 1 0 0 3 6 1 3 0 1 2 1 NA 2 5 1 1 1 
34 M 06.09.1999 04.03.2000 1 9 15 3 1 0 0 3 6 1 3 1 2 1 6 02.01.2000 4 1 1 1 0 
35 F 10.10.1997 09.05.2000 2 29 31 4 2 2 2 3 6 1 3 2 7 1 6 03.20.1998 3 2 1 1 2 
36 F 11.01.1999 05.25.2000 1 22 23 4 2 0 0 3 6 1 1 0 1 2 4 NA 2 2 1 1 1 
37 M 01.01.1994 07.17.2000 2 9 15 3 0 0 2 3 6 1 1 1 2 3 2 04.06.1999 2 0 1 1 0 
38 F 01.01.1994 09.25.2000 2 22 28 3 0 0 0 3 1 1 2 1 2 1 4 08.08.2000 2 2 1 1 0 
39 F 11.01.1999 10.25.2000 1 27 28 4 3 2 2 3 6 1 1 1 7 1 6 03.24.2000 4 1 1 1 2 
40 F 04.01.2000 10.16.2000 1 28 28 3 1 2 2 3 6 1 3 0 4 3 4 09.28.2000 1 1 1 1 1 
41 F 03.15.2000 11.03.2000 1 29 30 4 1 2 2 3 6 1 1 0 2 1 6 06.28.2000 4 5 2 1 2 
42 F 05.01.2000 08.07.2000 1 34 34 3 0 2 2 3 6 2 1 0 11 2 6 NA 3 1 1 1 2 
43 F 04.01.2000 01.08.2001 1 23 24 4 1 2 2 3 6 1 3 0 2 3 4 NA 1 1 1 1 1 
44 F 04.24.2000 01.25.2001 1 15 16 3 1 0 2 3 6 1 2 1 2 1 6 12.08.2000 4 2 1 1 2 
45 F 07.01.2000 02.05.2001 1 21 22 1 1 2 2 3 6 1 3 0 1 2 1 NA 3 1 1 1 2 
46 F 12.01.1999 02.14.2001 2 21 23 4 1 0 0 3 6 1 3 0 4 3 4 11.07.2000 3 2 1 1 2 
47 F 12.01.1995 11.07.2001 2 57 61 3 1 0 0 3 2 1 2 3 7 1 3 08.05.1997 1 4 1 2 1 
48 F 01.01.1995 05.23.2001 2 55 61 1 1 2 1 3 2 1 2 1 1 1 6 NA 4 2 1 2 2 
49 M 01.01.1996 10.08.2001 2 12 17 3 1 0 0 3 6 1 1 0 1 1 3 NA 4 1 1 1 2 
50 F 06.01.2000 11.19.2001 2 35 36 4 1 1 0 0 5 1 2 1 2 1 4 04.20.2001 3 1 1 1 1 
51 F 01.01.1999 07.12.2001 2 31 31 1 2 0 2 3 6 1 1 1 4 1 6 02.22.1999 1 1 1 1 1 
52 F 10.01.2001 04.29.2002 1 29 29 4 1 2 2 3 6 1 3 0 2 3 4 04.01.2002 2 1 1 1 1 
53 F 02.01.2001 05.13.2002 2 16 17 4 2 2 2 2 6 1 2 2 2 3 4 05.29.2001 3 1 1 1 2 
54 F 03.01.2002 09.09.2002 1 17 17 1 0 0 0 3 6 1 3 0 7 3 6 08.27.2002 3 1 1 1 2 
55 F 02.01.2002 09.30.2002 1 25 25 5 1 1 2 3 6 1 3 0 9 3 5 09.27.2002 1 1 1 2 1 
56 F 08.01.1999 08.12.2002 2 17 20 1 2 1 1 3 6 1 2 1 1 2 6 07.26.2002 4 1 1 1 2 
57 M 06.14.2000 03.17.2003 2 18 21 2 1 0 0 3 6 1 3 0 7 3 6 09.01.2002 3 1 1 1 1 
58 F 07.01.2002 06.23.2003 1 44 45 4 1 2 2 3 3 1 3 0 7 3 4 09.01.2002 4 1 1 1 2 
59 F 12.26.2002 06.30.2003 1 49 50 4 3 2 2 3 3 1 3 0 7 3 2 02.19.2003 2 1 1 1 1 
60 F 07.27.1995 07.02.2003 2 9 17 4 1 0 0 3 6 1 3 0 7 3 2 05.16.2003 1 1 1 1 1 
61 M 09.06.2002 07.28.2003 1 53 54 3 1 2 1 3 4 1 1 0 7 3 6 07.21.2003 2 1 1 1 1 
62 F 08.13.1999 09.10.2003 2 51 55 4 2 2 2 3 2 1 3 1 7 1 6 08.05.2003 3 2 1 1 2 
63 M 04.01.2003 10.27.2003 1 33 33 1 0 0 2 3 6 1 3 0 4 3 6 10.21.2003 3 1 1 1 2 
64 F 01.01.2000 11.10.2003 2 25 28 4 3 2 1 3 6 1 1 0 7 1 4 09.22.2003 1 1 1 1 1 
65 F 04.01.2003 11.17.2003 1 22 22 3 1 0 2 3 6 1 1 0 7 1 4 10.15.2003 4 1 1 1 2 
66 M 01.11.2000 07.07.2003 2 24 27 3 2 2 2 3 6 1 3 0 7 3 6 05.23.2003 3 1 1 1 2 
67 M 05.01.2002 12.22.2003 2 18 19 3 2 0 0 3 6 1 1 0 1 1 3 07.09.2002 2 2 1 1 1 
68 M 04.01.2003 07.28.2003 1 38 38 3 1 2 0 3 6 1 2 1 1 2 3 07.23.2003 1 1 1 2 1 
69 F 04.09.2003 01.28.2004 1 21 22 4 1 1 2 3 6 1 3 0 2 3 4 01.27.2004 1 5 1 1 1 
70 F 08.28.2003 05.20.2004 1 45 46 1 1 2 2 3 1 1 1 0 7 3 5 05.07.2004 2 1 1 2 1 
xxiii 
 
71 F 09.04.2001 06.14.2004 2 23 26 4 1 2 1 3 6 1 2 4 4 1 6 06.01.2004 3 1 1 1 2 
72 F 01.01.2004 06.21.2004 1 21 22 4 2 0 1 3 6 1 3 0 2 1 6 05.25.2004 4 1 1 1 2 
73 F 01.01.2004 08.12.2004 1 57 57 1 2 1 1 3 5 1 1 0 1 1 6 08.11.2004 3 1 1 1 2 
74 F 01.01.1993 10.06.2004 2 5 16 3 3 2 2 0 6 1 2 4 1 2 4 10.10.2003 2 1 1 1 2 
75 M 11.01.2003 02.25.2004 1 51 52 3 1 2 2 3 3 2 3 0 4 3 3 02.16.2004 1 2 1 1 1 
76 F 09.01.2003 02.16.2005 2 16 18 4 0 0 2 3 6 1 1 0 7 3 4 02.11.2005 1 5 1 1 1 
77 F 05.29.2003 02.23.2005 2 20 22 4 1 0 2 3 6 1 3 0 7 3 4 11.28.2003 1 5 1 1 2 
78 F 12.26.2003 02.28.2005 2 42 44 4 1 0 2 3 6 1 3 0 9 3 4 02.08.2005 3 1 1 1 1 
79 F 01.01.2000 03.02.2005 2 15 20 4 2 2 2 3 1 1 1 0 1 1 4 02.23.2005 1 1 1 1 1 
80 F 04.01.2004 03.14.2005 1 29 30 4 2 1 1 3 6 1 3 1 4 3 6 09.01.2004 4 1 1 1 2 
81 M 08.01.2004 07.13.2005 1 14 15 1 1 2 0 3 6 1 3 0 7 3 1 02.09.2005 1 5 1 1 2 
82 F 03.04.2005 11.16.2005 1 40 41 4 1 1 0 3 5 1 3 1 8 3 5 10.05.2005 1 1 2 2 1 
83 F 07.01.1999 03.16.2005 2 13 18 4 0 2 0 3 6 1 1 0 7 1 4 02.23.2005 2 5 1 1 2 
84 F 11.01.2003 09.21.2005 2 18 20 5 2 0 1 3 6 1 1 1 7 3 4 07.23.2005 1 5 1 1 1 
85 F 03.01.2000 06.01.2005 2 28 33 1 1 2 2 3 5 1 1 0 2 3 4 05.31.2005 4 1 1 1 2 
86 F 02.01.2005 05.29.2006 2 39 40 4 2 0 0 3 5 1 3 0 4 3 4 05.26.2006 2 1 1 1 1 
87 F 04.01.2006 09.27.2006 1 20 20 3 2 1 1 3 6 1 3 0 9 3 2 09.15.2006 1 1 1 1 2 
88 M 05.13.2004 07.24.2006 2 13 15 3 2 0 0 3 6 2 3 2 7 1 6 08.06.2005 3 1 1 1 2 
89 F 04.18.2005 08.02.2006 2 14 15 4 3 2 2 3 6 1 2 2 2 1 1 07.21.2006 1 1 1 1 1 
90 F 12.01.2005 03.27.2006 1 15 16 5 1 2 1 3 6 1 1 0 4 3 6 03.17.2006 4 1 1 1 2 
91 F 11.01.2005 02.08.2006 1 58 58 2 1 2 2 3 2 1 2 1 8 1 5 02.08.2006 1 1 1 2 1 
92 F 06.08.2004 06.06.2007 2 18 20 5 1 2 1 3 6 1 1 2 7 1 4 05.15.2007 4 1 1 1 2 
93 M 06.14.2005 03.26.2007 2 20 22 3 2 2 0 3 5 1 2 4 7 1 6 03.21.2007 3 1 1 1 1 
94 M 03.25.2006 04.02.2007 2 25 26 1 2 2 2 3 6 1 1 0 4 3 6 02.07.2007 1 5 1 1 2 
95 M 04.15.2006 04.09.2007 2 41 42 6 3 1 2 3 3 1 1 0 7 3 6 03.31.2007 1 1 1 1 1 
96 F 01.01.1999 04.16.2007 2 9 17 3 1 2 2 3 6 1 2 2 7 1 4 04.29.2005 3 1 1 1 2 
97 F 01.01.2001 07.30.2007 2 22 28 4 0 2 1 3 6 1 2 2 7 1 4 10.28.2003 3 1 1 1 2 
98 M 08.01.2006 10.31.2007 2 32 33 3 1 1 1 3 2 2 3 0 7 3 6 08.17.2007 2 1 1 1 1 
99 F 09.28.2006 08.06.2007 1 17 18 4 1 2 1 3 6 1 2 1 4 1 4 07.30.2007 4 1 1 1 2 
100 F 02.01.2007 11.02.2007 1 21 21 4 0 2 2 3 6 1 3 0 2 3 4 10.06.2007 3 1 2 1 2 
101 F 02.01.2004 08.06.2007 2 15 18 3 0 0 0 3 6 1 1 1 7 3 6 04.16.2007 1 1 1 1 1 
102 F 12.01.2006 06.06.2007 1 21 21 4 2 2 1 3 1 1 1 0 4 1 6 05.23.2007 4 1 1 1 2 
103 F 01.01.1997 01.07.2008 2 24 34 4 1 2 2 3 3 1 1 3 8 1 4 12.28.2007 4 1 1 1 2 
104 F 05.06.2000 12.26.2007 2 17 22 4 2 1 1 3 6 1 2 3 7 1 5 12.12.2007 2 1 1 2 2 
105 F 07.20.2005 01.15.2008 2 25 27 4 2 2 2 3 6 1 2 3 7 1 4 12.22.2007 2 1 2 1 1 
106 F 11.01.2005 02.18.2008 2 13 16 4 1 2 2 3 6 1 1 0 2 1 4 01.29.2008 2 1 1 1 2 
107 M 03.01.2006 03.11.2008 2 36 38 3 2 2 0 3 6 1 1 2 2 1 6 02.20.2007 2 5 1 1 1 
108 M 10.13.1984 07.30.2008 2 15 29 1 0 2 0 3 6 1 2 2 5 1 1 05.10.2008 3 1 1 1 2 
109 F 02.01.2008 08.13.2008 1 31 31 3 1 2 2 3 6 1 1 0 9 1 3 07.29.2008 3 1 1 1 1 
110 F 01.01.2007 04.15.2008 2 36 37 3 1 0 2 3 6 1 3 0 8 3 6 03.17.2008 2 5 2 1 1 
111 F 04.01.2004 02.19.2008 2 15 19 1 2 0 0 3 6 1 0 1 7 3 4 01.15.2008 1 1 1 1 1 
112 F 04.14.2003 05.09.2008 2 14 19 1 2 2 2 3 6 1 1 1 7 1 1 04.18.2008 4 2 2 1 2 
113 F 08.20.2005 05.22.2008 2 34 37 6 2 2 2 3 1 1 1 1 2 3 6 01.01.2008 4 2 2 1 2 
114 F 04.01.2006 06.17.2008 2 39 41 4 1 2 2 3 6 1 2 1 9 3 6 01.25.2008 1 2 2 1 2 
115 F 12.20.2007 01.11.2008 1 24 25 4 1 1 2 3 6 4 3 0 11 2 4 01.11.2008 1 1 1 2 1 
116 F 07.01.2008 02.25.2009 1 19 20 4 1 2 1 3 1 3 3 0 9 1 5 09.06.2008 3 1 1 1 2 
117 F 07.01.2008 02.17.2009 1 24 25 5 2 2 2 3 6 1 3 0 1 2 5 02.13.2009 1 1 1 2 1 
118 M 05.01.2008 06.22.2009 2 27 28 3 1 1 1 3 6 2 3 1 8 3 3 09.04.2008 3 1 1 1 2 
119 F 11.24.2007 07.17.2009 2 35 37 4 2 1 2 3 6 1 1 0 7 3 4 06.03.2009 3 1 2 1 2 
120 F 10.07.1994 06.06.1995 1 16 17 4 0 2 2 3 4 1 3 0 11 2 4 10.18.1994 1 5 1 1 0 
121 F 01.01.1995 08.04.1995 1 38 38 4 1 2 2 3 6 1 3 0 1 2 4 NA 1 5 1 1 2 
122 F 11.08.1994 11.28.1995 2 16 17 4 1 2 2 3 6 1 3 0 5 3 4 NOT GIVEN 1 5 1 1 1 
123 F 03.01.1996 10.23.1996 1 32 32 2 1 2 2 3 5 1 3 0 3 3 5 09.24.1996 3 5 1 2 1 
124 F 05.25.1996 12.05.1996 1 22 22 4 1 2 2 3 6 1 1 1 1 1 4 10.25.1996 3 2 1 1 2 
125 F 01.01.1996 01.03.1997 2 31 32 1 2 2 2 3 6 1 3 0 1 1 6 11.09.1996 2 1 1 1 0 
126 F 01.01.1997 06.17.1997 1 40 40 5 1 0 2 3 6 1 1 NA 1 2 5 NA 2 0 1 1 1 
127 F 08.20.1997 02.03.1998 1 14 15 4 1 2 0 3 6 1 3 1 7 3 4 12.17.1997 1 5 2 1 0 
128 M 02.01.1998 11.20.1998 1 19 19 3 1 0 0 0 5 1 2 1 2 3 3 NA 2 5 1 1 1 
129 F 03.9.1997 01.07.1999 2 21 23 4 2 1 1 3 6 1 2 1 1 2 2 12.11.1998 1 1 1 1 1 
130 M 02.11.1998 01.22.1999 1 59 58 1 2 0 0 3 2 1 1 0 7 3 6 07.10.1998 0 0 1 1 0 
131 F 01.12.1999 07.14.1999 1 33 33 3 1 2 2 3 5 1 1 0 2 3 3 06.08.1999 4 1 1 1 2 
132 F 01.01.1998 07.05.1999 2 34 35 4 1 0 0 3 6 1 1 0 2 3 4 NA 1 0 1 1 0 
133 F 03.01.1998 11.22.1999 2 18 19 4 1 2 2 3 5 1 3 1 2 3 4 10.31.1999 1 1 1 1 0 
134 M 10.01.1999 05.08.2000 1 52 53 3 3 0 0 3 6 1 3 0 4 3 2 04.08.2000 1 1 1 1 0 
135 M 01.01.1996 06.26.2000 2 13 17 3 1 0 0 3 6 1 3 0 9 3 5 06.09.2000 2 1 1 2 1 
136 M 09.01.1999 09.04.2000 2 24 25 3 2 0 0 3 4 1 2 1 1 2 6 08.10.2000 1 0 1 1 1 
137 M 06.01.2000 01.15.2001 1 17 18 3 1 0 0 3 6 1 3 0 2 3 3 10.03.2000 3 1 1 1 1 
138 M 09.01.2000 02.13.2002 2 12 16 3 0 0 0 3 6 1 2 1 2 1 6 01.10.2002 4 1 1 1 2 
139 F 10.01.2001 04.15.2002 1 53 54 3 1 0 2 3 3 1 3 0 4 3 6 12.01.2001 1 1 1 1 2 
140 F 01.01.1993 04.15.2002 2 52 61 3 2 0 0 3 1 1 2 1 9 3 1 04.06.1999 1 1 1 1 1 
141 F 05.27.1999 07.08.2002 2 47 50 1 3 2 2 3 5 1 1 3 2 3 6 06.02.1999 2 0 1 1 1 
142 F 01.01.2000 03.03.2003 2 19 22 4 2 2 2 3 6 1 3 0 9 3 4 02.05.2003 3 1 1 1 2 
143 M 10.01.2001 03.31.2003 2 60 61 1 2 2 2 3 3 1 1 0 7 1 6 03.25.2003 3 1 1 1 2 
144 M 12.01.2000 01.05.2004 2 23 27 3 2 0 0 3 6 1 1 0 9 3 6 05.11.2001 1 1 1 1 1 
xxiv 
 
145 M 04.14.1997 07.23.2004 2 57 59 3 2 0 0 3 1 1 1 0 9 3 6 07.21.2004 3 5 1 2 1 
146 F 06.09.2003 08.24.2004 2 26 27 3 1 1 0 3 5 1 1 2 7 1 3 07.23.2004 1 1 1 2 1 
147 M 01.01.2004 07.12.2004 1 40 40 3 1 2 2 3 3 1 1 0 2 3 6 06.08.2004 1 5 1 1 1 
148 F 02.01.2004 09.22.2004 1 16 16 4 2 2 2 3 6 1 1 0 7 3 2 04.30.2004 2 1 1 1 1 
149 F 01.01.1991 09.29.2004 2 34 47 3 1 0 0 3 6 1 2 4 9 1 2 09.24.2004 1 1 1 1 1 
150 F 09.01.2004 03.08.2005 1 21 22 4 2 2 0 3 6 2 3 0 4 3 4 01.11.2004 1 1 1 1 1 
151 F 04.01.2004 03.11.2005 1 29 30 4 2 2 1 3 6 1 3 0 3 3 4 NA 0 0 1 1 2 
152 M 01.01.2003 04.10.2006 2 47 50 2 1 2 2 3 3 1 1 0 7 3 6 10.08.2004 3 1 1 1 2 
153 F 04.01.2006 10.25.2006 1 35 35 4 2 2 2 3 6 2 3 0 2 3 4 10-16-2006 1 1 1 1 1 
154 F 03.01.2001 02.20.2006 2 52 57 1 1 0 0 3 1 1 1 1 8 1 6 02.14.2006 1 5 1 1 1 
155 F 06.26.2005 12.12.2007 2 17 19 4 1 2 0 3 1 1 1 2 2 1 4 11.27.2007 3 1 1 1 2 
156 F 01.01.2006 05.03.2007 2 27 27 4 1 1 2 3 6 1 1 0 9 1 4 04.19.2007 0 0 1 1 1 
157 F 10.15.2004 10.18.2007 2 24 27 1 2 2 2 3 6 1 1 1 2 1 6 10.18.2007 1 1 1 2 1 
158 M 11.04.2004 03.24.2008 2 21 24 2 0 0 2 3 6 1 1 1 7 3 6 NA 3 1 1 1 1 
159 M 01.01.1998 08.25.2008 2 39 48 3 1 1 2 3 5 1 2 1 1 2 6 08.18.2008 1 4 1 2 2 
160 M 03.01.2005 04.23.2008 2 37 40 3 1 0 0 3 2 1 3 0 7 3 6 02.22.2008 3 4 1 1 2 
161 M 12-01.2006 06-30-2008 2 48 50 1 2 2 1 3 4 1 3 1 9 3 6 05.02.2008 1 1 1 1 2 
162 M 01.01.2008 08.20.2008 1 58 58 3 1 2 2 3 6 1 3 0 8 3 2 08.06.2008 1 1 1 1 1 
163 F 04.04.2007 01.22.2008 1 32 33 3 0 2 2 3 5 1 1 1 9 1 6 12.04.2007 4 1 2 1 1 
164 M 05.01.2007 02.26.2008 1 17 18 3 0 2 2 3 6 1 3 1 2 3 1 02.09.2008 1 1 2 1 1 
165 F 01.01.1998 05.16.2008 2 22 32 4 0 2 2 3 1 1 2 2 2 1 1 03.14.2008 1 5 2 1 1 
166 F 01.01.2000 01.06.2009 2 12 21 4 3 1 2 3 6 1 3 0 4 3 6 11.25.2008 1 1 2 1 1 
167 M 11.01.2007 07.20.2009 2 17 20 3 2 2 2 3 5 1 2 1 7 3 2 03.13.2009 2 5 1 1 1 
168 F 11.01.1994 02.16.1995 1 9 10 3 2 0 0 3 6 1 3  1 2 6 01.21.1995 2 5 1 1 1 
169 M 01.01.1994 04.11.1995 2 10 11 3 0 0 0 3 6 1 3  1 2 3 02.24.1995 1 5 1 1 1 
170 F 01.01.1990 04.11.1995 2 9 14 0 0 0 0 0 0 1 2  1 1 0 NA 4 5 1 1 2 
171 F 01.01.1995 06.29.1995 1 6 6 1 0 0 0 0 0 1 2  0 1 6 NA 2 5 1 1 1 
172 F 12.01.1994 10.10.1995 1 10 11 1 0 0 0 3 6 1 2  1 1 6 NA 4 5 1 1 2 
173 F 12.01.1994 10.17.1995 1 11 12 3 2 2 1 3 5 1 2 1 1 2 3 09.26.1995 2 5 1 1 0 
174 F 01.01.1986 08.12.1995 2 5 14 1 0 0 0 3 6 1 2  1 1 6 NA 4 5 1 1 2 
175 M 01.01.1994 03.12.1996 2 7 9 3 1 0 0 3 6 1 2  1 1 6 NA 4 0 1 1 2 
176 M 10.05.1995 04.09.1996 1 9 9 1 2 0 0 3 6 1 1  1 1 6 NA 2 5 1 1 1 
177 F 01.01.1996 10.09.1996 1 5 6 1 0 0 0 3 6 1 3  0 2 6 NA 1 1 1 1 1 
178 M 02.06.1996 09.19.1996 1 7 7 1 0 0 0 3 6 1 3  0 2 0 NA 1 1 1 1 1 
179 F 01.01.1988 02.07.1997 2 5 14 3 1 0 0 3 6 1 3  1 2 2 NA 1 1 1 1 1 
180 M 12.01.1993 03.11.1997 2 7 11 3 2 0 0 3 6 1 3  1 2 1 03.01.1997 4 2 1 1 2 
181 M 06.01.1996 04.08.1997 1 8 9 3 1 0 0 3 6 1 1  1 1 3 03.21.1997 3 3 1 1 1 
182 M 11.01.1996 05.27.1997 1 6 7 3 0 0 0 3 6 1 3  11 2 3 05.09.1997 0 0 1 1 1 
183 F 05.01.1995 05.23.1997 2 12 14 4 1 2 0 3 6 1 2 1 1 2 3 04.02.1997 2 0 1 1 1 
184 F 01.01.1990 06.10.1997 2 4 11 3 0 0 0 3 6 1 2 1 1 2 3 05.24.1997 2 0 1 1 2 
185 M 04.01.1994 02.17.1998 2 4 8 1 2 0 0 3 6 1 3  9 3 1 NA 2 0 1 1 1 
186 M 01.01.1995 05.26.1998 2 4 7 1 2 0 0 3 6 1 2 1 1 2 6 05.05.1998 4 0 1 1 2 
187 M 04.01.1998 07.09.1998 1 9 9 3 0 0 0 3 6 1 2 1 1 1 3 06.23.1998 3 1 1 1 1 
188 M 07.01.1998 10.02.1998 1 14 14 2 1 2 2 3 6 1 3  4 3 5 09.30.1998 1 1 1 2 1 
189 F 04.02.1998 07.01.1999 2 7 8 3 1 0 0 3 6 1 1  2 3 3 05.20.1999 1 5 1 1 2 
190 M 01.19.1998 12.06.1999 2 13 14 3 2 0 0 3 6 1 1  2 3 3 01.19.1999 3 1 1 1 2 
191 F 01.01.1999 11.08.1999 1 13 13 4 0 2 2 3 6 1 3  2 3 4 09.01.1999 3 0 1 1 2 
192 M 01.01.1998 01.20.2000 2 3 5 1 1 0 0 3 6 2 3  8 3 1 09.01.1999 1 1 1 1 1 
193 M 05.01.1999 01.30.2000 1 12 13 1 1 0 0 3 6 1 1  1 2 1 NA 1 0 1 1 0 
194 M 05.11.1999 04.24.2000 1 13 14 1 1 0 0 3 6 1 3  2 3 6 12.28.1999 1 1 2 1 1 
195 M 01.01.1999 04.06.2000 2 11 12 1 2 0 0 3 6 1 2 1 1 3 6 03.15.2000 2 2 1 1 1 
196 M 10.01.1999 10.19.2000 2 10 11 3 1 0 0 3 6 1 1  2 1 6 09.20.2000 4 1 1 1 0 
197 M 04.01.2000 11.30.2000 1 6 7 1 0 0 0 3 6 1 3  4 3 6 NA 3 1 1 1 2 
198 F 07.01.2000 03.07.2001 1 11 12 4 1 2 0 3 6 1 3  4 3 4 NA 2 1 1 1 1 
199 M 05.01.2000 05.21.2001 2 10 11 1 1 0 0 3 5 1 3  1 2 6 NA 1 1 1 1 1 
200 M 10.01.2001 04.19.2002 1 10 11 1 0 0 0 3 6 1 1  1 1 6 NA 3 0 1 1 2 
201 F 09.01.1999 04.24.2002 2 4 7 1 0 0 0  6 1 2 3 2 1 1 10.01.2000 2 2 1 1 1 
202 F 01.01.2003 08.25.2003 1 9 10 1 2 2 2 3 6 1 3  7 3 1 07.11.2003 3 1 1 1 2 
203 F 01.01.2003 11.17.2003 1 9 9 3 3 1 2 3 6 2 2 1 9 3 3 08.01.2003 2 1 1 1 1 
204 F 01.01.2001 01.16.2004 2 6 9 1 2 2 2 3 6 1 3  2 3 6 01.02.2004 1 5 1 1 1 
205 F 02.05.2003 06.03.2004 2 13 14 6 2 0 0 1 5 1 3  2 1 2 06.02.2004 3 1 1 1 2 
206 M 10.18.2003 07.28.2004 1 11 12 3 1 2 2 3 6 1 3  7 3 6 06.15.2004 2 1 1 1 0 
207 M 01.01.2003 01.16.2004 2 3 4 3 1 2 2 3 5 1 3  4 3 3 12.27.2003 2 1 1 1 1 
208 F 08.10.2004 06.09.2005 1 9 10 1 1 0 1 3 6 1 3  7 3 6 12.07.2004 1 5 1 1 1 
209 M 12.01.2002 03.18.2005 2 7 10 3 0 2 2 3 6 1 1 1 8 3 1 03.09.2005 3 1 1 1 2 
210 M 09.01.2004 08.31.2005 2 12 13 1 0 0 2 3 6 1 1 1 2 3 1 08.25.2005 3 5 1 1 2 
211 F 04.11.2005 11.09.2005 1 7 7 5 1 1 1 3 5 1 3  9 3 6 10.28.2005 2 2 1 1 1 
212 F 06.01.2003 12.02.2005 2 3 6 3 0 0 2 3 6 1 1 2 7 3 2 11.22.2005 2 5 1 1 2 
213 F 08.01.2003 08.30.2006 2 10 12 3 0 2 1 3 3 1 1 1 7 1 6 02.03.2006 2 1 1 1 1 
214 M 05.23.2006 12.12.2006 1 8 8 3 1 2 2 3 6 1 1 1 2 3 6 08.22.2006 3 1 2 1 2 
215 F 01.01.1997 07.26.2006 2 3 12 1 0 2 2 3 6 1 2 1 2 3 4 07.22.2006 1 1 1 1 1 
216 M 03.01.2006 10.11.2006 1 10 10 1 1 1 2 3 6 1 3  7 3 6 08.22.2006 1 1 2 1 1 
217 M 03.02.2007 11.20.2007 1 11 12 1 2 1 1 3 6 2 1  4 3 1 10.26.2007 1 1 1 1 1 
218 F 08.01.2001 09.26.2007 2 5 10 1 0 2 2 3 6 1 3 1 7 3 6 NA 1 1 1 1 2 
xxv 
 
219 M 07.22.2004 11.29.2007 2 8 11 3 1 2 2 3 6 1 3  7 3 2 10.27.2007 1 1 1 1 1 
220 M 06.01.2005 07.23.2008 2 3 6 3 2 2 2 3 6 1 3 NA 7 3 2 06.27.2008 3 1 1 1 2 
221 F 11.01.2006 08.13.2008 2 8 10 1 2 2 2 3 6 2 2 1 9 3 1 08.05.2008 4 1 1 1 2 
222 M 11.08.2003 01.28.2008 2 2 7 3 1 2 2 3 6 1 3  7 3 2 01.12.2008 2 5 1 1 1 
223 F 01.01.2002 02.13.2008 2 5 11 3 3 2 2 3 6 1 2 1 7 3 4 09.26.2007 3 0 1 1 2 
224 F 11.13.2006 05.21.2008 2 8 10 1 1 2 1 3 4 2 1 2 7 1 2 01.01.2008 1 5 1 1 2 
225 F 01.01.2004 06.04.2008 2 10 14 1 1 2 2 3 6 1 2 3 9 1 1 04.02.2008 4 2 1 1 2 
226 F 07.01.2006 05.13.2008 2 12 14 1 0 2 2 3 6 1 1 1 8 1 1 04.26.2008 2 2 2 1 2 
227 M 03.01.2007 02.25.2008 1 10 11 1 2 2 2 3 6 1 1  2 1 1 11.14.2007 1 2 1 1 1 
228 M 03.06.2006 07.23.2008 2 4 6 3 2 2 2 3 5 1 3  7 3 3 03.07.2008 2 1 1 1 1 
229 M 01.01.2001 03.20.2009 2 5 13 3 2 2 2 3 6 1 3  7 3 2 06.13.2006 1 1 1 1 1 
230 M 04.03.2007 06.24.2009 2 6 8 3 1 2 2 3 6 2 1  7 3 1 01.22.2008 2 1 1 1 1 
231 M 04.01.2008 06.17.2009 2 5 9 1 1 0 0 3 6 1 1  7 1 6 06.02.2009 1 1 1 1 1 
232 M 01.01.1995 12.01.1995 1 14 14 1 0 1 2 3 6 1 3  11 2 1 NA 0 0 1 1 1 
233 M 01.01.1992 09.21.1995 2 4 7 3 0 2 2 3 6 1 2 1 1 2 2 02.05.1994 3 2 1 1 1 
234 F 02.01.1993 02.20.1996 2 6 9 1 1 0 0 0 6 1 3  9 3 1 NA 1 5 1 1 0 
235 M 01.01.1992 12.01.1996 2 6 10 2 0 0 0 3 6 1 3  0 2 2 NA 1 1 1 1 0 
236 M 12.01.1995 05.27.1997 2 2 4 1 0 0 0 3 6 1 2 2 1 1 1 05.10.1997 2 0 1 1 1 
237 M 10.01.1997 10.15.1998 2 8 9 3 0 0 0 3 6 1 1  1 1 3 NA 1 0 1 1 1 
238 M 01.01.1996 01.12.1999 2 3 6 1 2 2 2 3 6 1 3  2 3 6 08.04.1998 1 5 1 1 1 
239 F 04.09.1998 06.15.1999 2 10 10 2 1 1 2 3 6 1 3  2 3 1 NA 1 0 1 1 1 
240 M 12.25.1996 09.06.1999 2 9 12 3 0 2 2 3 6 1 2 2 8 1 6 05.28.1999 4 2 1 1 2 
241 F 10.01.1998 12.13.1999 2 6 7 3 0 0 2 3 6 2 1  7 3 3 08.03.1999 1 0 1 1 0 
242 M 07.01.2000 02.28.2001 1 5 6 3 3 0 0 3 6 1 1 1 8 1 5 NA 2 1 1 2 1 
243 M 03.01.2000 05.20.2002 2 10 12 3 0 1 2 3 6 2 1  9 3 2 05.09.2002 1 5 1 1 1 
244 F 04.19.2002 08.18.2003 2 12 13 3 1 0 0 3 2 1 3 1 7 3 3 07.30.2003 3 1 1 1 1 
245 F 12.01.2000 09.15.2004 2 4 8 3 1 2 2 3 6 1 3  9 3 6 01.23.2004 1 5 1 1 1 
246 F 01.01.2005 07.11.2005 1 5 6 1 2 2 2 3 6 1 3  7 3 1 07.01.2005 2 2 1 1 1 
247 M 10.01.2002 03.17.2006 2 5 9 3 1 2 2 3 6 1 3  7 3 3 10.21.2005 1 1 1 1 1 
248 F 01.01.2004 05.03.2006 2 7 9 3 2 0 2 3 6 1 1 2 7 1 5 05.02.2006 3 1 1 2 2 
249 M 05.01.2003 10.23.2007 2 9 13 3 2 0 0 3 6 1 2 1 7 1 6 09.07.2007 4 1 2 1 2 
250 F 07.01.2006 11.28.2007 2 4 5 1 3 1 2 3 6 1 3  9 3 3 11.19.2007 1 1 1 1 1 
251 M 11.01.2005 11.28.2007 2 10 12 1 1 2 0 33 6 1 2 2 7 1 6 11.09.2007 2 1 1 1 2 
252 M 01.01.2003 08.22.2008 2 10 14 3 1 2 2 3 6 2 2 1 1 2 3 NA 0 1 1 1 2 
253 F 03.27.2006 03.05.2008 2 12 14 4 1 1 2 3 6 1 1 1 7 1 4 02.27.2008 2 1 1 1 2 
254 M 01.01.2006 04.23.2008 2 10 12 3 2 2 1 3 6 1 3  7 3 1 11.01.2007 1 5 1 1 1 
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Spln SHPR PerSCo AB HS IPoSR DOIPoSR PePC TtPePC IPoSRDr PoSLOR DOPoSLOR PoSR-
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LFU 
OFUS Res-DOR Ref-DOR DODe 
2 3 5 1 12 2 03.17.1995 751000 10 1 0 NA 2 7 NA 03.24.1995 751000 1 1 1 6 2 03.15.1997 NA NA 
0 0 5 2 NA 2 05.24.1995 522000 7 1 0 NA 2 7 NA 05.30.1995 522000 1 1 1 6 2 05.24.1995 NA NA 
0 0 5 2 NA 2 06.23.1995 306200 10 1 0 NA 2 7 NA 06.30.1995 306200 1 1 1 6 2 06.23.1995 NA NA 
0 0 5 2 NA 1 08.12.1995 88000 1 1 0 NA 1 7 NA 02.26.2002 172000 1 1 1 6 2 11.09.1995 NA NA 
0 0 5 2 NA 2 11.16.1995 146600 10 1 0 NA 2 7 NA 11.23.1995 146600 1 1 1 6 2 11.16.1995 NA NA 
2 1 5 2 7 2 03.10.1996 325000 7 1 2 NA 2 6 NA 07.15.2009 130000 1 1 1 6 1 03.10.1996 NA NA 
0 0 5 2 NA 2 03.29.1996 884000 10 1 0 NA 2 7 NA 04.05.1996 884000 1 1 1 6 2 03.29.1996 NA NA 
0 0 5 2  2 07.19.1996 285000 3 1 0 NA 2 7 NA 06.14.2005 247000 1 1 1 6 2 07.17.1996 NA NA 
0 0 0 0 NA 2 12.02.1996 160000 30 1 2 NA 2 6 NA 03.20.2009 168000 1 1 1 6 1 12.02.1996 NA NA 
0 0 5 2 NA 2 11.02.1996 574000 7 1 0 NA 2 7 NA 11.08.1996 574000 1 1 1 6 2 11.02.1996 NA NA 
2 1 5 2 12 2 12.06.1996 355000 10 1 0 NA 2 7 NA 12.13.1996 355000 1 1 1 6 2 12.04.1996 NA NA 
2 0 5 2 12 2 12.03.1996 203000 3 1 0 NA 2 7 NA 12.09.1996 136000 1 1 1 6 2 12.03.1996 NA NA 
2 1 5 1 19 2 03.15.1996 335000 7 1 2 NA 2 6 NA 08.31.2009 134000 1 1 1 6 1 03.13.1996 NA NA 
2 1 5 2 24 2 02.17.1997 148000 3 1 0 NA 2 7 NA 02.23.1997 147000 1 1 1 6 2 02.15.1997 NA NA 
2 2 5 1 7 1 05.27.1997 132000 1 1 0 NA 1 7 NA 06.02.1997 60000 1 1 1 6 2 05.27.1997 NA NA 
2 1 5 1 14 1 09.12.1997 67000 1 1 0 NA 1 7 NA 09.18.1997 48000 2 1 1 6 2 09.12.1997 NA NA 
2 3 5 1 6 2 01.31.1998 287000 10 1 0 NA 2 7 NA 02.08.1998 287000 1 1 1 6 2 01.29.1998 NA NA 
0 0 5 2 18 2 03.05.1998 637000 7 1 0 NA 2 7 NA 03.14.1998 637000 1 1 1 6 2 03.05.1998 NA NA 
2 1 5 1 30 2 04.01.1998 407000 14 1 0 NA 2 7 NA 04.13.1998 407000 1 1 1 6 2 04.01.1998 NA NA 
0 0 5 0 10 2 05.21.1998 457000 50 1 0 NA 2 7 NA 04.02.2003 597000 1 1 1 6 2 05.21.1998 NA NA 
0 0 5 2 20 2 05.06.1998 200000 7 1 0 NA 2 7 NA 05.14.1998 200000 1 1 1 6 2 05.06.1998 NA NA 
2 0 5 2 16 2 04.29.1998 380000 3 1 0 NA 2 7 NA 05.28.1998 270000 1 1 1 6 2 04.29.1998 NA NA 
0 0 5 2 18 2 05.06.1998 274000 14 1 2 NA 2 6 NA 09.22.2009 228000 1 1 1 6 1 05.06.1998 NA NA 
0 0 5 0 NA 2 06.26.1998 572000 50 1 0 NA 2 7 NA 02.03.2006 439000 1 1 1 6 2 06.26.1998 NA NA 
2 1 5 2 8 1 12.23.1998 85000 7 1 0 NA 1 7 NA 12.29.1998 85000 1 1 1 6 2 12.23.1998 NA NA 
1 1 2 1 12 2 02.12.1998 400000 7 1 0 NA 2 7 NA 06.14.2006 60000 1 1 1 6 2 02.10.1998 NA NA 
2 0 5 2 8 2 01.15.1999 118000 7 1 0 NA 2 7 NA 01.22.1999 100000 1 1 1 6 2 01.15.1999 NA NA 
0 0 1 1 11 2 01.30.1999 160000 45 1 2 NA 2 6 NA 08.03.2009 295000 1 1 1 6 1 01.06.1999 NA NA 
1 1 5 2 8 1 02.11.1999 86000 14 5 2 NA 1 6 NA 08.12.2009 170000 1 1 1 6 1 02.11.1999 NA NA 
2 1 5 2 14 2 02.25.1999 567000 7 1 2 NA 2 6 NA 09.20.2009 420000 1 1 1 6 1 02.25.1999 NA NA 
2 1 5 2 15 2 06.12.1999 141000 3 1 2 NA 2 6 NA 07.30.2009 139000 1 1 1 6 1 06.10.1999 NA NA 
2 2 5 2 7 1 11.23.1999 247000 7 1 0 NA 1 7 NA 11.29.1999 247000 1 1 1 6 2 11.23.1999 NA NA 
2 1 5 1 8 2 11.24.1999 187000 7 1 0 NA 2 7 NA 09.01.2006 125000 1 1 1 6 2 11.18.1999 NA NA 
1 1 5 2 16 2 04.06.2000 670000 3 1 0 NA 2 7 NA 05.24.2002 32000 3 1 1 6 2 04.06.2000 NA NA 
0 1 5 0 10 2 09.12.2000 1324000 7 1 2 NA 2 6 NA 08.07.2009 280000 1 1 1 6 1 09.06.2000 NA NA 
2 1 5 1 11 2 05.26.2000 994000 7 1 2 NA 2 6 NA 07.01.2009 250000 1 1 1 6 1 05.26.2000 NA NA 
2 1 5 2 7 2 07.18.2000 481000 3 1 0 NA 2 7 NA 03.18.2005 190000 1 1 1 6 2 07.18.2000 NA NA 
0 0 2 1 10 2 10.09.2000 693000 14 1 0 NA 2 7 NA 11.29.2005 489000 1 1 1 6 2 09.26.2000 NA NA 
0 0 5 2 9 2 10.26.2000 289000 3 1 0 NA 2 7 NA 01.30.2003 101000 1 1 1 6 2 10.26.2000 NA NA 
0 0 2 1 8 1 12.10.2000 49000 54 5 2 NA 1 6 NA 07.01.2009 250000 1 1 1 6 1 12.10.2000 NA NA 
0 0 5 2 12 2 11.04.2000 427000 7 1 0 NA 2 7 NA 01.02.2001 423000 1 1 1 6 2 11.04.2000 NA NA 
1 3 5 2 9 2 08.08.2000 208000 7 1 0 NA 2 7 NA 08.14.2000 208000 1 1 1 6 2 08.08.2000 NA NA 
2 2 5 2 7 2 01.09.2001 665000 7 1 0 NA 2 7 NA 05.22.2001 100000 1 1 1 6 2 01.09.2001 NA NA 
2 1 5 2 10 2 01.26.2001 965000 14 1 0 NA 2 7 NA 04.11.2003 540000 1 1 1 6 2 01.26.2001 NA NA 
2 1 5 2 8 2 02.08.2001 306000 3 1 2 NA 2 6 NA 10.03.2009 215000 1 1 1 6 1 02.06.2001 NA NA 
2 1 5 2 7 2 02.15.2001 164000 1 1 0 NA 2 7 NA 10.23.2001 528000 1 1 1 6 2 02.15.2001 NA NA 
2 1 3 1 23 7 NA 11000 7 0 0 NA 7 0 NA 11.24.2001 5000 1 2 0 10 3 NA NA 11.24.2001 
2 0 5 1 17 2 05.30.2001 149000 7 1 0 NA 2 7 NA 06.06.2001 119000 1 1 1 6 2 05.26.2001 NA NA 
2 1 2 2 7 2 10.11.2001 859000 7 1 0 NA 2 7 NA 10.10.2003 303000 1 1 1 6 2 10.11.2001 NA NA 
2 1 5 0 7 2 11.20.2001 1082000 14 1 0 NA 2 7 NA 03.24.2002 424000 1 1 1 6 2 11.20.2001 NA NA 
2 1 5 2 12 2 07.13.2001 1067000 7 1 2 NA 2 6 NA 09.05.2009 265000 1 1 1 6 1 07.13.2001 NA NA 
2 1 5 2 14 2 04.30.2002 684000 7 1 2 NA 2 0 NA 09.01.2009 224000 1 1 1 6 1 04.30.2002 NA NA 
2 1 5 2 9 2 05.14.2002 384000 56 1 0 NA 2 7 NA 03.20.2008 403000 1 1 1 6 2 05.14.2002 NA NA 
2 1 2 1 11 2 09.10.2002 698000 14 1 0 NA 2 7 NA 04.24.2003 493000 1 1 1 6 2 09.10.2002 NA NA 
2 2 2 1 5 1 07.31.2003 71000 7 1 2 NA 1 6 NA 07.13.2009 80000 7 1 1 6 1 07.31.2003 NA NA 
2 1 2 1 24 2 09.11.2003 810000 14 1 0 NA 2 7 NA 01.20.2004 292000 1 1 1 6 2 09.11.2003 NA NA 
2 1 5 2 10 2 10.30.2003 383000 14 1 0 NA 3 7 NA 06.25.2004 46000 1 1 1 6 2 10.28.2003 NA NA 
2 1 5 1 16 2 11.24.2003 508000 14 1 2 NA 2 6 NA 10.12.2009 130000 1 1 1 6 1 11.24.2003 NA NA 
2 1 5 2 7 2 11.18.2003 729000 7 1 0 NA 2 7 NA 06.16.2006 90000 1 1 1 6 2 11.18.2003 NA NA 
2 1 2 1 12 2 07.08.2003 478000 7 1 0 NA 2 7 NA 08.19.2003 275000 1 1 1 6 2 07.08.2003 NA NA 
2 1 5 1 8 2 12.23.2003 532000 7 1 0 NA 2 7 NA 07.08.2006 197000 1 1 1 6 2 12.23.2003 NA NA 
2 1 3 1 14 7 NA 95000 3 0 0 NA 7 0 NA 08.01.2003 95000 1 2 0 10 3 NA NA 08.01.2003 
2 2 5 2 5 2 01.29.2004 311000 3 1 2 NA 2 6 NA 10.10.2009 342000 1 1 1 6 1 01.29.2004 NA NA 
2 1 2 1 38 2 05.23.2004 169000 7 1 2 NA 3 1 NA 07.29.2009 102000 1 1 1 6 1 05.21.2004 NA NA 
2 1 5 1 7 2 06.17.2004 763000 7 1 2 NA 2 6 NA 07.08.2009 219000 1 1 1 6 1 06.15.2004 NA NA 
2 1 2 1 9 2 06.22.2004 459000 14 1 2 NA 2 6 NA 07.01.2009 200000 1 1 1 6 1 06.22.2004 NA NA 
2 1 5 1 6 2 08.19.2004 131000 7 1 0 NA 2 7 NA 07.09.2005 120000 1 1 1 6 2 08.13.2004 NA NA 
2 1 5 2 10 2 10.07.2004 333000 7 1 0 NA 2 7 NA 10.13.2004 333000 1 1 1 6 2 10.07.2004 NA NA 
2 1 3 1 13 7 NA 18000 1 0 0 NA 7 0 NA 03.04.2004 1000 1 2 0 10 3 NA NA 04.03.2004 
2 1 5 1 7 2 02.17.2005 685000 3 1 0 NA 2 7 NA 02.23.2005 647000 1 1 1 6 2 02.17.2005 NA NA 
2 1 5 1 7 2 02.24.2005 1039000 7 1 0 NA 2 7 NA 03.04.2005 679000 1 1 1 6 2 02.24.2005 NA NA 
2 2 5 2 5 2 03.03.2005 245000 7 1 0 NA 2 7 NA 04.27.2007 152000 1 1 1 6 2 03.01.2005 NA NA 
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2 1 5 1 11 2 03.03.2005 251000 14 1 0 NA 2 7 NA 03.16.2005 251000 1 1 1 6 2 03.03.2005 NA NA 
2 1 5 2 9 2 03.15.2005 305000 7 1 0 NA 2 7 NA 03.21.2005 305000 1 1 1 6 2 03.15.2005 NA NA 
1 1 5 2 8 2 07.14.2005 884000 7 1 0 NA 2 7 NA 08.30.2005 372000 1 1 1 6 2 07.14.2005 NA NA 
2 1 5 1 20 1 11.30.2005 120000 14 4 2 NA 1 6 NA 07.01.2009 247000 1 1 1 6 1 11.30.2005 NA NA 
2 1 5 2 8 2 03.17.2005 773000 14 1 0 NA 2 7 NA 08.04.2005 289000 1 1 1 6 2 03.17.2005 NA NA 
2 1 5 2 10 2 09.22.2005 317000 7 1 2 NA 2 6 NA 08.25.2009 415000 1 1 1 6 1 09.22.2005 NA NA 
2 1 2 1 8 1 06.02.2005 58000 1 1 0 NA 1 7 NA 10.24.2005 67000 1 1 1 6 2 06.02.2005 NA NA 
2 1 5 1 7 2 06.01.2006 137000 3 1 2 NA 2 6 NA 09.08.2009 160000 1 1 1 6 1 05.30.2006 NA NA 
2 1 5 1 11 2 09.28.2006 761000 14 1 0 NA 2 7 NA 10.10.2006 761000 1 1 1 6 2 09.28.2006 NA NA 
2 1 5 2 9 2 07.25.2006 1831000 7 1 2 NA 2 6 NA 10.09.2009 395000 1 1 1 6 1 07.25.2006 NA NA 
2 1 5 1 7 2 08.09.2006 663000 7 1 0 NA 2 7 NA 12.28.2006 96000 1 1 1 6 2 08.03.2006 NA NA 
2 1 2 1 5 2 03.28.2006 530000 14 1 0 NA 2 7 NA 04.07.2006 530000 1 1 1 6 2 03.28.2006 NA NA 
2 1 5 1 30 2 02.09.2006 117000 7 1 0 NA 2 7 NA 02.16.2006 117000 1 1 1 6 2 02.09.2006 NA NA 
2 1 2 1 10 2 06.07.2007 852000 7 1 2 NA 2 6 NA 07.02.2009 508000 1 1 1 6 1 06.07.2008 NA NA 
2 1 5 1 14 2 03.27.2007 604000 7 1 0 NA 2 7 NA 07.20.2007 432000 1 1 1 6 2 03.27.2007 NA NA 
2 1 5 2 8 2 04.03.2007 1688000 7 1 0 NA 2 7 NA 05.18.2007 334000 1 1 1 6 2 04.03.2007 NA NA 
2 1 5 1 7 2 04.10.2007 371000 3 1 2 NA 2 6 NA 05.01.2009 138000 1 1 1 6 1 04.10.2007 NA NA 
2 1 5 2 8 2 04.17.2007 667000 7 1 0 NA 2 7 NA 04.25.2008 82000 1 1 1 6 2 04.17.2007 NA NA 
2 1 5 1 7 2 07.31.2007 554000 7 1 0 NA 2 7 NA 08.07.2007 554000 1 1 1 6 2 07.31.2007 NA NA 
1 1 5 1 8 1 12.20.2007 30000 54 1 2 NA 1 6 NA 11.02.2009 52000 1 1 1 6 1 12.20.2007 NA NA 
2 1 2 2 7 2 08.13.2007 517000 14 1 2 NA 2 6 NA 08.25.2009 212000 1 1 1 6 1 08.17.2007 NA NA 
2 1 5 2 7 2 11.05.2007 208000 14 1 0 NA 2 7 NA 11.20.2007 208000 1 1 1 6 2 11.03.2007 NA NA 
2 1 5 2 7 2 09.25.2007 100000 50 1 0 NA 2 7 NA 11.15.2007 134000 1 1 1 6 2 08.13.2007 NA NA 
2 1 5 1 9 2 06.07.2007 706000 7 1 2 NA 2 6 NA 09.10.2009 347000 1 1 1 6 1 06.07.2007 NA NA 
2 1 5 1 7 2 01.08.2008 453000 7 1 2 NA 2 6 NA 08.18.2009 170000 1 1 1 6 1 01.08.2008 NA NA 
2 1 1 1 2 7 NA 10000 1 0 0 NA 7 0 NA 12.27.2007 10000 2 2 0 10 3 NA NA 12.27.2007 
1 1 5 1 5 2 01.22.2008 404000 14 1 2 NA 2 6 NA 07.06.2009 424000 1 1 1 6 1 01.16.2008 NA NA 
2 1 2 1 7 2 02.21.2008 711000 7 1 0 NA 2 7 NA 05.26.2008 419000 1 1 1 6 2 02.19.2008 NA NA 
2 1 2 1 7 2 03.12.2008 564000 7 1 2 NA 2 6 NA 10.10.2008 187000 1 1 1 6 1 03.12.2008 NA NA 
1 1 2 2 10 2 08.19.2008 200000 3 5 0 NA 2 7 NA 08.19.2008 127000 5 1 1 6 2 08.19.2008 NA NA 
2 1 2 1 6 2 08.14.2008 555000 7 1 2 NA 2 6 NA 06.25.2009 168000 1 1 1 6 1 08.14.2008 NA NA 
2 2 2 1 6 2 04.16.2008 327000 3 1 2 NA 2 6 NA 06.16.2009 110000 1 1 1 6 1 04.16.2008 NA NA 
2 1 1 1 14 2 02.22.2008 1614000 7 1 2 NA 2 6 NA 04.24.2009 214000 1 1 1 6 1 02.20.2008 NA NA 
2 1 5 2 7 2 05.10.2008 210000 14 1 2 NA 3 6 NA 07.01.2009 295000 1 1 1 6 1 05.10.2008 NA NA 
2 1 5 2 10 2 05.23.2008 311000 40 1 2 NA 2 6 NA 11.11.2008 275000 1 1 1 6 1 05.23.2008 NA NA 
1 1 4 1 15 2 06.20.2008 1211000 14 1 2 NA 2 6 NA 06.09.2009 566000 1 1 1 6 1 06.18.2008 NA NA 
2 1 5 2 12 2 02.08.2008 312000 28 1 2 NA 2 6 NA 08.04.2009 374000 1 1 1 6 1 01.14.2008 NA NA 
2 2 5 1 7 2 02.26.2009 582000 14 3 0 NA 2 7 NA 03.10.2009 582000 3 1 1 6 2 02.26.2009 NA NA 
2 1 2 1 4 2 02.20.2009 330000 3 1 2 NA 2 6 NA 10.09.2009 331000 1 1 1 6 1 02.18.2009 NA NA 
2 1 2 1 7 2 06.23.2009 315000 3 1 0 NA 2 7 NA 07.10.2009 473000 1 1 1 6 2 06.23.2009 NA NA 
2 1 5 2 5 2 07.18.2009 490000 7 1 2 NA 2 6 NA 09.17.2009 324000 1 1 1 6 1 07.18.2009 NA NA 
0 0 5 2 NA 5  25000 50 0 0 NA 5 0 2a 05.05.2004 15000 1 1 2 7a 2 NA NA NA 
2 1 5 2 11 1 08.05.1995 340000 7 1 1 09.04.1995 4 1 4a 07.01.2009 19000 7 1 2 8 1 NA NA NA 
2 1 5 2 8 2 11.29.1995 849000 7 1 1 02.09.2000 2 1 2a 02.11.2000 6000 3 1 2 8 2 NA NA NA 
0 0 5 2 NA 5 NA 10000 28 0 0 NA 5 0 3a 09.25.2009 18000 1 1 2 7a 1 NA NA NA 
0 0 5 0 15 2 12.08.1996 336000 3 1 1 01.05.1997 4a 5 2a 07.01.2009 18000 1 1 2 8a 1 NA NA NA 
2 1 5 2 7 2 01.04.1997 723000 30 1 1 04.02.1998 2 1 2 10.20.2008 237000 1 1 2 2 1 NA 04.10.1998 NA 
2 1 5 2 10 2 06.20.1997 100000 3 1 1 05.05.1998 2 4 3 08.11.2009 133000 1 1 2 5 1 NA 12.19.2008 NA 
0 0 5 0 13 2 02.10.1998 229000 7 1 1 05.15.1998 2 2 2 07.04.2003 62000 1 1 2 3 2 NA 01.19.2001 NA 
2 1 2 1 5 5 NA 40000 3 0 0 NA 5 0 1 10.15.2001 121000 1 1 2 1 2 NA 04.01.1999 NA 
0 0 5 0 8 2 01.08.1999 200000 28 1 1 11.21.2007 2 1 2 10.05.2009 185000 5 1 2 2 1 NA 08.10.2009 NA 
0 0 5 0 30 1 02.05.1999 47000 14 1 1 03.24.1999 4 1 1a 05.06.2005 8000 2 1 2 8a 2 NA NA NA 
1 1 5 2 12 2 07.17.1999 153000 3 1 1 11.03.2000 2 1 1 10.27.2009 468000 1 1 2 2 1 NA 11.10.2000 NA 
0 0 5 0 NA 1 07.06.1999 57000 3 1 1 07.10.2001 1 1 2a 11.28.2006 7000 1 1 2 8 2 NA NA NA 
0 0 5 0 9 2 11.29.1999 140000 28 1 1 06.07.2002 2 2 2 01.25.2005 560000 1 1 2 3 2 NA 04.29.2003 NA 
2 1 5 2 9 5 NA 46000 1 0 0 NA 5 0 3 08.01.2009 128000 1 1 2 1 1 NA 01.27.2001 NA 
0 0 5 1 25 5 NA 1000 28 0 0 NA 5 0 2a 05.20.2003 5000 3 1 2 7a 2 NA NA NA 
1 1 5 2 6 5 NA 16000 3 0 0 NA 5 0 0a 09.10.2000 10000 1 1 2 7a 2 NA NA NA 
2 1 5 2 9 5 NA 45000 7 0 0 NA 5 0 2 03.12.2004 100000 1 1 2 1 2 NA 09.13.2002 NA 
2 1 5 2 7 2 02.14.2002 501000 7 1 1 03.29.2003 2 1 2a 03.29.2003 12000 5 1 2 8a 2 NA NA NA 
2 1 2 1 20 5 NA 30000 7 0 0 NA 5 0 0a 04.29.2002 29000 1 1 2 7a 2 NA NA NA 
1 1 5 2 17 5 NA 24000 7 0 0 NA 5 0 4a 08.16.2009 5000 6 1 2 7a 1 NA NA NA 
2 1 1 1 10 1 07.11.2002 75000 3 1 1 08.12.2002 4 1 2 07.01.2009 261000 1 1 2 2 1 NA 11.19.2002 NA 
1 1 5 2 9 2 03.06.2003 671000 7 1 1 04.25.2008 2 1 2 10.07.2008 120000 3 1 2 2 1 NA 10.06.2008 NA 
2 1 5 2 7 2 04.03.2003 254000 7 1 1 02.15.2005 2 1 3 06.30.2009 112000 6 1 2 2 1 NA 07.08.2008 NA 
2 1 5 2 8 2 01.08.2004 254000 7 1 1 02.25.2004 4 1 2a 04.22.2008 15000 5 1 2 8a 2 NA NA NA 
2 1 1 1 14 1 07.26.2004 46000 14 1 1 06.13.2009 1 1 0a 08.01.2009 20000 1 1 2 8a 1 NA NA NA 
2 1 5 1 7 2 10.17.2004 184000 50 6 1 02.11.2005 2 1 3 06.26.2009 361000 1 1 2 2 1 NA 08.11.2005 NA 
2 1 5 2 7 2 07.15.2004 153000 7 1 1 12.21.2004 2 1 2 07.30.2009 238000 1 1 2 2 1 NA 06.14.2005 NA 
2 1 5 1 7 5 NA 27000 1 0 0 NA 5 0 3a 04.03.2006 21000 4 2 2 10 3 NA NA 04.03.2006 
2 1 5 2 7 5 NA 5000 1 0 0 NA 5 0 3a 08.03.2009 25000 1 1 2 7 1 NA NA NA 
2 1 2 2 9 1 03.11.2005 111000 28 1 1 03.22.2005 4 1 1a 05.03.2005 8000 2 1 2 8a 2 NA NA NA 
0 0 5 0 NA 1 03.25.2005 38000 54 2 1 06.05.2005 1 1 2a 09.24.2007 7000 6 1 2 8 2 NA NA NA 
2 1 5 1 14 2 04.17.2006 505000 7 1 1 10.10.2008 2 1 0a 06.22.2009 30000 1 1 2 8 1 NA NA NA 
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2 1 5 1 21 5 NA 17000 1 0 0 NA 5 0 2 09.04.2009 333000 1 1 2 1 1 NA 12.12.2006 NA 
1 2 2 1 8 2 04.17.2006 198000 3 1 1 07.02.2007 2 1 3 01.28.2008 45000 6 1 2 2 2 NA 09.24.2007 NA 
1 1 1 1 11 2 12.19.2007 251000 14 1 1 04.01.2008 2 2 3a 04.23.2009 9000 6 2 2 10 3 NA NA 04.23.2009 
0 0 1 1 NA 2 05.06.2007 400000 7 1 1 05.29.2007 4 1 2a 06.15.2007 2000 5 1 2 8a 2 NA NA NA 
1 1 5 1 17 2 10.25.2007 231000 7 2 1 12.18.2007 4 1 1 10.29.2008 76000 1 1 2 2 1 NA 09.04.2008 NA 
2 0 5 1 5 5 NA 200000 3 0 0 NA 5 0 2 09.29.2009 248000 5 1 2 1 1 NA 09.16.2008 NA 
2 3 5 1 20 1 08.26.2008 83000 3 1 1 09.10.2008 4 1 2 08.11.2009 100000 3 1 2 2 1 NA 12.05.2008 NA 
2 2 2 1 7 2 04.24.2008 1021000 3 1 1 02.06.2009 3 1 2 11.20.2009 438000 3 1 2 2 1 NA 07.24.2009 NA 
2 1 5 2 11 1 07.03.2008 45000 7 1 1 04.20.2009 1 1 2 10.02.2009 42000 3 1 2 2 1 NA 09.28.2009 NA 
2 1 2 1 11 5 NA 16000 1 0 0 NA 5 0 2a 07.04.2009 48000 3 1 2 7 1 NA NA NA 
2 0 5 2 6 1 01.23.2008 75000 7 1 1 10.13.2008 1 1 1 09.26.2009 45000 1 1 2 2 1 NA 11.01.2008 NA 
2 1 5 2 4 2 02.27.2008 1406000 7 1 1 12.29.2008 2 1 2 11.06.2009 327000 5 1 2 2 1 NA 01.13.2009 NA 
2 1 2 1 8 2 05.23.2008 187000 7 1 1 06.16.2008 4 2 2 11.20.2009 105000 5 1 2 3 1 NA 03.13.2009 NA 
2 1 5 1 3 2 01.13.2009 236000 7 1 1 04.01.2009 2 1 2 05.01.2009 106000 3 1 2 2 1 NA 05.01.2009 NA 
2 1 5 1 12 5 NA 7000 1 0 0 NA 5 0 2a 10.27.2009 7000 5 1 2 7a 1 NA NA NA 
2 1 5 1 8 1 02.17.1995 272000 7 1 0 NA 1 7 NA 02.23.1995 272000 1 1 1 6 2 02.17.1995 NA NA 
2 2 5 1 9 1 04.12.1995 168000 7 1 0 NA 1 7 NA 04.18.1995 168000 1 1 1 6 2 04.12.1995 NA NA 
0 0 5 2 NA 2 04.12.1995 530900 7 1 0 NA 2 7 NA 04.18.1995 530900 3 1 1 6 2 04.12.1995 NA NA 
0 0 5 1 8 2 06.30.1995 250000 30 1 2 NA 2 6 NA 09.06.2009 376000 1 1 1 6 1 06.30.1995 NA NA 
0 0 5 1 NA 2 10.11.1995 224000 7 1 0 NA 2 7 NA 10.17.1995 224000 1 1 1 6 2 10.11.1995 NA NA 
0 0 5 1 6 2 10.20.1995 1450000 30 1 0 NA 2 7 NA 09.02.2003 412000 1 1 1 6 2 10.20.1995 NA NA 
0 0 5 2 NA 2 08.13.1995 334000 7 1 0 NA 2 7 NA 08.19.1995 334000 1 1 1 6 2 08.13.1995 NA NA 
1 1 5 1 6 2 03.13.1996 273000 1 1 2 NA 2 6 NA 07.30.2009 220000 1 1 1 6 1 03.13.1996 NA NA 
2 1 5 1 6 1 04.11.1996 1531800 9 1 0 NA 1 7 NA 04.18.1996 1531800 1 1 1 6 2 04.11.1996 NA NA 
0 0 5 2 NA 1 10.10.1996 99000 7 1 0 NA 1 7 NA 10.16.1996 99000 1 1 1 6 2 10.10.1996 NA NA 
0 0 5 1 NA 2 09.20.1996 373000 7 1 0 NA 2 7 NA 09.26.1996 373000 1 1 1 6 2 09.20.1996 NA NA 
2 1 5 1 7 2 02.10.1997 438000 3 1 0 NA 1 7 NA 02.17.1997 410000 1 1 1 6 2 02.08.1997 NA NA 
2 1 5 2 11 2 03.14.1997 328000 7 1 2 NA 2 6 NA 10.01.2009 240000 1 1 1 6 1 03.14.1997 NA NA 
2 1 5 2 6 2 04.09.1997 921000 7 1 2 NA 2 6 NA 09.25.2009 188000 1 1 1 6 1 04.09.1997 NA NA 
2 2 5 2 5 2 05.28.1997 281000 1 1 2 NA 2 6 NA 07.01.2009 250000 1 1 1 6 1 05.28.1997 NA NA 
1 1 5 1 11 1 05.24.1997 185000 7 1 0 NA 1 7 NA 05.31.1997 185000 1 1 1 6 2 05.24.1997 NA NA 
2 1 5 1 6 2 06.11.1997 416000 7 1 0 NA 2 7 NA 06.17.1997 416000 1 1 1 6 2 06.11.1997 NA NA 
2 1 5 2 5 1 02.18.1998 183000 7 1 0 NA 1 7 NA 02.24.1998 183000 1 1 1 6 2 02.18.1998 NA NA 
0 0 5 1 5 2 06.09.1998 200000 50 1 0 NA 2 7 NA 11.09.2000 150000 1 1 1 6 2 06.09.1998 NA NA 
2 1 2 1 8 2 07.10.1998 200000 1 1 0 NA 2 7 NA 07.16.1998 200000 1 1 1 6 2 07.10.1998 NA NA 
0 0 5 2 7 2 10.16.1998 648000 45 1 2 NA 2 6 NA 10.15.2009 645000 1 1 1 6 1 10.09.1998 NA NA 
0 0 5 1 6 2 07.02.1999 1055000 7 1 2 NA 2 6 NA 07.01.2009 150000 1 1 1 6 1 07.02.1999 NA NA 
1 0 5 2 8 2 12.07.1999 984000 7 1 0 NA 2 7 NA 12.14.1999 984000 1 1 1 6 2 12.07.1999 NA NA 
2 1 5 2 7 2 11.11.1999 767000 10 1 0 NA 2 7 NA 11.18.1999 767000 1 1 1 6 2 11.09.1999 NA NA 
2 2 1 1 3 7 NA NA NA 0 0 NA 7 0 NA 02.21.2000 1000 2 2 0 10 3 NA NA 01.21.2000 
0 0 5 2 6 2 01.31.2000 200000 30 1 2 NA 2 6 NA 08.01.2009 230000 1 1 1 6 1 02.01.2000 NA NA 
1 1 5 1 7 2 05.22.2000 173000 28 1 0 NA 2 7 NA 09.25.2000 167000 1 1 1 6 2 05.22.2000 NA NA 
0 1 5 2 6 2 04.09.2000 284000 7 1 0 NA 2 7 NA 05.13.2000 200000 1 1 1 6 2 04.07.2000 NA NA 
0 0 5 0 NA 2 10.20.2000 361000 7 1 0 NA 2 7 NA 06.03.2005 171000 1 1 1 6 2 10.20.2000 NA NA 
1 4 5 2 10 1 12.03.2000 210000 10 1 0 NA 1 7 NA 12.10.2000 210000 1 1 1 6 2 12.03.2000 NA NA 
2 1 5 1 7 1 03.08.2001 56000 3 1 0 NA 1 7 NA 03.13.2001 33000 1 1 1 6 2 03.08.2001 NA NA 
2 0 5 1 6 2 05.28.2001 141000 14 1 0 NA 2 7 NA 12.06.2001 141000 1 1 1 6 2 05.22.2001 NA NA 
1 1 5 2 NA 2 04.20.2002 682000 30 1 0 NA 2 7 NA 04.29.2003 552000 1 1 1 6 2 04.20.2002 NA NA 
2 1 5 2 7 2 04.25.2002 822000 7 1 2 NA 3 6 NA 07.16.2009 432000 1 1 1 6 1 04.25.2002 NA NA 
2 2 5 2 7 2 09.02.2003 130000 7 1 0 NA 2 7 NA 06.03.2005 184000 1 1 1 6 2 03.16.2004 NA NA 
2 1 5 2 7 2 11.20.2003 335000 7 1 0 NA 2 7 NA 02.13.2004 139000 1 1 1 6 2 11.20.2003 NA NA 
2 1 5 2 10 1 01.17.2004 120000 1 1 0 NA 1 7 NA 01.22.2004 60000 1 1 1 6 2 01.17.2004 NA NA 
1 2 5 2 11 2 06.04.2004 327000 3 1 2 NA 2 6 NA 07.25.2009 570000 1 1 1 6 1 06.04.2004 NA NA 
2 1 5 2 5 2 07.29.2004 533000 28 1 0 NA 2 7 NA 05.06.2005 464000 1 1 1 6 2 07.29.2004 NA NA 
2 1 5 2 10 2 01.19.2004 153000 3 1 0 NA 2 7 NA 01.26.2004 138000 1 1 1 6 2 01.19.2004 NA NA 
2 2 5 1 7 2 60.10.2005 894000 14 1 0 NA 2 7 NA 05-15-2007 674000 1 1 1 6 2 06-10.2005 NA NA 
1 1 5 2 6 1 03.25.2005 45000 14 1 0 NA 1 7 NA 04.01.2005 45000 1 1 1 6 2 03.25.2005 NA NA 
1 1 5 2 6 2 09.01.2005 796000 7 1 0 NA 2 7 NA 12.02.2005 200000 1 1 1 6 2 09.01.2005 NA NA 
1 1 5 1 8 1 11.16.2005 85000 14 1 0 NA 1 7 NA 11.22.2005 85000 3 1 1 6 2 11.16.2005 NA NA 
2 1 5 1 7 2 12.03.2005 1649000 7 1 0 NA 2 7 NA 01.24.2006 276000 1 1 1 6 2 12.03.2005 NA NA 
2 1 5 1 14 2 09.02.2006 901000 7 1 2 NA 2 6 NA 07.19.2009 486000 1 1 1 6 1 08.31.2006 NA NA 
2 1 5 1 4 2 12.19.2006 199000 7 1 2 NA 2 6 NA 04.11.2009 158000 1 1 1 6 1 12.13.2006 NA NA 
1 1 5 1 7 2 07.27.2006 380000 7 1 0 NA 2 7 NA 08.31.2007 30000 1 1 1 6 2 07.27.2006 NA NA 
2 1 5 1 7 2 10.18.2006 335000 7 1 2 NA 2 6 NA 04.24.2009 74000 1 1 1 6 1 10.12.2006 NA NA 
1 2 5 2 4 2 11.27.2007 1332000 7 1 2 NA 2 6 NA 09.08.2009 427000 1 1 1 6 1 11.21.2007 NA NA 
1 1 5 1 8 2 09.27.2007 2161000 7 1 2 NA 2 6 NA 07.17.2009 342000 1 1 1 6 1 09.27.2007 NA NA 
2 1 5 1 5 1 11.30.2007 90000 1 1 2 NA 2 6 NA 09.28.2009 45000 1 1 1 6 1 11.30.2007 NA NA 
2 1 5 1 6 2 07.26.2008 610000 14 1 2 NA 2 6 NA 07.28.2009 541000 1 1 1 6 1 07.24.2008 NA NA 
2 2 2 1 4 2 08.14.2008 855000 7 1 2 NA 2 6 NA 06.04.2009 151000 1 1 1 6 1 08.14.2008 NA NA 
2 2 5 1 5 2 01.29.2008 1030000 7 1 2 NA 2 6 NA 12.09.2008 563000 1 1 1 6 1 01.29.2008 NA NA 
2 2 2 1 9 2 02.14.2008 907000 7 1 0 NA 2 7 NA 02.20.2008 907000 1 1 1 6 2 02.14.2008 NA NA 
2 1 5 1 7 2 05.28.2008 276000 7 1 2 NA 2 6 NA 10.03.2008 75000 1 1 1 6 1 05.28.2008 NA NA 
2 1 5 2 7 2 06.05.2008 486000 7 1 2 NA 2 6 NA 10.06.2008 111000 1 1 1 6 1 06.05.2008 NA NA 
2 1 5 2 6 2 05.14.2008 849000 7 1 2 NA 2 6 NA 07.17.2009 469000 1 1 1 6 1 05.14.2008 NA NA 
xxix 
 
2 2 2 1 6 2 02.26.2008 494000 7 1 2 NA 2 6 NA 05.21.2009 112000 1 1 1 6 1 02.26.2008 NA NA 
2 2 5 1 6 2 07.26.2008 135000 3 1 2 NA 2 6 NA 09.26.2008 128000 1 1 1 6 1 07.26.2008 NA NA 
1 1 5 2 5 1 03.21.2008 323000 7 1 0 NA 1 7 NA 03.28.2009 323000 1 1 1 6 2 03.21.2009 NA NA 
2 1 5 2 4 1 06.25.2009 119000 7 1 0 NA 1 7 NA 06.30.2009 119000 1 1 1 6 2 06.25.2009 NA NA 
2 1 5 2 5 2 06.20.2009 1020000 7 1 2 NA 2 7 NA 07.21.2009 216000 1 1 1 6 1 06.18.2009 NA NA 
0 0 5 0 NA 5 NA 7000 28 0 0 NA 5 0 2 08.16.2005 339000 5 1 2 3 2 NA 04.07.2005 NA 
0 0 5 1 5 1 09.22.1995 104000 1 1 1 01.01.1998 1 1 1 04.26.2002 80000 1 1 2 2 2 NA 01.15.1998 NA 
2 0 5 2 5 2 02.27.1996 887000 7 1 1 09.29.1996 2 1 2a 03.04.1997 20000 3 1 2 8 2 NA NA NA 
0 0 5 0 NA 1 12.02.1996 50000 1 1 1 06.17.2006 1 1 2 07.17.2009 97000 1 1 2 2 1 NA 06.20.2006 NA 
2 2 5 2 5 2 05.28.1997 180000 1 1 1 12.14.1997 2 1 2a 12.19.1997 11000 3 1 2 8 2 NA NA NA 
2 1 5 2 5 1 10.16.1998 60000 1 1 1 09.20.2004 1 1 4 08.01.2009 160000 7 1 2 2 1 NA 04.01.2005 NA 
0 0 5 1 8 5 NA 67000 7 0 0 NA 5 0 0 10.03.2000 50000 1 1 2 9 2 NA 01.12.2000 NA 
0 0 5 0 NA 1 08.15.1999 43000 50 1 1 09.15.1999 1 1 3a 09.08.2009 7000 1 1 2 8a 1 NA NA NA 
2 1 5 2 8 2 09.09.1999 300000 3 1 1 07.01.2000 2 2 2 12.22.2003 150000 1 1 2 3 2 NA 05.01.2003 NA 
0 0 5 0 NA 2 12.14.1999 1173000 7 1 1 01.10.2000 4 1 2 12.08.2000 132000 1 1 2 2 2 NA 08.01.2000 NA 
2 0 5 0 NA 2 03.03.2001 179000 7 1 1 03.15.2001 2 1 3a 07.07.2009 7000 1 1 2 8 1 NA NA NA 
1 1 5 1 5 2 05.27.2002 120000 28 1 1 10.29.2002 2 1 2 08.25.2009 307000 1 1 2 2 1 NA 11.26.2002 NA 
2 2 5 2 22 2 08.21.2003 155000 30 1 1 11.25.2003 2 2 2 06.30.2008 380000 1 1 2 3 2 NA 09.10.2004 NA 
2 1 5 1 5 2 09.22.2004 125000 7 1 1 10.10.2004 4 1 2 08.16.2005 135000 1 1 2 2 2 NA 08.16.2005 NA 
2 1 5 1 9 5 NA 5000 1 0 0 NA 5 0 0a 02.01.2006 11000 1 1 2 7 2 NA NA NA 
2 1 5 2 7 5 NA 10000 1 0 0 NA 5 0 3a 08.26.2008 6000 3 1 2 7a 2 NA NA NA 
2 1 5 1 7 2 05.10.2006 523000 14 1 1 06.04.2006 4a 2 2a 05.02.2007 5000 3 1 2 8 2 NA NA NA 
2 1 5 2 6 2 10.24.2007 349000 1 1 1 02.01.2008 2 1 1 10.31.2008 372000 1 1 2 2 1 NA 06.13.2008 NA 
2 1 5 1 4 1 11.29.2007 151000 1 1 1 12.17.2007 4 1 2 09.17.2008 107000 3 1 2 2 1 NA 03.12.2008 NA 
2 1 5 2 5 2 11.29.2007 1738000 45 1 1 08.25.2008 2 1 2 05.19.2009 420000 1 1 2 2 1 NA 09.15.2008 NA 
0 0 5 0 NA 5 NA 10000 48 0 0 NA 5 0 2 07.03.2009 250000 5 1 2 1 1 NA 11.14.2008 NA 
1 1 5 1 7 2 04.01.2008 349000 50 5 1 04.28.2009 2 1 3 10.30.2009 92000 6 1 2 2 1 NA 05.12.2009 NA 
2 2 5 1 4 2 04.26.2008 139000 14 1 1 07.01.2009 3 1 1 10.23.2009 238000 2 1 2 2 1 NA 10.06.2009 NA 
 
 
 
************************************************************************************************************ 
